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Abbreviations 
Ab    Antibody 
AHR     Airway hyperresponsiveness 
Ag   Antigen 
APC    Antigen presenting cells 
AHR   Airway hyperreactivity 
BAL    Bronchoalvolar lavage 
b.i.d   twice daily 
BSA    Bovine serum albumin 
b.wt.   Body weight 
CD  Cluster of differentiation: International nomenclature 
for the cellular antigen 
cDNA    Complementary DNA 
CKR   Chemokine receptor 
°C    Degree Celsius 
DAPI   4'-6-Diamidino-2-phenylindole 
DC    Dendritic cells 
DNA    Deoxyribose nucleic acid 
DNase   Deoxyribonuclease 
EDTA    Ethylenediaine tetra acetate 
ELISA   Enzyme liked immunosorbent assay 
ELISPOT  Enzyme – linked immunospot assay 
FACS    Fluorescent activated cell sorter 
FBS    Fetal bovine serum 
FCS    Fetal calf serum 
FITC    Fluorescein isothiocyanate 
g     Gram 
GM- CSF   Granulocyte – macrophage colony stimulating factor 
HCl    Hydrochloric acid 
HEPES  n-2- Hydroxyethylpiperazine – n’- 2- ethane sulfonic 
acid 
HRP    Horseradish peroxidase 
hr(s)   Hour(s) 
ICAM    Intercellular cell adhesion molecules 
IFNg   Interferon gamma 
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Ig    Immunogloblin 
IL    Interleukin 
i.n.   Intranasal 
i.p.   Intraperitoneal 
IP- 10    Inducible protein- 10 
i.v.    Intravenous 
kb    Kilobase 
KO   Knockout 
l    Liter(s) 
µl    Microliter(s) 
µm    Micrometer(s) 
LFA-1   Lymphocyte function – associated antigen -1 
LN(s)   Lymph node(s) 
M    Molar 
mAb    Monoclonal antibody 
MCP   Monocyte chemotactic protein 
ME    Mercaptoethanol 
min(s)    Minute(s) 
MIP   Macrophage inflammatory protein 
ml    Milliliter(s) 
MHC    Major histocompatibility complex 
mol    Mole(s) 
mol wt   Molecular weight 
N    Normality 
n     number in a study or group 
NaOH    Sodium hydroxide 
No.    number 
OD    Optical density 
OPT o- Phenylenediamine dihydrochloride tablet sets 
(OPD peroxidase substrate) 
OVA    Chicken egg ovalbumin 
PAS    Periodic acid- Schiff’s reagent 
PBS    Phosphate -buffered saline 
PCI    Phenol chloroform isoamylalchol 
PCR    Polymerase chain reaction 
 3 
RT PCR   Reverse transcript polymerase chain reaction 
RANTES  Regulation on activation, normal T cells expressed 
and secreted 
RNA    Ribonucleic acid 
mRNA   Messenger RNA 
RNase    Ribonuclease 
sec     Seconds 
SD    standard deviation 
SDS    Sodium dodecyl sulfate 
SEM   Standard error of mean 
SLC    Secondary lymphoid chemokine 
t test    Student’s t test 
TARC   Thymus and activation-regulated chemokine 
TECK    Thymus – expressed chemokine 
TMB    3.3’, 5.5’-tetramethylbenzidine 
TCR    T cell receptor 
TGF    Transforming growth factor 
Th    T helper cells (Th1, Th2 cells) 
vol    Volume 
VCAM- 1   Vascular cell adhesion molecule- 1 
VLA    Very late activation antigens 
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1. Introduction  
1.1. Immunological memory 
Immunological memory is the ability of the immune system to 
rapidly elicit an immune reaction to a previously encountered antigen (Ag). 
During the first Ag exposure there is generation of a slower effector 
immune response, which gradually weans over time. Re-exposure to the 
same Ag, however, elicits a much rapid and exaggerated response. 
References to immunological memory dates back to Greek historian 
Thucydides who in 430 B.C said that ‘The same man was never attacked 
twice’ describing the plague of Athens. Later, Edward Jenner in 1976 
exploited this feature of immunological memory for the development of 
vaccine against small pox. Since then the concept of immunological 
memory has been widely associated in other fields such as tumor clearance, 
transplantation studies, vaccination and oncology. 
The unique features of immunological memory result in an increased 
number of specific resting B or T cells, that can be maintained in the 
absence of an Ag (1). Immunological memory is distinguished by a subset 
of lymphocytes that are situated in between naïve and effector cells (2). 
Immunological memory involves both T and B lymphocytes that eventually 
results in generation of T cell and B cell memory. There has been much 
work done to define both T and B memory cells (3-8). In the B memory cell 
work, there has been conflicting results shown by various groups in an 
attempt to mark memory B cells. Zan- Bar and coworkers showed that IgM- 
or IgD + cells could restore both secondary IgM and IgG responses, while 
IgG+ cells could only resore only IgG responses (8). Furthermore, IgG+ 
cells suppressed the secondary IgM responses and depletion of IgG+ cells 
resulted in increase in adoptive IgM response (8). In contrast, Herzenberger 
and coworkers showed that IgD+ cells were the precursors for IgD- memory 
cells that had higher antibody responses than IgD+ cells (7). In another set 
of experiments, the same group showed that while both IgD+ and IgD- cells 
could transfer memory to a naïve host and result in IgG and IgD antibody 
producing cells, only IgD- cells had the ability of self renewal and 
generation of more IgD- cells (9). Memory T cells on the other hand, are 
characterized by the presence of CD62Llow and CD45low and CD44high 
expression (5, 10). In addition, memory T cells upon stimulation produce a 
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wide array of cytokines (11) and maintain elevated ZAP-70 expression (12), 
enabling a rapid and exaggerated immune response. 
 
1.2. The difference between primary and memory immune responses. 
Primary and memory responses differ markedly in the several ways. 
The primary immune response has a slow onset, whereas the memory 
immune responses are hosted much rapidly. The primary immune response 
involves the stimulation and priming of naïve T and B cells, whereas 
memory responses are launched much faster due to presence of memory 
cells. Memory responses are elicited rapidly due to the increased frequency 
of Ag-specific T and B cells. Naïve T cells in the primary response 
proliferate and differentiate into effector cells that produce cytokines (13). 
Once the pathogen is cleared the effector cells die (14). However, a subset 
of effector cells survives as memory T cells and is quiescent but can be 
rapidly stimulated upon a second exposure to the same Ag. Memory 
responses are Ag-specific. While naïve T cells produce IL-2, memory T 
cells upon stimulation produce a wide array of cytokines (11). Humoral 
immunity is also involved where naïve B cells during the primary response 
differentiate into Ab-secreting plasma cells. During an ongoing primary 
immune response, a subset of Ab producing B cells becomes memory B 
cells, characterized by presence of Ab bound to their surface and Ab 
secreting plasma cells. Memory B cells reside in the secondary lymphoid 
organs and respond to secondary challenges to the same Ag by undergoing 
clonal expansion and differentiating into plasma cells. A small subset of 
long- lived plasma B cell resides in the bone marrow and constitutively 
secrete Abs (15). Another feature of the memory response is less 
dependence on costimulatory molecules for activation and the ability to be 
activated by macrophages and resting B cells (16). Besides being 
functionally distinct from naïve cells, memory T cells exhibit markers that 
allow them to migrate to non lymphoid tissues (17, 18).  
 
1.3. Markers for distinguishing naïve and memory CD4+ T cells 
Naïve and memory T cells are distinguished by the presence of 
surface markers. The most commonly described memory markers are 
CD62L (L-selectin) (3, 19, 20), CD44 (Pgp-1) (5, 6, 21) and CD45RB in 
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mouse and CD45RO/RA in humans (22). Naïve T cells have high 
expression of CD62L and CD45 and low expression of CD44 (3, 5, 6, 19, 
20). Memory T cells, on the other hand, express low CD62L and CD45 and 
high CD44 (5, 10).  
Naïve T cells have low CD44 expression and upon stimulation of the 
TCR acquire the CD44 expression and thereafter stably maintain the 
expression of CD44 (5, 6). CD62L expression on T lymphocytes is 
regulated following activation through the TCR/CD3 complex. Following 
activation, CD62L expression is induced and then gradually decreases. 
Furthermore, this down - regulation of the CD62L receptor is more rapid for 
CD8+ T cells and CD4+ cells down- regulate CD62L slowly (10). CD62L 
expression on CD4+ memory T cells is CD62Llow due to shedding of L-
selectin after activation. CD62Llow cells are unable to enter the LN via the 
high endothelial venule, but can gain entry through the afferent lymph. 
However, Ahmadzadeh and coworkers demonstrated that a resting memory 
CD4+ T cells expressing CD62L high were hypo- responsive to anti-CD3 
stimulation and showed slower activation kinetics (23). Another marker that 
has been used for memory T cells in rats is CD45RC (4). While CD45Rhigh 
defines naïve lymphocytes, CD45Rlow marks memory cells. This marker 
differentiates two subsets of memory cells; CD45Rlow cells are short-lived 
memory cells with a rapid kinetic and CD45Rhi which are long-lived 
memory cells (4).  
 
1.4. Naïve and memory CD4+ T cell life span 
There is variable literature on the lifespan of naïve and memory T 
cells (24, 25). On one hand there is data suggesting that the life span of 
naïve CD4+ T cells is short and depends on presence of IL-7 and contact 
with self MHC class II molecules (26-28), on the other, alpha/beta T cells 
survive in the secondary lymphoid organs for about eight weeks (24). It has 
been shown that naïve CD4+ T cells are short-lived and die in a few weeks 
in absence of activation (29). Although naïve CD4+ T cells do not require 
contact with Ag for survival, there seems to be a requirement for interation 
with MHC class II for long-term survival of naïve CD4 T cells (26, 27). 
Naïve CD4+ T cells do not proliferate, as shown by inability of naïve CD4+ 
T cells to incorporate BrdU (30, 31). Recently, it was demonstrated that 
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thymic involution results in decrease naïve CD4+ CD31+CD45RA+ cells in 
the periphery (32). However, the number of naive CD4+ CD31- CD45RA+ 
cells remains constant due to proliferation in the periphery (32). Hataye and 
coworkers demonstrated that the the low clonal abundance is crucial for the 
survival and activation of naïve CD4+ T cells and their memory cell 
progeny (33). To conclude, naïve CD4+ T cells are long-lived in the 
presence of MHC class II, whereas, memory cells may be long-lived and 
dividing in response to stimuli or remain undivided. 
 
1.5. Naïve and memory CD4+ T cell turnover rate and mechanisms of 
turnover 
It has been demonstrated that CD4+ and CD8+ memory T cells turn 
over more rapidly than naïve cells (31). Two weeks after administration of 
BrdU in athymectomized mice, 40-50% of the memory T cells in lymph 
nodes (LN) and spleen were BrdU+ compared to less than 10% of naïve 
cells (31). Additionally, about 20% of memory CD4+ T cells and 50% of 
memory CD8+ T cells remained BrdU-, indicating that a portion of memory 
T cells can survive for long periods without division. Early experiments by 
von Boehmer and coworker demonstrated that the life span of naïve CD8+ 
T cells was 8 weeks  and in the absence of Ag the naïve cells do not divide 
(24). Using a mathematical model, Mclean and coworkers showed that the 
unprimed T lymphocytes divide every 2.5 years, whereas the primed T cells 
divide every 22 weeks (25). By administrating BrdU in drinking water, 
Tough and co-workers showed that both CD4+ and CD8+ memory T cells 
divide rapidly and naïve cells remain in interphase for a long time (31).  The 
distinct proliferative responses of CD4+ T cells were demonstrated by the 
transfer of CD4+ T cells into lymphopenic mice. Min and coworkers 
showed that the transferred CD4+ T cells proliferate and differentiate into 
memory cells. This proliferation termed ‘spontaneous proliferation’ was IL-
7 independent, whereas ‘homeostatic  proliferation’ was IL-7 dependent and 
cells undergoing homeostatic proliferation had slow proliferation rate (34). 
In summary, CD4+ T memory cells divide more frequently than 
naïve CD4+ T cells and have a longer life span. 
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1.6. The factors for maintenance of CD4+Th cell memory 
The survival of memory cells could be attributed to either to the 
upregulation of anti-apoptotic genes or suppression of pro-apoptotic genes 
(35). The Bcl-2 subfamily which regulates survival of cells comprises the 
Bcl-2, Bcl-XL, Bcl-w, Mcl-1 and A1 genes (36). While the disappearance 
of effector cells after an Ag-specific immune response has been suggested to 
be mediated by ligation of Fas – FasL and thus, leads to activation induced 
cell death (AICD)(37).  The other possible mechanisms for maintenance of 
CD4+ Th cell memory are involvement of costimulatory molecules, Ag 
dose and duration of Ag contact and involvement of CKRs. 
 
1.6.1 Involvement of costimulatory molecules in maintenance of 
memory. 
Naïve T cell activation requires a signal from the TCR- MHC class 
II complex and a second signal from the costimulatory molecules (16, 38, 
39). Efficient CD4+ T cell activation has been shown to require both the 
TCR- MHC: peptide interaction and involvement of both ICAM-1 and B7-1 
for optimal response (40). While either ICAM-1 or B7-1 could activate 
naïve CD4+ T cells in combination with stimulation through the TCR; 
maximum activation was achieved when both ICAM-1 and B7-1 
costimulation were involved (40). 
CD40 a member of TNFR family is expressed by activated DCs and 
B cells and binds to CD40L (CD154) on activated T cells (41, 42). 
MacLeod and coworkers showed that primary and memory T cell response 
can be differentially regulated by CD40–CD40L interactions (43). These 
authors demonstrated that while, primary CD4+ T cells require CD40–
CD40L interactions for expansion; memory T cells do not require CD40 – 
CD40L interaction for survival and expansion. However, the requirement of 
CD40- CD40L seems essential for effector cell differentiation. Desbarats 
and coworkers demonstrated the dual nature of Fas- FasL signaling in CD4+ 
T cells (44). While naive CD4+ T cells (CD44low, CD45RBhigh, CD62Lhigh) 
do not survive as a consequence of Fas ligation in the presence of anti-CD3 
antibody; the memory T cells (CD44high, CD45RBlow, CD62Llow) were 
found to be co-stimulated to proliferate by Fas ligation (44). 
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1.6.2. Ag dose and duration of Ag contact affects memory CD4+ T cell 
maintenance 
Initiation of T cells signaling requires an interaction between T cell 
and APC. There is evidence indicating that the duration of signaling is 
distinct for naïve and effector T cells. While naïve T cells become commited 
to proliferate only if the duration of stimulation is long; effector T cells can 
be stimulated to proliferate with a shorter duration of stimulation. Moreover, 
a sustained antigenic stimulation can be lethal for the effector T cells. 
Additionally, signaling through costimulatory molecules e.g. CD28 can 
decrease the time required for effector cells to proliferate and thus protect T 
cells for death (45).  
The presence of cytokine and the duration of TCR stimulation can 
also determine the differentiation of T cells. Early experiments 
demonstrated that Th1 differentiation could be induced with a short duration 
of TCR stimulation in presence of IL-2 (46). Th2 differentiation, however, 
required a longer duration of TCR stimulation and presence of IL-4 (46). 
Following stimulation, the production of cytokines by naïve and memory 
CD4+ T cells also differs (47). Memory CD4+ T cells rapidly (within 12-24 
hrs)  initiate the production of interleukins whereas naïve T cell require 
longer duration ( 3- 5 days) for cytokine production (47). In summary, naïve 
T cells require longer duration of TCR stimulation and duration for 
production of cytokines than memory T cells. Although memory and naïve 
T cells have different kinetics of cytokine production after Ag stimulation, 
both naïve and memory CD4+T cells produce the same amounts of IL-2 in 
response to titrated doses of Ag (48). Memory cells proliferate in response 
to low antigenic stimulation, whereas, naïve CD4+T cells require more 
antigenic stimulation and divided slower than memory cells (48). Moreover, 
the production of cytokines IL-4, IL-5 and IFNg was higher by memory 
cells compared to naïve cells (48). In summary, the CD4+ memory T cell 
provide efficient immunity by eliciting rapid effector functions in response 
to Ags (48). 
 
1.6.3. Role of CKR in memory CD4+ T cell maintenance 
The maturation of thymocytes involves two types of selection 
processes, positive and negative selection (49). The T cells first undergo 
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negative selection where those T cells that have a TCR with strong avidity 
for the self MHC are eliminated (49). Thus the negative selection permits 
thymic tolerance (50). The maturing thymocyte after negative and positive 
selection enters the circulation. Chemokines present in the thymus 
differentially regulate the response of maturing thymocytes. In mice, the 
source of CCL25 or TECK (thymus – expressed chemokine); a ligand for 
CCR9 (51), is produced by selectively by thymic DCs and chemotactically 
attracted thymocytes, DCs and macrophages but not PBLs and neutrophils 
(52). Mature single positive T cells acquire the  expression of  CCR7 at later 
stages of development (53) and respond to the two ligands of CCR7; EBL 
(54) and secondary lymphoid chemokine (SLC) (55). Campbell and co 
workers demonstrated that there is an increased response to MDC, a 
chemokine expressed in the thymus and a ligand for CCR4 (56), by cells 
that migrate from cortex to medulla (57). Taken together, these data indicate 
that CCR9 retain the cells in the thymus until the process of maturation is 
complete and then CCR4 drives the migration of cells from cortex to 
medulla (52, 57).  The CKRs expressed at all developmental stages are 
CCR7 and CXCR4 and might play a role in migration of T cells. D’Apuzzo 
and coworkers demonstrated a role of SDF-1 in promotion of proliferation 
of B cell progenitors (58). The importance of SDF-1 or CXCR4 is 
demonstrated by the fact that mice deficient in with SDF-1 or CXCR4 die 
perinatally.  
Although CKRs have been demonstrated to play a critical role in 
recruitment of T cells to sites of inflammation (59, 60) and development of 
T cells, there is lack of information about the requirement of CKR in 
maintenance of memory T cells in the peripheral organs.  
 
1.7. The circulation and homing properties of memory and naïve CD4+ 
T cells 
The migration pattern of naïve and Ag-experienced T cells is distinct 
(29, 61, 62). Naïve T cells encounter Ags presented by APCs in the 
secondary lymphoid organs (61). Naïve T cells express CD62L and the 
ligands for CD62L are GlyCAM 1, CD34, MAdCAM-1 and podocalyxin-
like protein (PCLP) which are expressed on high endothelial venules 
(HEV). Interaction of CD62L with its ligand on the HEV facilitate the 
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migration of naive T cells into the LNs (63), which is followed by the 
interaction of CCR7 present on naive T cells with its ligand CCL21 (62). As 
a result of this interaction, an activation signal is initiated that induces the 
expression of integrins on naïve T cells and allows them to bind to ICAM-1 
or ICAM-2 and inhibit cells from rolling and migration (62). 
Early experiments using sheep cells have been instrumental in 
understanding the migration patterns of naïve and memory T cells. Mackay 
et al. showed that majority of the sheep T cells from the efferent lymph 
were naïve and those T cells derived from the afferent lymph were memory 
cells (17). This finding led to the concept that the naive T cells egress the 
blood through the HEV to enter lymphoid tissues (63, 64). The increased 
expression of various adhesion molecules by memory cells permit the 
migration of memory cells into nonlymphoid tissue (65). The migration of 
subtypes of memory T cells is distinct from naïve T cells and migration of 
memory T cells to secondary lymphoid tissues is directly from blood, 
whereas for naïve T cells its via HEV (29, 61). Investigation of the subtype 
of effector/memory T cells in humans indicate that based on the expression 
of surface markers there is preferential migration of T cells to specific 
organs. Using surface markers CD45RAlow/ROhigh for defining effector and 
memory cells respectively in humans, Picker et al. demonstrated that T cells 
in the skin are CTL+/ CD62L+/ α4β7+/memory/effector T cells (66). Lung 
memory /effector T cells exhibited a different phenotype that was CTLnegative 
to low/ CD62L –/ α4β7+ (66). This provided evidence that memory effector 
cells, depending on their migration to non- lymphoid tissues, express 
different homing receptors (66). In addition, other markers have been used 
to identify two subsets of memory T cells that exhibit preferential migration 
to either gut or skin (67-69). Skin homing T cells express cutaneous 
lymphocyte – associated Ag (CLA) (67, 68) that binds to the endothelial 
selectin on inflamed skin. In addition to CLA, a subset of memory and 
effector T cells also expresses CCR4 (69). The ligand of CCR4; TARC is 
expressed on the inflamed skin but not in inflamed intestine (69). Another 
ligand of CCR4 that is involved in driving the migration of effector and 
memory T cells is monocyte derived chemokine (MDC) (70). The 
chemokine, MDC, is produced by lung cells like alveolar macrophage and 
smooth muscle during inflammatory reaction (70). 
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Another marker that is expressed on a subset of memory T cells and 
drives the migration of memory T cells in response to MIP3 a is CCR6 (71). 
Memory T cells have been subdivided further based on the functional and 
anatomical location and are termed ‘effector’ and ‘central’ based on whether 
they can exert immediate effector function upon Ag challenge or not (72). 
Furthermore, effector memory T cells lack expression of CD62L and are 
also CCR7- do not migrate to secondary LN (72). Central memory cells on 
the other hand, express CD62L and CCR7 which allows them to migrate to 
LN (72). To summarize, naïve T cells have a different migration pattern 
compared to memory T cells. Naïve T cells migrate via the HEV to 
lymphoid organs and encounter Ag, memory T cells migrate and home to 
non- lymphoid organs.  
 
1.8. Effector and central memory CD4+ T cells 
Memory cells have been divided into 2 subsets depending on their 
preferential site of migration and activation state. Effector memory cells 
reside in the non-lymphoid tissues and are CCR7- whereas central memory 
cells are CCR7+ and reside in the lymphoid organs (72). CD8+ effector 
memory cells closely resemble effector cells and have a rapid turnover rate 
and express activation markers CD25 and CD69 (73-75). Effector memory 
cells express high levels of integrins and CKRs that allow them to enter 
nonlymphoid tissue (72). These effector cells can also migrate to blood and 
spleen but due to the loss of LN homing receptors CD62L and CCR7 they 
are restricted in their ability to enter LNs (72). However, a small number of 
these effector memory cells can enter the LN via the afferent lymphatic 
vessels (76).  
Central memory cells have a slower turnover rate (73), lack 
activation markers and are distributed in the lymphoid tissue , thus 
resembling naïve T cells (72). Central memory cells express CD62L and 
CCR7, two molecules that facilitate the entry of central memory cells 
through the high endothelial venules. Despite having a quiescent phenotype 
the central memory cells are less inert than naïve T cells. CD8+ central 
memory cells divide intermittently (77) and remain in the G1 phase of 
cycling. In addition, CD8 central memory cells express perforins (77, 78) 
suggesting that central memory cells remain in a low activation state. 
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 The association between effector and central memory cells is 
unclear. It seems that central memory cells can generate effector memory 
cells after an immune response (72, 79, 80) by stimulation through 
cytokines, cross reactive Ag or presence of persistent Ag. 
 
1.9. Mechanisms of maintenance of CD4+ T memory 
1.9.1. Ag persistence in memory CD4+ T cell maintenance 
Antigenic persistence and its association with maintenance of 
memory CD4+ T cells remain unclear. Contrasting studies demonstrate 
either the requirement (81, 82) or a redundant (83) role of Ag in memory 
maintenance. Kieper et al. demonstrated that naïve T cells from normal mice 
proliferate in immunodeficient RAG- and SCID mice, however, the 
proliferation is slow when SCID mice are kept in germfree conditions 
suggesting the importance of foreign Ag in expansion and proliferation of 
naïve T cells (84). Using a mathematical model, Antia et al. calculated the 
half-life of Ag-specific cells in the absence of Ag stimulation to be more 
than 1 year (85). Mojtabavi et al. using a mouse model of allergic asthma 
demonstrated that the long-term survival of Th2 memory cells is 
independent of presence of Ag stimulation (86). Several studies explain the 
maintenance of CD4+ memory (87) and CD8+ memory (88) in the absence 
of MHC. Maruyama et al. demonstrated the maintenance of B cell memory 
is  independent of Ag (89). Müllbacher et al. transfered memory cells into 
naïve or previously primed mice and found long lasting CTL memory cells 
in both groups (90). Thus confirming that the Ag is not necessary for the 
maintenance of memory (90). In another experiment, LCMV specific 
memory CD8+ cells were adoptively transferred into naïve mice and 
resulted in immunity for over 2 years (1). To conclude, the requirement of 
Ag for persistence of memory CD4+ T cells is unclear. 
 
1.9.2. Cross reactive Ags maintain memory CD4+ T cells 
The maintenance of memory CD4+ T cells could also be a result of 
stimulation by cross reactive Ags. It has been shown that presence of cross 
reactive short peptides at high concentrations can stimulate T memory cells 
clones (91). Selin et al. demonstrated that prior immunization with LCMV 
protected mice against Pichinde virus and Vaccinia virus, by rapidly 
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reactivating memory cells specific for LCMV (92).  Recently, Kudela et al. 
demonstrated that the tumor Ag- specific CD4+ T cells are proficient in 
recognizing the tumor epitope- peptide in context of multiple HLA-DR and 
HLA-DP molecules (93). In patients with allergy to peanut, it has been 
shown that there are cross reactive B cell epitopes that react to tree nut 
proteins (94, 95). Thus, prior exposure to unrelated pathogens may protect 
the host against infections. However, crossreactivity may result in elicitation 
of immune responses against unrelated proteins in food.  
 
1.9.3. Self peptide required for maintenance of CD4+ T cell memory 
While there is requirement of continuous contact with self- MHC – 
peptide ligand for naïve T cells to survive (27), this requirement for memory 
cells is not clear. There are reports that indicate that interaction with MHC 
ligand is critical for survival of memory T cells and with less specificity 
than that for naïve T cells (96). Markiewicz et al. demonstrated that number 
of anti-H-Y memory CD8+ T cells 70 days after transfer to MHC low 
(RAG1-TAP1-) mice was significantly reduced compared to those recovered 
from mice expressing normal levels of MHC I (97). In summary, naïve T 
cells require self peptide interaction but the role of self peptide MHC 
interaction for memory T cells maintenance is unclear. 
 
1.9.4. A critical role of MHC class II in CD4+ T cell memory 
maintenance 
Naïve T cell activation requires signaling through the TCR and 
costimulatory molecules. There is data indicating that the continuous 
contact with self MHC class II – peptide ligand is critical for survival of 
naïve T cell (38, 98-101). Boker showed that the survival of peripheral 
CD4+ T cells needs peripheral MHC class II expression and contact of 
CD4+ T cells with MHC class II expressing DC (38).  
While naïve T cells require MHC class II for survival and 
proliferation the role of MHC class II in maintenance of memory CD4+ T 
cells is controversial. Swain et al. using a TCR transgenic mice model 
showed that the in vitro generated effector CD4+ T cells when transferred 
into MHC class II KO mice persisted in the absence of MHC class II. The 
transferred CD4+ T cells were quiescent and survived as non dividing cells 
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(87). Kassiotis et al. showed that MHC class II interaction was not critical 
for the survival of memory T cells, but the absence of MHC class II 
impaired the functionality of the memory T cells. Thus MHC class II was 
essential for maintaining functional memory T cells (102). Tanchot et al. 
demonstrated that interaction with self MHC class II- peptide ligand is also 
required for the survival of memory T cells, but is less specific for naïve T 
cells (96). Martin and cowokers showed that in the absence of MHC class 
II, the expansion and proliferation of CD4+ T cells is affected (103). To 
summarize, memory T cells survive in the absence of MHC class II 
interaction. However, there is a requirement of MHC class II to maintain the 
functional properties of memory T cells. 
 
1.9.5. Chemokine and cytokine involvement in maintenance of CD4+ T 
cell memory 
Cytokines are linked to the survival of T cells and different 
cytokines are involved in the maintenance and survival of CD8+ and CD4+ 
T cells (104-106). Early studies from Sprent et al. demonstrated that two 
factors polyinosinic – polycytidylic acid (poly I:C) (107) and 
lipopolysaccharide (LPS) (105) could in a non specific manner result in 
turnover of CD8 memory cells. In addition, IFN-I and component of 
microbial cell wall LPS, results in secretion of IL-15 by APCs (30). IL-15 
has been demonstrated to be critical for survival of naïve and memory CD8 
T cells (106), but this cytokine has no effect on the proliferation of CD4+ 
memory cells (108). Furthermore, IL-15 has been shown to be critical for 
the generation of Ag-specific memory CD8+ T cells (109). Using transgenic 
mice lacking either IL-15 (IL15-/-) or the receptor for IL-15Rα-/- mice, 
Schluns et al. demonstrated that IL-15 was required for the primary 
expansion of CD8+ T cells specific for vesicular stomatitis virus (109). In 
addition, naïve CD8+ T cells expressed low IL-15R alpha but upregulated 
this receptor on Ag-specific effector cells and memory cells (109). 
Kondrack et al. demonstrated that IL-7 was essential for the survival and 
generation of memory CD4+ T cells (104). There was a dependence on IL-7 
for both central and effector memory CD4+ T cells survival (104). Using a 
transgenic Lck deficient mice, Seddon et al. demonstrated the influence of 
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TCR signaling and IL-7 -mediated signal and suggested an overlapping role 
of these two in the maintenance of CD4+ T memory cells (110). 
 The role of chemokines in memory cell maintenance is still unclear. 
Marcais et al. demonstrated that CD8+ T cells maintain CCL5 expression 
after induction of primary response (111). These authors showed that CD8+ 
T memory cells constitutively transcribe ccl5 gene and the half life of CCL5 
mRNA is increased in the memory CD8+ T cells (111). Furthermore, 
treatment of murine CD8+ T cells with IL-4 inhibited CCL5 mRNA 
transcription and this inhibiton was reversible as removal of IL-4 
reconstitute the ability of CD8+ memory T cells to immediately secrete 
CCL5 (111, 112). In addition, it was shown that resting memory CD8+ T 
cells expressed high levels of RANTES (CCL5) mRNA enabling them to 
secrete high amounts of RANTES after antigenic stimulation (113). 
These data indicate that CD8+ memory cells require IL-15 for 
survival, whereas CD4+ memory cells survival is IL-7 dependent. 
Information regarding the role of chemokines in memory CD8+ T cells 
maintenance is limited to CCL5 and no chemokine has been specified for 
CD4+ memory T cell maintenance. 
 
1.10. Generation of CD4+ T cell memory require cell- cell contact 
1.10.1. Memory CD4+ T cells maintained in absence of B cells 
Early studies to demonstrate the importance and requirement of B 
cells and immunoglobulins (Ig) was performed by the groups of Doherty 
and Ahmed; both confirming that CD8+ memory T cells are maintained 
independently of B cells (114, 115). Topham et al. demonstrated that virus 
specific memory CD8+ T cells can be maintained in B cell deficient mice 
(µMT) for upto 6 months (114). Whereas Asano et al. studied the 
requirement of B cells during the initial expansion of virus specific CD8+ T 
cells and effector CTL development, during the contraction phase and the 
phase of long- term memory CTL (115). These investigators found no 
differences in the number of LCMY virus specific CTL memory cells in 
µMT and wild- type (WT) mice (115) suggesting that neither B cells nor 
Ag-Ab complexes are required for CD8+ memory cells maintenance. Di 
Rosa et al. demonstrated that the H-Y specific CD8 memory cells is 
maintained in mice depleted of CD4+ cells and deficient in B cells for upto 
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9 months (116). In contrast, studies by van Essen et al. demonstrated that 
µMT mice immunized with soluble keyhole limpet hemocyanin (KLH) 
display a decline in the CD4+ memory cells (117). These authors suggested 
that B cells provide an environment where Ag is presented to CD4+ T 
memory cells and thus maintained CD4+ T memory cells (117). Linton and 
coworkers showed that B cells are required for the development of CD4+ T 
memory cells (118). CD4+ T cell responses to KLH in WT and B cell 
deficient mice were compared and the authors observed a decreased IL-2 
production by cells primed in absence of B cells (118). They attributed this 
diminished production of IL-2 to lower frequencies of Ag responsive cells 
and not due to the decreased production of IL-2 by individual cells, 
suggesting that optimal CD4+ memory generation requires the presence of 
B cells. Recently, Lui and coworkers showed that B cells were not 
mandatory for the activation of T cells but the subsequent proliferation and 
differentiation into Th2 cells is dependent on B cells (119). Furthermore, 
IL-4 expressing Ag-specific T cells first develop in the T - B zone of the LN 
(119). Crawford and coworkers showed that when the B cell compartment is 
deficient in MHC class II, and other APC are largely normal, T cell clonal 
expansion is significantly reduced and the differentiation of T cells into 
cytokine-secreting effector cells is impaired (in particular, Th2 cells) (120). 
In addition, the development of memory T cell populations is also decreased 
(120). To conclude, maintenance of CD4+ and CD8+ T memory cells differ. 
While, CD8+ T cells do not require B cells for memory generation and 
maintenance the role of B cell in CD4+ T memory cells is unclear. 
 
1.10.2. Persistence of CD8 cells in absence of CD4+ cells 
There is ample evidence suggesting the induction of anti viral CD8+ 
T cells responses in mice in the absence of CD4+ T cells in case of acute 
LCMV (121, 122), Sendai virus (123), MHV- 68 (124, 125), influenza virus 
(126, 127), Vaccinia virus (128), and Ectromelia virus (128) infections. In 
contrast, other viruses such as chronic LCMV, adenovirus, Japanese 
encephalitis virus, and Herpes simplex virus induce anti viral CD8 T cell 
responses that are CD4+ T helper- cell- dependent. Blocking costimulatory 
interactions reduces T helper cell dependent CD8+ T cells responses to 
adenovirus (129). Di Rosa et al. demonstrated that the H-Y specific CD8+ T 
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memory cells is maintained in mice depleted of CD4+ T cells and deficient 
in B cells for upto 9 months (116). To conclude, the exact mechanism 
underlying the maintenance of CD8+ T cells and the requirement of CD4+ 
T cell help is not completely understood and probably depends on the type 
of Ag. 
 
1.11. Molecular/signaling mechanisms of generation of immunological 
memory 
The cross linking of the TCR complex activates signaling pathways 
downstream of the TCR, which eventually results in the activation and 
proliferation of the T cell. Lck and Fyn are activated by the common 
leukocyte antigen (CLA) CD45 by removal of phosphate from the inhibitory 
site of Lck and Fyn (130). Once Lck and Fyn are activated they 
phosphorylate tyrosines of ITAM of CD3 complex. The ζ chain of CD3 is 
phosphoryalted which enables ZAP-70 to bind to the ζ chain (131). Upon 
binding to ζ chain, ZAP-70 is activated by catalytic activity of Lck or Fyn. 
Phosphorylation of ZAP-70 protein tyrosine kinase leads to activation of 
several proteins. ZAP-70 initiates phosphorylation of phospholipase Cγ1 
(PLCγ), which in turn hydrolyses phosphatidylinositol 4.5- biphosphate 
(PIP2) into Inositol 1,4,5- triphosphate (IP3) and diactylglycerol (DAG) 
(131). The two secondary messengers are involved in initiating two 
important T cell activation cascade (132). IP3 results in increase in 
intracellular cytosolic Ca2+ levels which in turn activates Calcineurin. 
Calcineurin dephosphorylates the transcription factor NF-AT in the cytosol 
which enables NF-AT to enter the nucleus by binding to important genes 
and thus increase their expression (132). DAG can also activate PKC 
(Phospholipase C) which activates NF-κB by removing the inhibitory IκB 
subunit allowing NF-κB to enter the nucleus and activate IL-2 gene (133). 
Crosslinking of the TCR also activates small G protein Ras. Upon 
crosslinking of TCR, Ras is activated and initiates the mitogen activated 
protein kinase (MAP kinase) pathway. A series of signal cascade ensue that 
eventually results in phosphorylation of Fos and Jun transcription factors 
and formation of AP1 heterodimers. This result in promotion of 
transcription of genes required for cell proliferation. 
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Chandok and coworkers found that the expression of ZAP-70 was 
elevated in resting Ag specific memory and polyclonal memory cells 
compared to naïve CD4+T cells (12). These authors found that in naïve T 
cells the expression of ZAP-70 increases after stimulation, whereas the 
memory cells maintained elevated ZAP-70 expression (12). Furthermore, 
rapid effector functions were possible only if a high level of ZAP-70 protein 
was available. Blocking or down-modulating ZAP-70 by siRNA resulted in 
reduced effector functions (12). Maxwell and coworkers demonstrated the 
role of OX40 in the generation of memory CD4 T cells (134). The authors 
found that the optimum generation of memory CD4+ T cells required three 
signals: presence of Ag, a danger signal and the ligation of OX40 to its 
ligand OX40L (134). Another group showed that OX40 KO mice develop 
late Ag specific CD4+ T cell primary responses and low numbers of 
memory cells (135). Furthermore, the OX40 deficient CD4+ T cells 
proliferated less compared to WT controls and also produced lower amounts 
of IL-2 (135). Recently, Cannon and co- workers demonstrated the CD43 -/- 
cells are hyperproliferative, produce Th2 cytokines upon stimulation and 
express high levels of GATA-3 and are more susceptible to Th2 -mediated 
disease which was not due to the inability to host Th1 responses (136). In 
another study, the importance of Bax in allergic asthma was demonstrated 
(137). The bronchial epithelial cells from asthmatic patients had reduced 
expression of Bcl-2- associated protein X (Bax) compared to healthy 
individuals thus affecting the resolution of Ag induced mucous cell 
metaplasia (137). Another signaling molecule CARMA1 has been 
demonstrated to be important for Ag stimulate activation of NF-kB in 
lmphocytes in vitro (138). CARMA1 -/- mice failed to develop airway 
eosinophilic inflammation with reduced T cell recruitment into the airway. 
The other features of allergic asthma, such as AHR , production of IgE, 
mucus production and Th2 cytokine IL-4, IL-5 and IL-13 production was 
reduced or absent in CARMA1 -/- mice (138). Interestingly, adoptive 
transfer of WT Th2 cells into CARMA1-/- mice restored all the signs of 
allergic asthma, indicating the importance of CARMA1 expression by 
lymphocytes in allergic asthma development (138). In another set of 
experiments, adoptive transfer of OVA-specific Th2 cells followed by 
OVA- inhalation did not induce eosinophilia, AHR or mucus hypersecretion 
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in STAT-6 deficient mice. These investigators found that the defect in 
STAT -6-dependent eotaxin production was responsible for the failure of 
eosinophilia in BAL fluid and administration of eotaxin intranasally 
reconstituted eosinophilia only (139). The role of Bcl6 in memory CD4 T 
cell generation was explored by adoptive transfer of Bcl6-deficient 
DO11.10 naïve CD4 T cells into BALB/c mice followed by immunization 
with OVA peptide and LPS (140). The authors examined the spleen, lung 
and liver 4 weeks after immunization and did not detect any transferred 
Bcl6-deficient KJ1.26+ CD4+T cells. This led them to further investigate 
whether the effector CD4+ T cells from Bcl6- deficient mice were 
functionally defective. They found same number of effector CD4+ T cells 
between Bcl6 deficient and WT CD4+ T transferred cells; however the 
percentage of apoptotic cells in Bcl6- deficient effector CD4 T cells was 
higher. Thus, suggesting the Bcl6 in CD4+ T cells plays a critical role in 
protecting precursors of memory CD4+ T cells and thus prolong the 
survival of memory CD4+ T cells (140). Another adaptor molecule TNFR-
associated factor (TRAF) 1 has been linked to the development of allergic 
asthma. TRAF1-/- mice fail to develop allergic asthma suggesting that 
TRAF1 expression by lung cells is pertinent for development of allergic 
asthma (141). 
In summary, the downstream signaling pathways in naïve and 
memory cells differ. Memory cells are maintained at a higher threshold 
allowing the memory cells to be rapidly activated upon stimulation.  
 
1.12. B cell memory and its role in allergic asthma 
B cell memory is characterized by rapid Ab responses upon Ag 
rechallenge higher IgG, IgA or IgE production, lower threshold for 
activation and increased Ag affinity (142). The generation of memory B 
cells is initiated in the T zone of secondary lymphoid organs after antigenic 
stimulation. Following antigenic stimulation, the B cells rapidly proliferate 
and differentiate into plasma cells (143, 144). During the first week, plasma 
cells produce mostly IgM, which has low Ag affinity. The memory B cell 
precursors proliferate and form germinal centers (GCs) in their secondary 
lymphoid organs, within the first 3 weeks following Ag exposure (143, 
144). The GCs serve as sites for the further differentiation of naïve B cells 
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to undergo proliferation and somatic hyper mutation of IgV region genes 
and isotype switching (143). The initial interaction of B cells with the Ag 
drives the selection and differentiation into memory B cells and plasma cells 
(143). The interaction of Ag and B cells drives selection and differentiation 
into memory B cells and plasma cells (145). The interaction of B cells with 
Ag activates and drives the selection and differentiation of B cells into 
plasma cells and memory B cells. The activation and recruitment of 
activated B cells into GC is Ag dependent (146, 147). Rapid clonal 
expansion of B cells in the B cell rich region results in the formation of 
secondary follicles (148). The germinal center can be distinguished into 2 
distinct regions: (i) the dark zone that consists of densely packed large 
lymphoid cells and few follicular dendritic cells (FDC); and (ii) the light 
zone where the lymphoid cells are smaller and loosely packed interspersed 
by a dense FDC network (148). The dark zone centroblasts clonally expand 
and the continuous somatic mutation of the variable region of the 
immunoglobulin results in variable B cells receptor (149). The centroblast 
expressing their diversified BCR exit the dark zone and enter the light zone 
where the interact with the FDC that have Ag–Ab complexes on their 
surface (150, 151). The memory B cells exit the GC and enter the 
circulating pool of lymphocytes, or home to the marginal zone of the spleen  
(148). 
The generation of B cell memory is T cell-dependent and the 
interaction between the B cell and T cell is critical for GC formation and 
generation of B cell memory (152).  Using a CD40 KO mice, CD40- 
CD40L interaction has been shown to be important in the generation of GC 
and in mounting an Ag specific humoral response (153). Korsgern and 
coworkers showed that mice deficient in B cells and immunoglobulin 
develop pulmonary and airway eosinophilia when subject to immunization 
and allergen challenge (154). 
 
1.13. The spleen as a secondary lymph organ that maintains memory 
Spleen is a secondary lymphoid organ with a constant influx of 
lymphocytes. Previous experiments from our lab demonstrated that spleen 
harbours memory Th2 cells that can be stimulated in vitro to produce Th2 
cytokines and could thus contribute to enhancing the allergic response (86).  
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There are reports suggesting that splenectomy results in decreased disease in 
a chronic relapsing experimental autoimmune encephalomyelitis (EAE) 
(155). Moreover, adoptive transfer of spleen lymphocytes from pre- treated 
mice to naïve mice results in transfer of relapsing EAE. (155). Although this 
paper showed that memory cells were harbored in the spleen and disease 
could be transferred through adoptive transfer, the experiments are not 
properly controlled for the disease (no positive for the disease shown). 
Work by another group showed that splenectomy has no effect on 
respiratory syncytial virus infection on the recall responses (156). Although 
most of the memory cells  ere present in the spleen after sensitization, but 
removal of spleen had no effect on the disease relapse (156). Torres and 
coworkers evaluated the effect of splenectomy on several strains on mice 
and the effect on plasma IL-10 levels following LPS injection (157). The 
authors found that the IL-10 production by peritoneal macrophages was 
elevated after LPS injection in splenectomized mice and the levels of TNF-a 
and IL-6 was decreased. The authors suggested a potential role of spleen in 
clearance of IL-10 and also a negative regulation of TNF-a and IL-6 by IL-
10 (157). 
 
1.14. CD4+ Th2 memory cells and allergic asthma  
The association of CD4+ Th2 cells and allergic asthma is evident 
from the production of Th2 cytokine upon disease induction. Using different 
allergen and various protocols the induction of allergic asthma has been 
shown to be regulated by Th2 cells (86, 158). Furthermore, blocking CD4+ 
T cells with anti-CD4 mAB GK1.5 prior to Ag exposure resulted in 
abrogation of AHR and eosinophilic infiltration (159). Li et al demonstrated 
that mice receiving hemagglutinin-specific Th2 cells induced eotaxin 
expression and eosinophilia that was not inhibited by the co-transfer of Th1 
cells. These results suggested the in a Th2 -mediated allergic lung 
inflammation, Th1- Th2 -mediated responses coexist (160). Mojtabavi et al. 
demonstrated that long-lived memory Th2 cells are maintained in the lungs 
of mice recovered from a single episode of allergic asthma (86). 
Removal of CD4 lymphocytes by irradiation should reduce disease 
in mice because of the decrease of CD4+ T and other immune cells. 
Sublethal irradiation allows the depletion of peripheral cells while still 
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maintaining the bone marrow to reconstitute the depleted cells 1-2 weeks 
post irradiation. Based on the early studies by Miller and coworkers who 
demonstrated that long lived lymphocyte and plasma cells are resistant to X- 
radiation (161), we wanted to test whether memory Th2 cells harboured in 
the lung could be depleted by sublethal irradiation and whether these cells 
are regenerated from the bone marrow. Studies on the inhibitory effect of 
irradiation on antibody production by Dixon et al. suggested that the Ag 
exposure prior to irradiation still results in antibody production. Irradiation 
followed by Ag exposure resulted in decreased antibody production (162).  
Additionally, there are reports demonstrating that repeated low doses of 
irradiation results in exacerbation of asthma. Splenocytes stimulated in vitro 
from the irradiated group produced higher IL-4 and IL-5 compared to 
unirradiated disease control (163). Sechler and co workers showed that the 
survival of T memory cells after sublethal gamma irradiation was 
determined by the Ag presentation by immunostimulatory APC (164). The 
authors found that accelerated graft rejection in irradiated mice was restored 
when the mice were infused with bone marrow cells expressing the priming 
Ag on APC and that this effect of rapid rejection was not seen when the 
priming Ag was on a nonstimulatory APC (B cell) (164). Mor and 
coworkers demonstrated that pretreatment of T cells with IL-2 increased 
their survival by increasing their apoptosis threshold and a dose dependent 
survival of T cells was observed with increasing dose of IL-2 (165). 
Treatment of T cells with IL-2 prior to irradiation protected the cells from 
radiation induced apoptosis. The workers demonstrated that the IL-2 can 
prevent the apoptosis of Ag-specific memory T cells by induction of bcl-2 
gene and production of Bcl-2 protein (165). Mueller and coworkers showed 
that the bcl-2, an anti- apopotic protein was strongly upregulated upon IL-
2R stimulation and thus was responsible for the survival of the helper T cell 
clones against radiation induced apoptosis. The authors suggested that 
intermittent expression of bcl-2 and bcl-x were important for the survival of 
memory T cells (166).  
 
1.15. Allergic asthma 
Allergic asthma is characterized by airway hyperreactivity, lung 
inflammation, lymphocytic and eosinophilic infiltration, mucus 
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hypersecretion, elevated serum IgE levels and reversible airway obstruction 
(167).  
Studies on animal models and information available from clinical 
studies on humans, indicate an important role for Th2 cells in allergic 
asthma (168). Following Ag presentation by Ag presenting cells (169, 170), 
the CD4+ T cells are activated and differentiate to Th2 helper cell (171). 
Th2 cells produce elevated levels of Th2 cytokines IL-4, IL-5, IL-13 and IL-
6. These cytokines result in IgE isotype switching (172), recruitment of 
eosinophils into the airway, AHR (173) and airway remodeling(174, 175). 
Cross- linking of the IgE receptors on the mast cells through FcR results in 
degranulation and release of inflammatory mediators such as histamines, 
leukotrienes and prostaglandins. Release of these mediators results in early 
asthmatic responses after Ag challenge which peaks at about 30 mins post 
challenge and subsided in 3 hrs (176). The main cytokine involved in the 
differentiation of naïve T cells to Th2 cells is IL-4 and the presence of IL-4 
regulates the further production of the cytokines, such as IL-5 and IL-13. 
IL-5 is mainly responsible for activation and degranulation of eosinophils 
during the allergic inflammatory response (177, 178). 
 
1.15.1. Pathogenesis of allergic asthma 
Asthma is a common respiratory disease with an increasing 
incidence in industrialized countries. The severity and mortality associated 
with asthma appears to be increasing in industrialized countries. 
 The cascade resulting in allergic asthma is initiated when allergen is 
taken up by APC followed by processing and presentation of immunogenic 
peptides through the MHC class II to CD4+ T cells. Naïve CD4+ T cells 
proliferate and clonally expand into Th2 cells (171, 179). Th2 cells are 
characterized by the high amounts of Th2 cytokines they secrete such as IL-
4, IL-5, IL-9 and IL-13 (180). Besides producing inflammatory cytokines, 
Th2 cells also help B cells to switch isotype to IgE and proliferate (172). 
The binding of soluble IgE to FcєRI on mast cells, basophils and 
eosinophils results in degranulation and release of vasoactive amines from 
these cells. Inflammatory mediators such as histamine, prostaglandin, 
leukotrienes, cytokines and proteloytic enzymes released by mast cells and 
basophils mediate airway smooth muscle contraction and mucus 
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hypersecretion (181, 182). The Th2 cytokine IL-5 mediates recruitement of 
eosinophils to lung resulting in the characteristic feature of lung 
eosinophilia (183).  The involvement of airway epithelium, and cells 
recruited to the lung during the disease such as eosinophils, activated T cells 
and alveolar macrophages secrete chemokines like RANTES, eotaxin and 
MIP1a which further aggravate the disease (184, 185). The milieu created 
by the production of inflammatory chemokines in the lung further promote 
recruitment of lymphocytes and other inflammatory cells and exacerbate the 
disease (186). In conclusion, Ag exposure has multiple consequences that 
include lung inflammation, mucus hypersecretion, edema and airway 
obstruction. 
 
1.15.2. Allergic asthma as an inflammatory disease 
Patients with allergic asthma after allergen provocation revealed the 
presence of inflammatory infiltration in BAL and lungs (187, 188) mast cell 
degranulation (189) suggesting that allergic asthma in an inflammatory 
disease. The consequences of these inflammatory processes are airway 
smooth muscle hyperplasia, airway damage, and mucus hypersecretion 
(190, 191). Studies based on mouse models that mimic allergic asthma also 
reveal the presence of inflammatory infiltrates 24 hrs after sensitization and 
allergen challenge (192). Besides infiltration there is also epithelial damage, 
mucus hypersecretion and edema in the airway (192, 193). There is presence 
of inflammatory infiltrates in perivascular and peribronchial areas of the 
lungs (192, 194). It is suggested that airway inflammation is followed by 
degranulation of mast cells after allergen challenge (154). The release of 
inflammatory mediators e.g. cysteinyl leukotrienes and histamine results in 
lung inflammation, mucosal edema (154, 192), and remodeling of the 
airway (195), defined by the airway thickening and subepithelial fibrosis 
with deposition of collagen and fibronectin. 
 An important event occurring early at the initiation of the 
inflammatory process is the elevated expression of cell adhesion molecules. 
Interaction of adhesion molecules like E- selectin, ICAM-1 and VCAM-1 
with their receptors on leukocytes results in migration of leukocytes to the 
site of inflammation and thus increases tissue damage (196, 197). Following 
allergen exposure, the increased expression of ICAM-1, ICAM-2, VCAM-1, 
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VCAM-2, selectins (L-, P-, E-), LFA-1 and CD11b by endothelial cells 
(198, 199) leads to the increased recruitment of leukocytes to the inflamed 
tissue (197, 199-201). To summarize, both human and mouse studies reveal 
that allergic asthma is an inflammatory disease characterized by presence of 
inflammatory infiltrates that result in tissue damage and remodeling of lung.  
 
1.15.3. Allergic asthma - a Th2 -mediated disease 
Experiments performed in late 1980s by Mosmann and Coffman 
demonstrated that CD4+ T cells can be classified into two subpopulations 
called Th1 and Th2 cells (180). This classification was based on the 
cytokine production profile by CD4+ T cells. Th1 cells produce IFNg and 
IL-12 but no IL-4 and IL-5 and were found to be involved in mediating 
protection against intracellular pathogens, whereas Th2 cells produced IL-4, 
IL-5, IL-6 and IL-13 but no IFNg (180). In addition to production of 
cytokines, Th2 cells provide help to B cells for production of IgE and IgG1 
(in mouse) and IgG4 (in humans) antibodies (202, 203). Studies performed 
on mice and data obtained from humans strongly suggest that allergic 
asthma is mediated by allergen-specific Th2 lymphocytes and their 
cytokines (204), (205, 206). Analysis of BAL from asthmatic patients shows 
an increase number of activated CD4+ T cells, eosinophil recruitment to the 
airway and increased transcript expression for Th2 cytokines IL-4 and IL-5 
(204). Additionally, elevated levels of IL-4, IL-5 and GM-CSF mRNA was 
also detected in the bronchial biopsies (204, 207, 208) and in T cells from 
BAL of allergic asthma patients (209). Findings in humans were mirrored in 
mouse models of allergic asthma (199, 210). Using mice deficient in CD4+ 
T cells it was demonstrated that CD4+ T cells are required for Ag-induced 
airway eosinophilia and AHR (159, 199, 210). Furthermore, Th2 cytokines 
are necessary for allergic asthma, as IL-4 and IL-5 KO mice failed to 
develop allergic asthma (211-213). Transferring Th2 cells into naïve 
syngenic mice followed by allergen aerosol challenge resulted in airway 
eosinophilia, mucus hypersecretion and AHR (214, 215). The role of Th2 
cells in allergic asthma was validated by the inability of Th2 cells derived 
from IL-4 KO to induce allergic asthma when transferred into naïve 
syngeneic mice, followed by aerosol challenge (215). Treatment with 
steroids results in increased IFNg levels with a subsequent decrease in IL-4 
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and IL-5 levels in BAL of asthmatic patients (216). Allergic asthma is also 
associated with an increase in activated CD4+ cell numbers, eosinophils and 
decrease in the peak expiratory flow rates in asthmatic patients (209, 217). 
Recently, it was demonstrated that treatment with anti-Tim-3 mAb reduced 
Ag-induced inflammation of the airway by skewing the response toward 
Th1 response (218). In summary, allergic asthma is a Th2-mediated disease 
that elicits a cascade of inflammatory processes leading to severe tissue 
damage and lung remodeling. 
 
1.15.4. Eosinophilia as a vital sign of allergic asthma disease 
A characteristic feature of allergic asthma is eosinophilia which is 
detected both in lungs and peripheral blood (187, 219, 220). Recruitment of 
eosinophils is mediated due to the expression of IL-5 (183, 221, 222), 
eotaxin (186, 223), and RANTES (186). After allergen exposure the 
maturation and growth of eosinophils occur in the bone marrow followed by 
migration to the lungs via blood (192, 224, 225). Eosinophils reach a peak 
24-48 hrs after aerosol challenge and can persist for upto 10 days (192). The 
severity of disease is correlated with the eosinophilic infiltration (192), 
(226, 227). The deletrious effects of eosinophil are mediated by the release 
of its chemical mediators. The contents of eosinophils are major basic 
protein (MBP), eosinophil peroxidase (EPO) and eosinophilic cationic 
protein (ECP), which have detrimental effect on the lung tissue (220, 228). 
Recently, the role of eosinophils in allergic asthma was debated by two 
groups showing conflicting results (229, 230). Lee and coworkers 
demonstrated that the eosinophils were critical for the airway 
hyperresponsiveness and mucus production, whereas Humbles and 
coworkers found no changes in the mucus production and AHR in the 
absence of eosinophils. Humbles et. al., however, claimed that eosinophils 
played an important role in the airway remodeling (229, 230). In summary, 
eosinophils are effector cells that cause severe pathogenic effect by directly 
acting on the lung.  
 
1.16. Role/Significance of IgE in allergic asthma 
IgE plays an important role in allergic asthma. The Ag specific IgE 
binds the FcR on the mast cells and a subsequent Ag challenge results in 
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cross-linking of the FcR and degranulation of mast cells. which causes early 
asthmatic reactions (231, 232). Additionally, IgE augements the Ag 
presentation capacity of B cells via its low affinity receptor, FcERII (CD23) 
(233, 234) and deviate the immune response towards a Th2 response by 
presenting allergen to T cells (235). 
 IgE is detectable in both soluble and in an Ag- IgE complex form 
(Ag-IgE). Soluble IgE results in recruitment of eosinophils into the airway, 
which can be reversibly inhibited by administration of anti -IgE antibody 
before allergen challenge (233). The severity of Ag – IgE complex was 
demonstrated by Zuberi and coworkers, who demonstrated that the Ag IgE 
complexes trigger extensive infiltrates into the airway compared to Ag alone 
(236). Besides causing inflammatory infiltration, passive transfer of Ag 
IgE/IgG1 complexes into naïve mice resulted in AHR and eosinophilia 
(237). In addition to eliciting inflammation, IgE has also been identified as a 
factor critical for mast cell survival (238). This survival mechanism was 
mediated by the binding of IgE to the FcERI on mast cells which suppresses 
apoptosis of mast cells (239).  
In contrast, to the work demonstrating the association of IgE in 
allergic asthma, there exists several data indicating that IgE is not required 
for induction of allergic asthma. Using µMT mice that lack B cells and 
antibodies, Hamelmann et al. demonstrated that AHR and eosinophilia 
development did not require B cells and immunoglobulins (240, 241). 
Similar results were shown by Korsgren et al. with the OVA induced 
eosinophilia in µMT mice (154). Using Aspergillus as an Ag Mehlhop et al  
induced AHR and eosinophilia in IgE KO mice, again demonstrating that 
IgE was not required for allergic asthma (242). IL-4 and IL-13 are critical 
cytokines that drive the production of IgE. Using transgenic mice lacking 
IL-4, IL-13, IL-4+IL-13 or the common receptor IL-4R , it was 
demonstrated the the serum IgE levels were undetectable under resting 
conditions. Peritoneal mast cells from IL-4-/- or IL-13-/- mice has partial 
decrease in surface IgE levels whereas IL-4 and IL-13 double deficient mice 
had severely deficiency of  surface IgE on peritoneal mast cells. Thus 
suggesting a role of IL-4 and IL-13 in IgE production (243). To conclude, 
induction of allergic asthma in humans is associated with IgE; however, in 
mice IgE does not seem to be critical for allergic asthma induction in mice.  
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1.17. Mucus hypersecretion as a clinical feature of allergic asthma 
Under normal physiological conditions, mucus in the lung maintains 
the viscoelasticity and aids in clearing of trapped inhaled particles. However 
mucus hypersecretion is a characteristic feature of allergic asthma. 
Hypersecretion of mucus results in plugging of the airway, thereby 
increasing the airway hyperresponsiviness and can be fatal (244, 245). IL-4 
mediates airway mucus production by Th2 cells. In vitro differentiated Th1 
and Th2 cells were adoptively transferred to naïve mice followed by aerosol 
challenge. The infiltration in the lungs of Th1 adoptively transferred mice 
consists mainly of neutrophils, lymphocytes and macrophages; whereas the 
infiltration of Th2 adoptively transferred mice consisted of eosinophils and 
lymphocytes (168). Transfer of Th1 cells did not induce mucus production 
upon aerosol challenge, whereas Th2 receiving mice had mucus-producing 
goblet cells in the airway (168). Furthermore, the in vitro differentiated Th2 
cells from IL-4-/- mice could induce mucus production in WT mice 
suggesting that IL-4 has a role in infiltration but not in mucus production. 
(168). By disrupting the IL-4R  gene in Clara cells that give rise to mucus-
producing goblet cells, it was demonstrated that both WT and Clara cell-
specific IL-4R - mice developed similar levels of serum IgE, airway 
inflammatory cell numbers, AHR and produced Th2 cytokines following Ag 
sensitization and challenge (246). However, absence of mucus production 
was observed in Clara cell-specific IL-4R - mice (246). The effect of IL-13 
was shown to directly act on lung airway epithelium to result in mucus 
hypersecretion and blocking IL-13 resulted in decreased mucus production 
(247). The exact mechanism for mucus hypersecretion is not completely 
understood, but it seems that decreased expression of Bax gene by the 
airway epithelial cells of asthmatic patients allow mucus-producing cells to 
not undergo apoptosis (137). 
 
1.18. Airway hyperresponsiveness 
Airway hyperresponsiveness (AHR) is an increased ability of the 
airways to narrow after exposure to constrictor agonists. AHR 
responsiveness is one of the cardinal features of allergic asthma. The exact 
mechanism underlying the development of AHR is not known however 
 30 
there is evidence suggesting the association of Th2 cells and eosinophils 
(248, 249). There is involvement of NFkB/ Rel transcription factor that 
promotes allergic airway inflammation and increase the expression of 
inflammatory chemokines that are critical in induction of AHR (250). 
Beside Th2 cells that are involved in mediating AHR, Akbari and coworkers 
showed NKT cells are also contribute to AHR in mice (251). Using a 
CD1d1-/- KO mice that lack NKT cells, they showed that CD1d1-/- mice fail 
to develop AHR and adoptive transfer of NKT cells restored AHR in 
CD1d1-/- mice (251). iNKT cells were also shown to play a role in  
induction of AHR. Meyer and coworkers demonstrated that iNKT-mediated 
AHR by using CCR4 for migration to the lung (252). Bilenki and coworkers 
using a CD1d KO mice model of ragweed allergic asthma model 
demonstrated that in absence of NKT cells there was reduced pulmonary 
eosinophilia and mucus production (253). Furthermore, these mice had 
lower ragweed- specific IgE and IgG1 responses (253). Data demonstrating 
the importance of CD4+ T cell derived IL-13 in the induction of AHR by 
adoptively transferring OVA-specific CD4+ T cells from IL-13-/- mice 
(254). There was absence of AHR, eotaxin production and lung eosinophilia 
in the mice adoptively transferred with OVA-specific I CD4+ T cells from 
IL13-/- mice. Furthermore IL-13+/+ T cells failed to induce disease in STAT6 
deficient mice, indicating that the IL13 receptor involves the STAT 6 
signaling pathway (254). Furthermore, data suggesting the critical role of 
IL-13rα1 in mediating AHR was shown by using IL-13rα1-/- mice. IL-13rα1 
was shown to by essential for IgE production and AHR, mucus, eotaxin and 
TGF-b production was also IL-13rα1 dependent (255). Another cytokine 
that is secreted by Th2 cells is IL-9 (256). However in IL9-/- mice there was 
no difference in the extent of eosinophilic inflammation and AHR 
suggesting that IL-9 was not required for AHR induction in mice (257).To 
summarize, induction of AHR involves the interaction of several cells type 
and is primarily mediated by IL-13. 
 
1.19. Chemokines are important in inflammatory disease and allergic 
asthma 
Chemokines belong to the family of cytokines that are secreted by 
cells and chemotactically attract cells towards the cell producing the 
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chemokine (258). Chemokines play an important role in inflammatory cell 
recruitment during inflammation. By adoptively transferring Th2 cells in a 
mouse model of allergic asthma, Lloyd et al. demonstrated that eotaxin / 
CCR3 and Monocyte- derived chemokine (MDC) /CCR4 are involved in the 
homing of Th2 cells to the lung after Ag challenge (259). Interestingly, after 
the initial Ag challenge, eotaxin and CCR3 contributed primarily to the 
acute phase of the disease and MDC and CCR4 were involved continuous 
recruitment of allergen specific Th2 cells in later stages of the disease. This 
suggested a sequential role of chemokines and their receptors during 
different phases of allergic asthma (259). Furthermore, eotaxin KO mice 
had partially reduced eosinophilia upon Ag challenge, suggesting the 
importance of eotaxin in mediating inflammatory processes (260). MacLean 
and coworkers found that of the 3 main eosinophils attracting chemokines 
MIP1a, RANTES and eotaxin, only eotaxin and MIP1a mRNA was elevated 
after Ag-induced pulmonary eosinophilia (261). Furthermore, treatment 
with anti-CD3 mAb prior to challenge inhibited the expression of eotaxin 
and not of MIP1a and RANTES and significantly reduced the lung 
eosinophilia (261). Thus, indicating that eotaxin was involved in Ag-
specific T cell activation and recruitment of eosinophils to the lung after Ag 
challenge (261). Yang and coworkers showed that absence of eotaxin did 
not affect the migration of eosinophils in a mouse model of OVA - induced 
allergic asthma (262). The investigators used eotaxin KO mice and induced 
allergic asthma in mice and found that eotaxin KO mice also recruited 
eosinophils to the lung (262). Absence of eotaxin affected the early 
recruitment of eosinophils but 48 hrs after the aerosol challenge no 
difference could be seen between the WT and eotaxin KO mice (262). These 
investigators also reported that WT mice had expression of eotaxin in the 
lung at 6 hrs after the aerosol challenge (262). The role of RANTES was 
demonstrated by using a transgenic mouse that over expresses the 
chemokine RANTES in the lung (263). In this transgenic mouse there was 
increased neutrophilia in the lung suggesting that RANTES was primarily 
involved in mediating migration of neutrophils in the allergic lung (263). 
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1.20. Chemokine receptors involved in allergic asthma 
Chemokine receptors (CKRs) are transmembrane G protein coupled 
receptor that play a role in leukocyte migration (264). CKRs have been used 
to differentiate Th1 and Th2 cells depending on the CKRs these cells 
express. CCR1, CCR5 and CXCR3 are Th1 associated CKR, whereas 
CCR3, CCR4, CCR6, CCR8 and CRTH2 are associated with Th2 cells 
(265, 266). CKRs also enable cells to differentially migrate to lymphoid and 
non lymphoid tissues. CKRs that mediate homing to extra-lymphoid tissue 
or sites of inflammation are CCR2, CCR1, CCR5, CCR6, CXCR3, CXCR4 
and CXCR6, and the CKRs that mediate homing to lymphoid tissue are 
CCR7 and CXCR5 (264). 
The involvement of a single CKR in allergic asthma is unclear 
mainly due to the involvement of various cell types harboring different 
CKRs on their surface. However, researchers have been attempting to 
characterize the CKRs that have a pivotal role in allergic asthma in both 
humans and animal models of allergic asthma. While human studies 
involving BAL or peripheral blood obtained from asthmatic patients (50, 51, 
52) provides information about the CKR expression during ongoing disease, 
animal models of allergic asthma allow the investigators to examine the role 
of individual CKRs by using KO  mice as a tool (53, 54, 58).  
 Studies on asthmatic patients have been limited and contradictory. 
Campbell et al. found no differences in the CKR expression patterns on lung 
T cells between the asthmatics and normal human subjects (267). However, 
results from Thomas et al. on the CKR expression in asthmatic patients, 
before and after allergen provocation indicate that the T cells that infiltrate 
the lung during allergen challenge were CCR6+ and CXCR3+ in the BAL 
(268). Another study, done on human asthmatic peripheral blood memory 
cells showed no upregulation of CCR3, CCR5, CCR8 and CXCR3 after 
allergen challenge (59). These authors took peripheral blood from normal, 
asymptomatically sensitized and allergic rhinitis patients and stimulated the 
cells in vitro for 7 days. They found no change in the percentage of CCR3+ 
memory Th cells between the groups and allergen stimulation did not 
induce any changes in the CCR3, CCR8 and CXCR3 expression (59).  
With the availability of KO mice for several CKR receptors, 
investigations are underway to identify critical CKRs that could potentially 
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serve as targets for treating allergic asthma. Studies on CCR4 KO mice 
showed that CCR4-deficient mice develop less airway eosinophilia and 
bronchial hypreresponsiveness following Ag challenge (269). Another study 
on CCR8 KO mice demonstrated that CCR8 KO mice develop airway 
inflammation and therefore CCR8 was not necessary for development of 
allergic airway inflammation. The CCR8-/- mice developed similar 
eosinophilia, IgE as WT mice. Also the CCR8-/- had elevated IL-4, IL-5 and 
IL-13 in BAL (270). Another study using the CCR8 KO mice showed that 
there these mice developed airway disease to the same extent as the WT 
mice (271). WT and CCR8-/- mice had increased IL-4, IL-5 and IL-13 in 
sera (271). WT mouse had elevated levels of CCR8 and its associated 
ligands (CCL1/TCA3) therefore CCR8 was blocked in the WT mice by i.p. 
administration of mAb 8F4 given before Ag challenge (271). There was no 
reduction in disease in mice treated with the mAb (271). Wendland et al 
demonstrated that plasmacytoid DC (pDC) express CCR9 which was 
important for migration of pDCs to small intestines (272). Invariant NKT 
(iNKT) cells from human asthmatic patients express CCR9, which is not 
expressed on iNKT cells from normal humans (273). These CCR9 
expressing iNKT cells could induce CD3 T cells to a Th2 bias by signaling 
through CD226 (273). Robays and coworkers used mixed bone chimeric 
mice to show that the CCR2 controlled the migration and accumulation of 
pulmonary DC in allergic lung inflammation (274). In this study CCR2 was 
demonstrated to mediate the egress of monocytic DC precursors into the 
blood stream (274). The authors also investigated the role of CCR5 and 
CCR6 contribution in DC migration and found that these CKRs (CCR5 and 
CCR6) did not contribute to DC migration in their model of airway 
inflammation (274). Similarly, mice that are deficient in CCR6 (CCR6-/-) 
exhibited decreased inflammatory responses that was due to reduced 
pulmonary DC numbers (275). In another study, the investigators observed 
a reduced early accumulation of lung DCs in mice that were CCR2 deficient 
and CCR6 deficient (276). CCR2 apparently plays a role in activation and 
maturation of DCs because in the absence of CCR2 these functions 
(activation and maturation) were impaired (in CCR2-/- mice) (277). In 
addition, selective blocking of CCR1 and CCR5 using antagonists 
effectively blocked the recruitment of DC precursors into resting airway 
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epithelium and upon bacterial challenge (278). Lukacs and coworkers found 
that CCR6 KO mice had reduced AHR, less eosinophilia, less IL-5 and 
decreased IgE levels (279). Their findings demonstrate the importance of 
CCR6 (which is present on several cell types e.g. memory T cell, DC and B 
cells) in mediating allergic inflammation by affecting several cell types 
(279). Osterholzer and coworkers showed that DC migration was 
independent of endothelial selectins in response to particulate Ag (276). 
They found that CCR2 -mediated the early recruitement of DC into the lung 
interstitum and CCR6 contributed later in the migration and transit of DC 
across epithelia into the airway. Role of CCR9 has been associated with the 
migration of NKT cells in allergic asthma (280). CXCR2 is expressed on 
neutrophils and is a marker of inflammation (280, 281) was shown to be 
necessary for the development and persistence of chronic fungal asthma in 
mice (281). CXCR3 a Th1 marker highly expressed on lung T cells was 
increased in OVA sensitized mice had in addition to higher expression of 
CCR5 and CCR3 in the lung (282). Furthermore, targeting of CXCR3 using 
a molecule TAK- 779; blocked CCR5 and CXCR3 and reduced pulmonary 
inflammation by decreasing the gene expression of IFN g and TNF- alpha 
(282). Another CKR that is expressed in human and is preferentially 
expressed on memory and effector T cells, NKT and NK cells is CXCR6 
(283). The ligand of CXCR6; CXCL16 is expressed in the lung (284). 
CXCR6 plays a role in the homeostasis of T cell in the lung, because there 
were no differences in the expression of CXCR6 in the lung of normal and 
asthmatics (285). CXCR6 is expressed on 4-6% CD4+ T cells in blood, 
spleen and LN majorly on memory cells (286). Meyer and coworkers 
recently demonstrated that the iNKT cells are involved in the induction of 
AHR and iNKT cells required CCR4 for migration to the lung and induction 
of AHR (252). These investigators used 2 models of allergen-induced and 
glycolipid-induced models of AHR and demonstrated that  wild-type but not 
CCR4-/- mice developed AHR (252). Furthermore, reconstituting the iNKT 
mice with iNKT cells of WT by adoptive transfer resulted in AHR in the 
iNKT mice (252). It was also reported that most of the NK cells in humans 
primary cells lines express CXCR1, CXCR3, and CXCR4 (287), thus NK 
cells harboring these CKR could play an important role in allergic asthma . 
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CRTH2 (also called DP2) is a PGD2 receptor that is expressed on 
Th2 cells, eosinophils and basophils. Studies on CRTH2 KO mice by 
Chevalier and coworkers demonstrated that CRTH2 KO mice had elevated 
lung eosinophilia and produced more IL-5 compared to WT mice (288). 
They, thus, suggested that CRTH2 has a role in restricting eosinophil in 
allergic asthma (288). In an another approach to demonstrate the role of 
CRTH2 in allergic asthma, Fujitani and coworkers used a transgenic mouse 
that over expressed prostaglandin D synthase and found that the transgenic 
mice developed increased lung eosinophilia (289). High levels of Th2 
cytokines were also detected in the lung of prostaglandin D synthase 
transgenic mice (289). The authors thus concluded that the PGD2 released 
from mast cells and whose major receptor is CRTH2 is involved in allergic 
asthma.  
T1/ST2 is an IL-1 receptor homologue and has been described as a 
marker for Th2 effector cells (290, 291). However, T1/ST2 signaling has 
also been shown to have no effect on the Th2 cytokine production (blocking 
the signaling had no effect on the Th2 cytokine production and both treated 
and untreated group had same IL-4, IL-6 levels) however, the IFNg 
production was increased. There was no difference in the production of IL-4 
and IL6 by the CD4+T1/ST2+ or T1/ST2- subset (292). Furthermore, 
analysis of T1/ST2 KO mice showed no reduction in IL-4, IL-5 IL-10 and 
IFN- g production and that T1/ST2 is not essential for development of naïve 
T cells to Th2 cells (293). The T1/ST2 KO mice however, failed to develop 
primary synchronous pulmonary granuloma when injected i.v. with S. 
mansoni indicating the impairment of early Th2 reactions in T1/ST2 KO 
mice. The secondary granuloma formation in the KO mice was comparable 
with WT however the Th2 cytokines IL-4 and IL-5 were significantly lower 
in the KO mice (293). T1/ST2 has also been used to distinguish 2 
populations that produce IL-5 upon in vitro stimulation (294). CD4+ 
T1/ST2+ and T1/ST2- cells were sorted and stimulated in vitro. Both 
T1ST2+ and negative cells produce IL-4. T1/ST2- cells make IFNg in 
addition to IL-4. IL-5, however, is produced only by T1/ST2+ cells. The 
T1/ST2- cells produce no IL-5. So production of IL-5 by T1/ST2+ cells can 
be used as a marker to distinguish these cell types. GATA-3 was expressed 
by both T1/ST2+ and T1/ST2+ cells (295). Another study showed that after 
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repeated stimulation under Th2 conditions the T1/ST2 is expressed on the 
surface of Th2 cells; at early stimulation time points the IL-4+ cells were 
T1/ST2- but after repeated stimulation on the IL-4+ cells also acquired 
T1/ST2+ expression (296). T1/ST2+ cells made more Th2 cyotkines 
compared to T1/ST2- cells after stimulation and production of IL-4 was 
correlated with IL-10 production in both T1/ST2+ and T1/ST2- fraction 
(296). Furthermore, Addition of IL-6 increased the expression of T1/ST2 
most when the CD4 + T cells were polarized under Th2 conditions and 
supplemented with IL-6, IL-5, IL-1b and TNF-α also increased the 
expression of T1/ST2 but the effect was minimal. Although IL-6 increased 
the expression of T1ST2, it is not required for T1/ST2 production because 
IL-6-/- mice and their heterozygous littermates had similar CD4+ T1/ST2+ 
cells. Furthermore, LN cells from both these mice when polyclonally 
stimulated had similar IL-4 and surface T1/ST2 expression. These authors 
also found that the expression of T1/ST2 was independent of stimulation 
from APC or cell-cell contact btw T cells and APC. When in vitro polarized 
Th2 cells were incubated on plates coated with anti T1/ST2 antibody the 
Th2 cells proliferated and produced more IL-4 and IL-5. This was seen only 
for Th2 cells and not for Th1 cells (296). In humans, however, the 
expression of ST2 is shown to be inducible and expressed only by activated 
Th2 cells. Resting human T cells do not express ST2 (297). These authors 
showed that freshly isolated peripheral CD4+ T cells don’t express ST2. 
Another group used OVA transgenic mice or crossed OVA transgenic 
mouse to ST2- mice to get OVA transgenic ST2- T cells. T cells from these 
mice were polarized in vitro under Th2 conditions and then injected i.v. into 
a mice that was OVA primed. Upon aerosol challenge of recipient mice, the 
mice that received ST2+/+ Th2 cells had less inflammation, eosinophilia ( in 
both BAL and lung) and mucus production compared to mice that received 
ST2-/- cells (298). The pattern of CKR expression changes with age. Aging 
was associated with expression of CCR1, 2, 4, 5, 6, 8 CXCR2, 3, 4, 5 and 
decreased expression of CCR7 and CCR9 on CD4 T cells. Stimulation of 
CD4+T cells from old mice (20-22 months old) resulted in down regulation 
of the CCR1, 2, 3, 5, 9 CXCR2-5 (299). 
In summary, human studies indicate the importance of CKRs in 
allergic asthma and CCR6 and CXCR3 have been demonstrated to 
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contribute to the pathogenesis of allergic asthma. Mice models of allergic 
asthma have been instrumental in identifying not only the CKRs involved in 
the disease pathogenesis but also the dissecting the role of various cells 
marked by various CKRs. Although there is evidence for role of CKRs in 
ongoing allergic asthma the role of CKR in maintenance of Th2 cells is 
lacking. 
 
1.21. Treatment of Th- memory cell exacerbations and chronic allergic 
asthma 
1.21.1. Gluocorticoids 
Glucorticoids are a class of steroid hormone that binds to the 
cytosolic gluocorticoid receptor. Binding of the glucocorticosteroid to the 
cytolic receptor results in the translocation of the receptor ligand complex 
into the nucleus, where this complex exerts its effect. The receptor ligand 
complex can either binds to the glucocorticoid response elements in the 
promoter region of the target genes and thus upregulate the expression of 
the gene or the receptor ligand interacts with the other transcription factors 
like NF-kB, STATs and activator protein-1 (300). Mathur and coworkers 
demonstrated that treatment with dexamethasone  reduces eosinophilic 
inflammation and AHR in a mouse model of allergic asthma (301). They 
further showed that treatment with TRFK-5, an anti-IL-5 mAb. reduced 
airway eosinophilia with  no effect on the established AHR (301). Recently, 
Zhao and coworkers demonstrated that administration of dexamethasone  
results in down regulation of chitinases, lungkine, and gob-5 and increased 
expression of Vitamin D binding protein, suggesting a novel anti 
inflammatory action for dexamethasone  (302). Steroids have a direct effect 
on T cell activation and suppress cytokine expression in the airway of 
asthmatics (303-306). The mechanism of inhaled corticosteroids appears 
mainly by inhibiting T cells recruitment in the airway (307-309). 
Corticosteroids inhibit TCR driven apoptosis of T cells (310). Withdrawal 
from steroids is often associated with disease relapse with increased lung 
eosinophilia and airway T cells (311). Long-term treatment with 
corticosteroids however can increase the Th2 cytokines (312). The efficacy 
of corticosteroid treatment also varies with the stage of disease. 
Jungsuwadee and coworkers demonstrated that administration of inhaled 
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dexamethasone has differential effect during overt and relapse allergic 
asthma disease. dexamethasone  efficiently reduced AHR during both 
relapse and overt disease (313). Furthermore, there was less mucus 
production and OVA-specific IgG1 and IgE in mice treated with 
dexamethasone during relapse compared to mice treated during overt 
disease. However, there was reduced infiltrates in mice treated with 
dexamethasone during overt compared those treated during relapse. This 
suggested that dexamethasone has an effect on infiltrating leukocytes (313). 
 
1.21.2. Inhaled beta 2 agonist 
Inhaled beta 2 agonists are drugs that dilate the bronchial tubes in 
the lungs. The mechanism of action of bronchodilaters involves the 
stimulation of beta 2 receptors in the airway, which allows airways muscles 
to relax and expand (314). This dilation permits more air to pass through the 
lungs. Depending on the duration of action of inhaled beta – agonists are of 
2 types: short acting beta 2 agonist (315), that have an effect lasting for few 
hours and usually used for immediate relief (e.g. salbutamol) and long 
lasting beta -2 agonists (eg. salmeterol) (316) that are used on a continual 
basis to be effective and their effects last for several hours.  
 
1.21.3. Omalizumab 
Omalizumab is a recombinant humanized anti IgE mAb used for 
treatment of allergic asthma. The drug is delivered subcutaneously. 
Omalizumab binds to free IgE and thus, inhibits binding of IgE to the high 
affinity IgE receptor FcERI. This mAb has been used successfully to treat 
severe cases of allergic asthma (317). It has also been demonstrated that 
allergic asthmatics who remain symptomatic despite being on inhaled 
corticosteroid tolerated treatment with Omalizumab and showed less 
dependence on inhaled corticosteroid (318). This drug is well tolerated by 
children as well (319). 
 
1.21.4. Chemokine receptor antagonists 
Allergic asthma pathology involves the coordination of eosinophils, 
mast cells, T cells and APCs. These cells have CKRs on there cell surface 
which enables them to be recruited to the site of inflammation in response to 
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chemokines. The presence of CKRs on these cells could be used as a 
potential marker to target these cells. Currently, the approach has been to 
block CCR3 and CCR4 due to the presence of these receptor on eosinophils, 
mast cells, basophils, macrophages, activated T cells (CCR3) and 
monocytes and Th2 cells (CCR4)(320, 321).  Another area of intense 
research is the neutralization of chemokines associated with allergic asthma. 
Neutralizing either TARC (CCL17)(322) or MDC (CCL 22)(70) has been 
demonstrated to decrease airway inflammation and AHR in mice.  
Currently, there are 2 molecules that block CKRs. AMD3100 is an 
antagonist of CXCR4 and reduces AHR, peribronchial eosinophilia, reduced 
IL-4 and IL-5 and increases IFNg and IL-12 (323). AMD3100 was 
delivered through an osmotic pump before in challenge. The authors 
demonstrate that the decrease in lung inflammation was due to decrease in 
the migration of the leukocytes to the lung and altered CD4+ T cell 
migration. CCL22, CCL17 were significantly reduced after treatment with 
AMD3100 (323). However, this study was done on an ongoing disease 
model, whether AMD3100 can also abolish Th2 memory cells in the lung is 
not shown. Another molecule that blocks CCR5 and CXCR3 is TAK -779. 
OVA sensitized mice had higher expression of CCR5, CCR3 and CXCR3 in 
the lung. The authors targeted CXCR3 using a molecule TAK- 779 that 
block CCR5 and CXCR3 and found reduced pulmonary inflammation. 
However, only data from RT PCR was shown and TAK 779 could only 
decrease gene expression of IFN g and TNFa and not IL-4  and IL 13 
expression (282). 
 
1.22. Aim of the study 
 Several factors influence the maintenance and survival of memory 
cells. CKRs have been implicated to mark memory cells. We investigated 
whether CKRs play a role in maintenance of pathogenic Th2 cells in a 
mouse model of allergic asthma leading to exacerbation. Additionally, to 
further characterize pathogenic Th2 cells in the lung, we investigated the 
role of spleen in maintenance of memory Th2 cells.  
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2. Materials and methods 
2.1. Animals 
Six to 8 week-old female BALB/c or B6 mice, maintained in the 
pharmacology facility and provided OVA-free food and water ad libitum 
were used in all experiments. All experimental protocols complied with the 
requirements of Austrian Ministry of Science. 
 
2.2. Apparatuses and instruments 
Aerosol nebulizer (Kendall aerodyn) 
Beckman GS- 6KT centrifuge (Beckman, Munich, Germany) 
Balance (Sartorius, Vienna, Austria) 
Cooling centrifuge (eppendorf) 
Cytospin (Shandon Scientific Ltd., England) 
Dissection board 
Forceps 
Freezers -20°C (Liebherr, Bischofshofen, Austria) 
Hemocytometer (Neubaur) 
Homogenizer Ultra Turrax, T25 Basic (IKA Laboetechnik) 
Incubator (Heraeus Instruments) 
Laminar flow (Heraeus Instruments) 
Milk (Fixmilch, Maresi, Dried milk powder, under 1.5% Fat) 
Microscope (Nikon Eclipse 80i) 
Microwave (Daewoo) 
PCR machine Master cycler gradient (Bio RAD) 
Imager (Lumi Imager, Boerrhinger Mannheim) 
Refrigerator (Liebherr) 
Scissors 
Water bath ( Geprg Albrecht Labortechnik) 
Vortex (Genie) 
ELISA plate reader: Molecular Devices, SpectraMax M5. The software for 
the reader is Soft Max Pro 4.8.  
Theratron 780  
FACS Calibur (BD) 
Electrophoresis apparatus (Bio Rad) 
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2.3. Plastic materials 
Centrifuge tubes (Falcon, New Jersey, USA) 
Cytofunnel (Shandon Scientific Ltd, England) 
Flow cytometry microtubes (Micronic, Lelystad, The Netherlands) 
Microtitre plate 96 wells flat bottom (Nunc, Roskilde, Denmark) 
Needles 27G 3/4  
Pediatric cathetor (BD Venflon IV cannula, 22GA 0.98IN, 0.8 x 25mm, 31 
ml/min). 
Corning Incorporated COSTAR 3516, 6 well cell culture cluster fat bottom 
lid, tissue culture treated. 
Pipettes (Costar, Cambridge, USA) 
Sterile tips 
Sterile filters Millex- GS (Millipore S.A., Molsheim, France) 
Syringes  
Plastic cryomold (Sakura, Tissue-Tek Cryomold Standard, 4557, 
25mmx20mmx 5mm) 
 
2.4. Glassware 
Beakers 
Cover slips 
Coplin jars 
Funnels 
Glass bottles 
Homogenizer (glass) KONTES  
Reservoirs 
Slides (Menzel) 
Slides (Starfrost) 
 
2.5. Reagents 
Acetone 
Agarose (GibcoBRL) 
Antibodies: 
CD3 PE (clone 145/2C11, BD Pharm) 
CD 3 Cy 5 (clone 500A2, Caltag) 
CD4 PerCP (clone RM4-5, BD) 
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CD8a FITC (clone CT-CD8a, CALTAG) 
CD44 APC (clone IM7, BD Pharm) 
CD45R APC (Caltag) 
CD45R PE (BD Pharmingen) 
CD62L FITC (clone MEL-14, BD Pharmingen) 
CD62L-biotin (clone MEL-14, eBioscience) 
CCR3 AF 647 (clone 83103, BD pharmingen) 
CCR4- pure (Novus Biologicals) 
CCR5 PE (clone C34-3448, BD pharmingen) 
CCR6 AF647 (clone 140706, BD) 
CCR7 PE (clone 4B12, eBioscience) 
  CCR8 pure (polyclonal, Novus Biologicals) 
CCR9 PE (clone 242503, R&D Systems) 
CCR10 PE (clone 248918, R&D Systems) 
CXCR2 PE (242216, R&D System) 
CXCR3 PE (clone 220803, R&D Systems) 
CXCR4 PE (clone 2B11/CXCR4, BD pharmingen) 
CXCR5 PE (clone 2G8, BD pharmingen) 
CXCR6 PE (clone 221002, BD pharmingen) 
CX3CR1 (pure, ProSci) 
CRTH2 PE (clone BM16, Milteni Biotec) 
MHC class II PE (clone M5/114.15.2, BD Pharmingen) 
T1/ST2 FITC (clone DJ8, MD Bioscience) 
Swine anti goat IgG (H+L) R-PE (CALTAG) 
Goat anti rabbit AF 647 (Invitrogen) 
Albumin from bovine serum (BSA) minimum 96% electrophoresis (Sigma ) 
Biotinylated anti- mouse IgE clone R35-92 (Pharmingen) 
Blue juice (10X) Gel loading buffer (Invitrogen) 
Chicken ovalbumin grade V ( Sigma – Aldrich Chemie GmbH) 
Chloroform (for spectroscopy), Merck 
Collagenase I (Gibco, Invitrogen) 
2’- Deoxynucleoside 5’- Triphosphate ( Amershan Pharmacia biotech) 
2´ Deoxyadenosine 5´ triphosphate, 100mM solution, (100µM) (Amersham 
Pharmacia Biotech. Inc.) 
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2´ Deoxyguanosine 5´ triphosphate, 100mM solution, (100µM) (Amersham 
Pharmacia Biotech. Inc.) 
2´ Deoxythymidine 5´ triphosphate, 100mM solution, (100µM) (Amersham 
Pharmacia Biotech. Inc.) 
2´ Deoxycytidine 5´ triphosphate, 100mM solution, (100µM) (Amersham 
Pharmacia Biotech. Inc.) 
3.3’- Diaminobenzidine ( Sigma – Aldrich Chemie GmbH) 
Diethyl pyrocarbonate (DEPC), Calbiochem) 
Diethyl pyrocarbonate (DEPC), Calbiochem 
DNA ladder 100bp (Invitrogen) 
DNase I ( Sigma- Aldrich Chemie GmbH) 
DTT (Promega) 
Eosin Y: Sigma 
Ferric chloride (iron (III) chloride hexahydrate, (Sigma) 
Fetal calf serum (FCS, GIBCO) 
Formaldehyde (Neuber, Vienna, Austria) 
Giemsa solution (Merck GmbH, Darmstadt, Germany) 
Goat anti mouse IgG1 – biotin (Southern biotechnology associates Inc., 
Birmingham, USA) 
HCl (Merck) 
Hematoxyline: Sigma Aldrich Hematoxylin solution, Gill No. 3 
Immersion oil (Sigma) 
Isopropanol, Merck 
IL-4- minikit, 40 x 96 test (Endogen) 
IL-5- minikit, 40 x 96 test (Endogen) 
IFNg- minikit, 40 x 96 test (Endogen) 
Ketanest (Pfizer) 
Lithium carbonate (Li2CO3, Merck) 
Lympholyte M (Cederlane laboratory) 
Lysis solution (BD) 
May- Gründwald solution (Sigma) 
Mercaptoethanol (Sigma) 
Methanol (Merck GmbH) 
Milk (Fixmilch low fat milk powder, Maresi, Austria) 
Mounting media: Eukitt (O. Kindler GmbH and Co., Germany 
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n-butyl acetate (Merck GmbH, Germany) 
o-Pheneylenediamine dihydrochloride (OPT) ( Sigma, Germany) 
(Oligo DT)12-18 Primer (Invitrogen)  
Papanicolaous solution 1a Harris hematoxilin solution (MERCK) 
Periodic acid (FLUKA Chemika) 
Penicillin Sterptomycin (Gibco, Invitrogen) 
Phosphate buffered saline (Gibco) 
Phenol -Chloroform -Isoamyl Alcohol, 25:24:1 (Sigma) 
Primers XCR1 sense 5'-CATCCCTGATGCTGTCTTCCA C-3' 
XCR1 antisense 5'-AATGAGAGAAGGCCAAATGGCG-3' (Invitrogen) 
Primer CXCR2 sense 5'-AACAGTTATGCTGTGGTTGTA-3'  
CXCR2 antisense 5'-CAAACGGGATGTATTGTT ACC-3' (Invitrogen) 
Primer CXCR3 sense 5'-GAACGTCAAGTGCTAGATGCCTCG-3'  
CXCR3 antisense 5'-GTACACGCAGAGCAGTGC G-3' (Invitrogen) 
Primer CXCR4 sense 5'-AAACGAAGCGGAAACTAGAGCC-3'  
CXCR4 antisense 5'-GCCCAGCTTGGTCAGAAGCC-3' (Invitrogen) 
Primer CXCR5 sense 5'-AAA CGA AGC GGA AAC TAGAGCC-3' 
CXCR5 antisense 5'-GCC CAG CTT GGT CAG AAG CC-3'(Invitrogen) 
Primer CXCR6 sense 5'-AGC CTA CCC CAC AAC TAC AGA A-3'  
CXCR6 antisense 5'-CTT GTA GGG GAA ATG AGG GCT A-3' 
(Invitrogen) 
Primer sense CCR2 5'-GGT CAT GAT CCC TAT GTG G-3'  
CCR2 antisense 5'-CTG GGC ACC TGA TTT AAA GG-3' (Invitrogen) 
Primer CCR3 sense 5'-TGG GCA ACA TGA TGG TTG TG-3'  
CCR3 antisense 5'-GCT GTC TTG AGA CTC ATG GA-3' (Invitrogen) 
Primer CCR4 sense 5'-CCA AAG ATG AAT GCC ACA GAG-3' 
CCR4 antisense 5'-CCT TAC AAA GCG TCA CGG AAG-3' (Invitrogen) 
Primer CCR5 sense 5'-GCT GAA GAG CGT GAC TGA TA-3' 
CCR5 anti sense 5'-GAG GAC TGC ATG TAT AAT GA-3' (Invitrogen) 
Primer CCR6 sense 5'-GGG CAA CAT TAT GGT GGT GAT GAC-3' 
CCR6 antisense 5'-ACC GCA GTC ACG AGG AGG ACC ATG-3' 
(Invitrogen) 
Primer CCR7 sense 5'-ACA GCG GCC TCC AGA AGA ACA GCG G-3' 
CCR7 antisense 5'-TGA CGT CAT AGG CAA TGT TGA GCT G-3' 
(Invitrogen) 
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Primer CCR8 sense 5'-CGA TGG AGC CCA ACG TCA CG-3' 
CCR8 antisense 5'-GTG CTT GGA TGA CTT CTT GG-3' (Invitrogen) 
Primer CCR9 sense 5'-TGC TGA TCT GCT CTT TCT TG-3' 
CCR9 antisense 5'-GTG CTT GGA TGA CTT CTT GG-3' (Invitrogen) 
Primer CCR10 sense 5'-CCATTTGGAAGCTGTACCTGCG-3' 
CCR10 antisense 5'-CTCTCAGAATGGTTAGAGGAAGG-3' (Invitrogen) 
Primer CX3CR1 sense 5'-GCC ATC GTC CTG GCC GCC AAC TCC-3' 
CX3CR1 antisense 5'-GAC CGC ACA GGA CGG CCA GGC AC-3' 
(Invitrogen) 
Primer IFNg sense 5'- CTT CTT CAG CAA CAG CAA GGC GAA AA- 3' 
IFNg antisense 5'-CCC CCA GAT ACA ACC CCG CAA TCA- 3' 
(Invitrogen) 
Primer IL-4 sense 5'-CCA GCT AGT TGT CAT CCT GCT CTT CTT TCT 
C - 3' 
IL- 4 antisense 5'- CAG TGA TGT GGA CTT TGA CTC ATT CAT GGT 
GC- 3' (Invitrogen) 
Primer IL- 5 sense 5'- ATG AGA AGG ATG CTT CTG CAC TTG A - 3' 
IL-5 antisense 5'- GTC ACC ATG GAG CAG CTC AGC C - 3' (Invitrogen) 
Primer IL-10 sense 5'- TCA AAC AAA GGA CCA GCT GGA CAA CAT 
ACT GC- 3' 
IL -10 antisense 5'- CTG TCT AGG TCC TGG AGT CCA GCA GAC TCA 
A- 3' (Invitrogen) 
Primer IL- 13 sense 5'-ATA CAT AAC TCT GCT ACC TCA C - 3' 
IL-13 antisense 5'- CCC CAT TCA CTA CAC ATC - 3' (Invitrogen) 
Ponceau S (practical grade, C16 H12 N4 O12 Na4, Sigma) 
Rompun 2% ige Lösung (Bayer AG, Leverkusen) 
Sulphuric acid H2SO4 (Roth) 
TMB substrate (BD OptEIA) 
Tris (Merck, Germany) 
TBE buffer: Tris (1M) + Boric Acid (1M) + 20mM EDTA – Na2.2 H2O  
Trypan blue (0.4%) (Sigma) 
Random primers (Invitrogen) 
Recombinant RNasin (Ribonuclease inhibitor) (Promega) 
Reverse transcriptase AMV (Roche) 
Reverse transcriptase AMV buffer (Roche) 
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RQ1 DNase buffer (Promega) 
RQ1 RNase – free DNase (Promega) 
Schiff’s reagent (MERCK) 
Sodium disulfite (MERCK) 
Sodium pyruvate 
TMB (BD OptEIA) 
TRIzol (Invitrogen) 
Tween 20 (polyoxyethylene sorbitan monoslaurate) (BioRad Laboratories, 
CA) 
Tissue Tek OCT (Sakura Finetek, Netherlands) 
Xylene xylol isomerengemisch ( Fluka, Chemika) 
 
2.6. Special preparation 
2.6.1. Anesthesia 
10ml of Ketanest (25mg/ml) was mixed with 2ml of Rompun (2% 
solution) and the volume was adjusted to 20ml with autoclaved distilled 
water. 400µl of the mixture was used to lethally anaethesise the mice. For 
performing splenectomy the volume of anesthesia was made up to 40ml 
with autoclaved distilled water. 300- 400µl of this solution was used to 
anaesthetize the mice. 
 
2.6.2. Tissue culture medium 
RPMI 1640 + L- glutamine + 25mM HEPES ( GIBCO) 
supplemented with 10% heat inactivated FCS ( GIBCO), 1% Pencillium- 
streptomycin (10000 units/ml, GIBCO) and 0.1% Beta mercaptoethanol 
50mM (GIBCO). Heat inactivation of FCS/ FBS was done at 56°C for 1 hr 
in a water bath. 
 
2.6.3. FACS buffer 
Heat inactivated FCS/ FBS was sterile filtered using 0.20µm syringe 
filter. PBS was supplemented with 2% heat inactivated FBS/ FCS.  
 
2.6.4. ELISA buffer 
ELISA buffer was prepared by adding 50mM Tris and 0.2% Tween 
20 in distilled water. 
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2.6.5. MACS buffer 
Heat inactivated FBS was sterile filtered using a 0.20µm syringe 
filter. PBS was supplemented with 0.5% FBS.  
 
2.6.5. Solution for PAS staining 
To prepare SO2 water, 30 ml of 10 % Na2S2O5 was added to 565 ml 
of distilled water and 5.75 ml of 37% HCl solution. 
 
2.6.6. Solution for Luna staining 
To prepare 30% Ferric chloride solution, 3gm of FeCl3.6H2O was 
dissolved in 10ml of distilled water. Biebrich Scarlet solution was prepared 
by dissolving 0.5 gm of Ponceau S (practical grade, Sigma) in 50ml of DW.  
Working solution was prepared by mixing 8ml of ferric chloride solution 
and 2ml of fuming HCl and the volume made up to 390ml with distilled 
water. Finally, 45 ml of Biebrich Scarlet solution was added and mixed 
well. To prepare 1% Lithium carbonate solution, 0.5gm of lithium carbonate 
in 500ml of distilled water and stirred with a magnetic stirrer. 
 
2.7. Experimental protocol for disease induction 
2.7.1 OVA model of allergic asthma 
To establish acute allergic asthma, BALB/c female mice (6-8 weeks 
old) were immunized i.p. with 10 µg of OVA (Grade V; Sigma Chemical 
Company, Vienna, Austria) in 200 µl PBS or PBS on days 0 and 21. One 
week later on days 28 and 29, mice were placed in a plastic chamber and 
aerosol challenged with 1% OVA in PBS or PBS alone using an ultrasonic 
nebulizer for 60 minutes twice daily. To evaluate acute disease, mice were 
assessed for lung inflammation, mucus production, elevated serum IgG1, 
IgE and BAL 48 hrs after the last aerosol challenge (day 31). For Th2 
memory model, mice with acute disease were allowed to recover, and then 
rechallenged a second time with aerosolized 1% OVA for 60 minutes twice 
daily on 2 consecutive days. Evaluation for secondary disease was done at 
the time points indicated.  
 
 
 48 
2.7.2. Milk model of allergic asthma 
Allergic asthma was established in B6 mice by immunizing mice 
with 10µg milk/200µl of 1X PBS on day 0 and 21, followed by aerosol 
challenge with 2% milk on day 28 and 29 for 1hr b.i.d. Disease assessment 
was done 48 hrs after the last aerosol challenge. To check for cross 
reactivity of milk proteins with other proteins; mice recovered from milk-
induced allergic asthma were rechallenged with 1% OVA aerosol on b.i.d 
on 2 days for 1hr. The mice were assessed 48 hrs after the last aerosol 
challenge. 
 
2.8. Bronchoalveolar lavage (BAL)  
Forty-eight hrs after the last aerosol challenge, mice were evaluated 
for lung inflammation and mucus hypersecretion. Mice were injected i.p 
with Rompun- Ketanest and the tracheas of lethally anesthetized mice were 
cannulated with IV cannula. The lungs were lavaged with 1-2 ml of PBS. 
Total leukocytes in the bronchoalveolar lavage fluid (BAL) were counted 
with a hemocytometer. Trypan blue dye was used to determine viable cells. 
BAL cells were centrifuged at 1200 rpm for 10mins and the supernatant was 
stored at -20°C for further analysis. The cell pellet was resuspended in 1ml 
of PBS and cytospin slides (105 cells/slide) were prepared. The slides were 
air dried and stained with May-Grünwald-Giemsa to determine the 
differential cell counts.  
 
2.8.1. May-Grünwald staining for differential BAL counts 
BAL cytospins were prepared by spinning 105 BAL cells/slide. The 
slide was allowed to air dry followed by fixing the methanol for 5mins. The 
slides were then incubated in May- grünwald for 15 mins followed by 
washing with tap water. The slides were then incubated in 10% Giemsa for 
20 mins followed by washing with tap water. The slides were air dried and 
at least 300 cells were counted. Macrophages, eosinophils, neutrophils and 
lymphocytes were enumerated using light microscope. 
 
2.9. Histological evaluation of lung tissue 
Following BAL, tracheas were perfused with PBS and then 4% 
formalin. Paraffin-embedded lung sections of 4 µm were stained with 
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Hematoxylin and Eosin (H&E) for morphological evaluation or with 
periodic-acid-Schiff stain (PAS) for mucopolysaccharide staining, which 
reflects mucus production by respiratory epithelial goblet cells. 
Additionally, LUNA staining was done on lung tissue to grade for 
eosinophilic infiltration.  
 
2.9.1 H&E staining 
The lung tissue was cut at 4µm and incubated at 60°C for 50 mins 
for deparaffinization. The slides were then incubated in xylene for 10 mins 
and then the slides were transferred to another reservoir of xylene and 
incubated for another 10 mins. The tissue was rinsed in distilled water for 
10 times. The tissue was rehydrated using an ethanol gradient (100 %, 96% 
and 50% ethanol) for 5 mins each. The tissue was then incubated in 
Hematoxyline solution for 5 mins and rinsed with tap water for 5 mins. The 
slides were then incubated in HCl water (1% HCl in water) for 5 sec, 
followed by rinsing in tap water and distilled water for 5 mins each. The 
tissue was dehydrated by using an ethanol gradient (50%, 96% and 100% 
ethanol) for 30 sec each. To counter stain the tissue, slides were incubated 
in eosin for 30 sec and rinsed with tap water till the water was colorless. The 
tissue was then dehydrated by placing in an ethanol gradient (50%, 96% and 
100% ethanol) for 30 sec each. Finally, the tissue was incubated in xylene 
for 5 mins and mounted with mounting medium. 
 
2.9.2. Periodic acid Schiff staining 
4µm cut paraffin tissue was deparaffininzed by incubating the lung 
tissue at 60°C for 50 mins. The slides were then incubated in xylene for 10 
mins. Tissue was rehydrated by passing through an ethanol gradient (100%, 
96% and 50% ethanol) for 1 min each, followed by washing in tap water for 
5 mins. Slides were then incubated in 0.5% periodic acid for 10 mins 
followed by washing with distilled water for 5 mins. Slides were incubated 
in Schiff’s reagent for 30 mins at 60°C and then washed with SO2 water in 3 
different chambers for 2 mins each. To remove traces of SO2 water, the 
slides were washed with lukewarm tap water for 15 mins. Finally, the slides 
were incubated in PAP solution for 20 secs and washed with tap water. A 
final ethanol gradient (50%, 96% and 100%) for 5mins each was done to 
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dehydrate the tissue. The slides were then incubated in n- butyl acetate for 5 
mins and the tissue mounted immediately. 
2.9.3. LUNA staining 
Lung tissue sections cut at 4µm were incubated at 60°C for 50 mins 
for deparaffinization. The slides were then incubated in xylene for 10 mins 
and then transferred to another reservoir of xylene and incubated for another 
10 mins. The slides were dipped in distilled water for 10 times and the 
incubated in an ethanol gradient (100%, 96%, 70%, 50% ethanol) for 5 mins 
each. The slides were then incubated in working solution for 5 mins 
followed by rinsing with tap water till the water was colourless. For counter 
staining the slides were incubated in Hematoxyline for 5 mins followed by 
washing in tap water for 5 mins. The slides were then incubated in 1% HCl 
water for 5 sec. Slides were quickly transferred and washed with tap water 
for 5 mins. The slides were then dipped (2 – 3 dips) in Lithium carbonate 
and washed with distilled water for 5 mins. The tissue was dehydrated by 
placing the slides in an ethanol gradient (50%, 70%, 96%, 100%EtOH) for 2 
mins each and then finally in xylene for 5 mins. The slides were left in 
xylene and mounted with mounting medium. 
 
2.9.4. Immunofluorescence staining 
For immunofluorescence studies, lungs were perfused with diluted 
OCT (1:1) in PBS. The lungs were placed on a plastic cryomold and 
covered with OCT. The cryomold was then kept in a box containing liquid 
N2 and the OCT embedded tissue was allowed to freeze. The tissue was then 
stored at -20°C till further analysis. 5µm sections of OCT embedded lung 
tissue were cut and stained for immunofluorescence microscopy. The tissue 
was stained for CD4+ (clone RM4-5, BD), CCR3 (clone 83103, BD 
pharmingen), CCR4 (Novus Biologicals), CCR5 (clone C34-3448, BD 
pharmingen), CCR6 (clone 140706, BD), CCR7 (clone 4B12, eBioscience), 
CCR8 (polyclonal, Novus Biologicals), CCR9 (clone 242503, R&D 
Systems), CCR10 (clone 248918, R&D Systems), CXCR2 (clone 242216, 
R&D System), CXCR3 (clone 220803, R&D Systems), CXCR4 (clone 
2B11/CXCR4, BD pharmingen), CXCR5 (2G8, BD pharmingen), CXCR6 
(clone 221002, BD pharmingen), CX3CR1 (pure, ProSci), CRTH2 (clone 
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BM16, Milteni Biotec), MHC class II (M5/114.15.2, BD Pharmingen). For 
stainings with secondary fluorochrome conjugated antibody, the secondary 
antibody was incubated at room temperature for 35 mins followed by 
washing with PBS for 5 mins. To control for unspecific antibody staining, 
the tissue section was stained omitting the primary antibody. Finally, DAPI 
staining was performed by incubating tissue sections with 100µl of DAPI at 
37°C for 10 mins. The tissue was rinsed with 1X PBS for 10 mins and 
mounted with Fluoroprep and the coverslip sealed with fixogum. The 
stained slides were stored at 4°C. The stained slides were observed under a 
fluorescence microscope. 
 
2.10. Measurement of serum OVA – specific IgG1 
Sera for the measurement of OVA- specific immunoglobulin was 
obtained 48 hrs after the last aerosol challenge. For the measurement of 
OVA-specific IgG1, ELISA plates were coated with OVA at 10 µg/ml 
overnight at 4°C. The plates were washed and blocked with 2% BSA for 2 
hrs at room temperature. Titrated sera were incubated at 4°C overnight. 
After washing, biotinylated anti-IgG1 detection mAb (PharMingen) was 
added and plates were incubated at 4°C for 2 hrs. The plates were washed 3 
times with ELISA wash buffer and streptavidin-HRP (Southern Biotech 
Assoc., Alabama) was added and incubated at RT for 1 hr. The plates were 
washed 3 times with wash buffer and 100µl of o-phenylenediamine 
substrate (Sigma) was incubated at room temperature in the dark for 10 
mins. If TMB (BD OptEIA) was used as a substrate then 100µl of TMB was 
added to the plate and incubated for 10 mins. The color reaction was 
stopped by addition of 100µl of 0.18M H2SO4 and OD was measured at 
450nm using ELISA plate reader SpectraMax M5 (Molecular Devices). 
 
2.11. Measurement of serum OVA – specific IgE 
Sera for the measurement of OVA- specific immunoglobulin was 
obtained at 48-96 hrs after the last aerosol challenge. For the measurement 
of OVA-specific IgE, ELISA plates were coated with OVA at 10 µg/ml 
overnight at 4°C. The plates were washed and blocked with 2% BSA for 2 
hrs at room temperature. Titrated sera were incubated at 4°C overnight. 
After washing, biotinylated anti-IgE detection mAb (PharMingen) was 
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added and plates were incubated at 4°C for 2 h. The plates were washed 3 
times with ELISA wash buffer and streptavidin-HRP (Southern Biotech 
Assoc., Alabama) was added and incubated at RT for 1 hr. The plates were 
washed 3 times with wash buffer and o-phenylenediamine substrate (Sigma) 
was incubate at RT in the dark for 10 mins. The OD was measured at 
450nm using ELISA plate reader SpectraMax M5 (Molecular Devices). 
 
2.12. Gel electrophoresis: agarose gel 
1.5% agarose gel was prepared in TBE buffer and boiled in a 
microwave. The agarose was allowed to cool to about 50°C and Ethidium 
bromide (final concentration 0.5µg/ml) was added to the agarose and mixed 
by swirling the agarose solution. The agarose was poured immediately to 
the casting tray and allowed to solidify. The agarose gel was then placed in 
the electrophoresis unit containing TBE buffer as running buffer. The PCR 
amplified product was mixed with 2.5µl of Blue juice and 15µl of sample 
was loaded to the agarose gel. The gel was run at 100V and the DNA was 
visualized using the Lumi imager.  
 
2.13. Total RNA isolation 
Lungs were removed from the mice and immediately frozen in liquid 
nitrogen. To each lung 2ml of Trizol reagent was added and homogenized 
using Homogenizer Ultra Turrax. 1ml of lung homogenates were transferred 
into DNase RNase free eppendorfs and incubated for 5 mins at room 
temperature. 200µl of chloroform was added to the lung homogenates and 
vortexed for 15 seconds followed by incubation for 5 mins. The mixture 
was then centrifuged at 13000 rpm for 15 mins at 4°C. The upper aqueous 
layer was transferred into another Eppendorf tube and 500µl of isopropanol 
was added to each tube. The mixture was vortexed for 15 seconds followed 
by incubation at -20°C for at least 3 hrs to allow RNA to precipitate. The 
RNA was then centrifuged at 13000rpm for 15mins at 4°C. The isopropanol 
layer was removed and the RNA pellet was washed with 500µl of 70% 
ethanol, followed by centrifugation at 13000 rpm at 4°C for 5mins. Ethanol 
was removed and the RNA pellet was allowed to air dry for 10 – 15 mins at 
room temperature. The RNA pellet was dissolved in nuclease free water 
(60µl / lung) and incubated at room temperature. The concentration of RNA 
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was measured by spectrophotometer. The RNA was diluted to a 
concentration of 1µg/µl and stored at -80°C. 
 
2.14. DNase digestion of total RNA 
To remove traces of DNA from the RNA solution, 15µg/µl of RNA 
was incubated with 5µl of RQ1 buffer, 5µl of RQ1 DNase, 5µl of 0.1M 
DTT, 1µl of RNasin and 19µl of RNase free water. The final volume of 
50µl of RNA digestion was incubated at 37°C for 25 mins. The reaction was 
stopped by addition of 150µl of nuclease free water and 200µl of Phenol- 
chloroform- isoamyl alchol (25:24:1) and vortexed for 30 seconds. The 
solution was centrifuged at 13000 rpm for 10mins at 4°C and the upper 
aqueous layer was transferred into a RNA free eppendorf. To the RNA 20µl 
of 3M sodium acetate and 500µl of chilled absolute ethanol was added and 
vortexed for 30 sec. This solution was incubated at -20°C for overnight. The 
next day, RNA was centrifuged at 13000 rpm for 15mins at 4°C and the 
supernatant discarded. The RNA pellet was washed with 500µl of 70% cold 
ethanol and centrifuged at 13000 rpm for 10 mins. The RNA pellet was air 
dried at room temperature and resuspended in 15µl of nuclease free water.  
 
2.15. First strand cDNA synthesis (AMV- RT) 
The prepared 15µl of RNA was reverse transcribed to cDNA. 15µl 
of RNA was added to 2.5µl dNTPs, 10µl of AMV buffer, 1µl Oligo dT, 1µl 
of random primers, 1µl of DTT, 1µl of Rnasin, 1µl of AMV-RT, and 17.5µl 
of nuclease free water to make a final volume of 50µl of mix. The reaction 
mix was incubated in a PCR machine at 42°C for 50mins, 95°C for 5mins 
and 4°C for 10mins. The cDNA was then stored at -20°C till further 
analysis. 
 
2.16. Polymerase chain reaction (PCR) 
To confirm whether equal amount of DNA was used being used in 
each PCR reaction within experiments, the house-keeping gene 
hypoxanthine- guanine phosphoribosyl transferase (HPRT) was amplified. 
For each HPRT reaction mix, 1µl of cDNA, 0.5µl of Advantage 
polymerase, 2.5µl of 10X Advantage buffer, 0.5µl of 10mM dNTPs 
(Amersham), 1µl of HPRT forward primer, 1µl of HPRT reverse primer and 
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18.5µl of nuclease free water was added to make the end volume of the 
reaction mix to 25µl. The PCR reaction was set for 27 cycles. The PCR 
cycles used was  
Step 1: 95°C for 60 sec (denaturing) 
Step 2: 95°C for 30 sec (denaturing)  
Step 3: 60°C for 30 sec (primer annealing) 
Step 4: 72°C for 30 sec (elongation)  
Repeat step 2 to 4 for 27 cycles  
Step 5: 72°C for 5 mins 
Step 6: 4°C forever 
For amplifying chemokine receptor genes and interleukins genes the 
amplification temperature was determined for each primer pair and then the 
following cycles were used.  
Step 1: 95°C for 60 sec (denaturing) 
Step 2: 95°C for 30 sec (denaturing)  
Step 3: variable annealing temperature (°C) for 30 sec (primer annealing) 
Step 4: 72°C for 60 sec (elongation)  
Repeat step 2 to 4 for 34 cycles  
Step 5: 4°C forever 
The annealing temperatures for the different primer pairs were as follows: 
 
XCR1 – 55°C CXCR2- 62°C CXCR3 - 62°C CXCR4 – 62°C 
CXCR5 – 55°C CCR1 – 62°C CCR2 – 62°C CCR3 – 62°C 
CCR4 – 62°C CCR5 – 55°C CCR6 – 62°C CCR7 – 62°C 
CCR8 – 62°C 
IL-5- 68°C 
CCR9 – 55°C 
IL-10 – 62°C 
CX3CR1 – 68°C 
IL-13 – 55°C 
IL -4 – 62°C 
IFNg – 57°C 
 
2.17. CD4+ cell isolation from Lung 
Mice were killed by cervical dislocation and the lungs were flushed 
through the right ventricle to get rid of the circulating lymphocytes. Single 
cell suspension was prepared by mincing the lung and incubating the lung 
pieces in a DNase I (150U) collagenase I (50U) solution. The lungs were 
digested for 1hr at 37°C water bath and then manually homogenized and 
passed through a 70µm cell strainer. The cells were washed with RPMI 
1640 + 5%FCS to remove traces of collagenase- DNase. The cells were 
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centrifuged and for RBC lysis, 1ml of BD lysis solution was added to the 
pellet and placed on ice for 2min. The lysis reaction was stopped by 
addition of 1X PBS+ 2% FCS and centrifuged at 1200 rpm for 10 mins. The 
pellet was resuspended in RPMI 1640+ 5%FCS and viable cells were 
determined using Trypan blue. For CD4+ cells isolation, cells were 
resuspended in MACS buffer and 10µl CD4+ beads /107 cells was added 
and incubated for 15 mins at 4°C. The reaction was stopped by addition of 
MACS buffer and the cells centrifuged at 1200 rpm for 10 mins. The pellet 
was resuspended in MACS buffer and then passed through a LC MACS 
column placed on a magnet. The LC column was removed from the magnet 
and the column was flushed with MACS buffer to get the positive fraction 
of CD4+ cells. The viable CD4+ cell was determined by Trypan blue and 
the cells were stained with CD4 mAb to determine the percent purity by 
FACS. 
 
2.18. FACS lung 
Mice were killed by cervical dislocation and the lungs were flushed 
with 15ml of PBS+ 2% FCS through the right ventricle to get rid of the 
circulating lymphocytes. To obtain single cell suspension, lungs from naïve 
and recovered mice (n= 3-5) were pooled and minced followed by digestion 
in DNaseI (150U)- Collagenase I (50U) in RPMI 1640 +5% heat inactivated 
FCS at 37°C for 1hr. The lung tissue was manually homogenized and 
filtered through a 70µm cell strainer. The cells were washed with 
RPMI1640 – 5%FCS to remove traces of collagenase – DNase solution. 
Lympholyte –M (Cedarlane) gradient was then used on the lung cell 
suspension to separate the viable from non viable cells. The interphase 
containing the viable cells was washed with RPMI 1640 + 5% heat 
inactivated FCS and 106 cells/ staining was taken. For staining, to the pellet 
containing 106 cells, FcR was blocked with FcRg III/II Receptor (CD 16/ 
CD32) in FACS buffer for 15 mins at room temperature followed by 
washing with FACS buffer. The cells were centrifuged at 2000 rpm for 2 
mins and the supernatant was discarded. The cells were then stained with 
the mAb antibodies for 25 mins on ice followed by washing with FACS 
buffer. The cells were stained with the following mAbs: CD4 (clone RM4-
5, BD), CD3 PE (clone 145/2C11, BD Pharm), CD 3 Cy 5 (clone 500A2, 
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Caltag), CD62L FITC (clone MEL-14, BD Pharm), CD62L-biotin (clone 
MEL-14, eBioscience), CD44 APC (clone IM7, BD Pharm), CD8a FITC 
(clone CT-CD8a, CALTAG), CCR3 AF 647 (clone 83103, BD 
pharmingen), CCR4- pure (Novus Biologicals), CCR5 PE (clone C34-3448, 
BD pharmingen), CCR6 AF647 (clone 140706, BD), CCR7 PE (clone 
4B12, eBioscience), CCR8 pure (polyclonal, Novus Biologicals), CCR9 PE 
(clone 242503, R&D Systems), CCR10 PE (clone 248918, R&D Systems), 
CXCR2 PE (242216, R&D System), CXCR3 PE (clone 220803, R&D 
Systems), CXCR4 PE (clone 2B11/CXCR4, BD pharmingen), CXCR5 PE 
(clone 2G8, BD pharmingen), CXCR6 PE (clone 221002, BD pharmingen), 
MHC class II PE (clone M5/114.15.2, BD Pharmingen), CX3CR1 (pure, 
ProSci), CRTH2 PE (clone BM16, Milteni Biotec), T1/ST2 FITC (clone 
DJ8, MD Bioscience), swine anti goat IgG (H+L)R-PE (CALTAG). For 
stainings with secondary fluorochrome conjugated antibody, the secondary 
antibody was incubated for 25 mins on ice followed by washing with FACS 
buffer. For biotinylated antibodies, Streptavidin conjugated to fluorochrome 
was added and incubated for 15 mins on ice followed by washing with 
FACS buffer. A total of 200000 cells were acquired on FACS Calibur.  
 
2.19. FACS spleen  
Spleen from mice (n=3-4) were placed on a 70µm cell strainer and 
homogenized using the back of a 2ml syringe. The cell suspension was 
transferred to a 50 ml falcon and the volume was made up to 30 ml and the 
cells were placed on ice. The cell suspension was centrifuged for 1200rpm 
for 10 mins and the supernatant was discarded. To the pellet 3-4 ml of lysis 
buffer was added and pipetted on ice for 2 mins. 40ml of RPMI1640 + 5% 
heat inactivated FCS was added to stop the lysis and the cells were 
centrifuged at 1200rpm for 10 mins. The cell pellet was resuspended in 40 
ml of RPMI1640 + 5%FCS and cells were counted using Trypan blue. For 
staining 106 cells/ stain was taken FcR was blocked with FcRg III/II 
Receptor(CD 16/ CD32 ) in FACS buffer for 15 mins at room temperature 
followed by washing with FACS buffer. The cells were centrifuged at 2000 
rpm for 2 mins and the supernatant was discarded. The cells were then 
stained with the mAb antibodies for 25 mins on ice followed by washing 
with FACS buffer. The cells were centrifuged at 2000 rpm for 2 mins, 
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supernatant discarded and the pellet resuspended in FACS buffer. The 
stained cells were covered with aluminum foil and kept on ice till 
acquisition with FACS Calibur. A total of 200000 cells / sample were 
acquired. 
 
2.20. FACS lung draining LNs 
Lung draining LNs (cervical and mediastinal) from mice (n=5) were 
placed on a 70µm cell strainer and homogenized using the back of a 2ml 
syringe. The cell suspension was transferred to a 50 ml falcon and the 
volume was made up to 10 ml with PBS + 2%FCS and the cells were placed 
on ice. The cells were counted using Trypan blue. For staining, 106 cells/ 
stain was taken and FcR was blocked with FcRg III/II Receptor(CD 16/ 
CD32 ) in FACS buffer for 15 mins at room temperature followed by 
washing with FACS buffer. The cells were centrifuged at 2000 rpm for 2 
mins and the supernatant was discarded. The cells were then stained with 
the mAb antibodies for 25 mins on ice followed by washing with FACS 
buffer. The cells were centrifuged at 2000 rpm for 2 mins, supernatant 
discarded and the pellet resuspended in FACS buffer. The stained cells were 
covered with aluminum foil and kept on ice till acquisition with FACS 
Calibur. A total of 200000 cells / sample were acquired. 
 
2.21. in vitro restimulation of recovered lung and spleen cells 
Single cell suspension from recovered lungs and spleen was 
prepared as mentioned above. 2 x 106 cells/ml/ well of recovered lung or 
spleen cells were either left unstimulated in RPMI 1640 medium or 
stimulated with a titrated dose (0.1µg/ml, 1 µg/ml, 10µg/ml, 100µg/ml or 
1000µg/ml) of sterile filtered OVA. The cells were incubated at 37°C + 5% 
CO2 for 43 hrs. Cells from different wells were pooled according to the 
groups and centrifuged at 1200 rpm for 10 mins. The supernatant was 
collected and stored at -20°C for ELISA. The cells were stained for FACS 
analysis of activation markers.  
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2.22. Detection of OVA-specific cytokine production from restimulated 
lung and spleen cells 
IL-4, IL-5 and IFN-g ELISA was performed using the ENDOGEN 
mini kit. The 96 well plate was coated with coating antibody and incubated 
overnight at room temperature. The plate was then blocked with 2%BSA for 
1 hr at room temperature followed by washing with wash buffer 3 times. 
100µl of IL- 4 standard (650pg/ml), IL- 5 standard (1000pg/ml) or IFNg 
(12000pg/ml) was then diluted 1:2 down the plate. 100µl of culture 
supernatant was added in duplicate. The standards and the samples were 
incubated overnight at room temperature. The plate was washed 3 times 
with wash buffer and biotinylated detection antibody was added to the plate 
and incubated at room temperature for 1 hr. the plates were washed with 
wash buffer and 100µl of Streptavidin- HRP (Southern biotec, 7100-05, 
D126-786H) was added to the plate and incubated for 30 mins at RT. The 
plates were washed 3 times with wash buffer and 100µl of TMB substrate 
(BD OptEIA) was added to each well and the color was allowed to develop. 
The colour reaction was stopped by addition of 0.18M H2SO4. Optical 
density (OD) was measured at 450nm using the ELISA plate reader from 
Molecular Devices, SpectraMax M5 using the software Soft Max Pro 4.8.  
 
2.23. Dexamethasone  treatment experiment 
BALB/c mice recovered for a single episode of allergic asthma were 
intranasally treated either with placebo or with 7 doses of 10mg/kg of 
dexamethasone, 3 doses during recovery and 2 doses b.i.d. before 1% OVA 
aerosol challenge. The mice were assessed 48 hrs after the last aerosol 
challenge. 
 
2.24. Irradiation experiment  
Sublethal irradiation was done using Theratron 780 with the Cobalt60 
as a source. Mice were placed in a glass chamber and covered with 
pexiglass. The radiation time was calculated every time for 6.5 Gy. Post 
irradiation, mice were kept in filter top cage and provided food and 
autoclaved water. One week post irradiation mice were rechallenged with 
1% OVA on two consecutive days 1hr b.i.d. Forty eight hrs after the last 
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aerosol challenge the mice were killed by administrating an excessive dose 
of anaesthesia and assessed for disease. 
 
2.25. Splenectomy experiment 
Recovered mice were anaesthetized and the reflex of the mice was 
checked by pinching the hind limb of the animal. The mouse was laid on its 
right side and sprayed with ethanol. An incision was made from the last rib 
and the connective tissue was detached from the body cavity using the 
scissor. Once the spleen was visible in the peritoneum a small cut was made 
in the peritoneal wall and the spleen was gently pulled to the exterior 
surface of the peritoneum. Using a 4-0 suture the artery (attached to the 
helium of the spleen) and the efferent venule was tied off. The spleen was 
then removed starting from the free end and moving towards the knot end of 
the spleen. The sutures were cut and the peritoneal wall was sealed with 2-3 
sutures. The skin was brought together and sealed with the wound clips. The 
animals were allowed to recover in a cage with filter top. A heating lamp 
was placed close to the cage until the mice recovered and started moving. 
The mice were checked daily for survival. 1 month or 4 months post- 
splenectomy the mice were aerosol challenged on two consecutive day with 
1% OVA for 60 mins b.i.d. Disease was assessed 48 hrs after the last 
aerosol challenge. The following control groups were included: naïve, 
recovered- splenectomized, recovered and rechallenged mice. 
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3. Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overview of results 
 
3.1. Establishment of allergic asthma mice model using OVA. 
We used a model of allergic asthma disease induction established in 
our laboratory. BALB/c mice were i.p. sensitized with 10µg OVA on day 0 
and 21 followed by aerosol challenge with 1%OVA for 1hr b.i.d on days 28 
and 29 (Diagram 1). To determine whether mice sensitized and aerosol 
challenged with OVA developed allergic asthma, mice were bled on day 31 
of the disease protocol. Age matched naïve mice were also bled on the same 
day as controls and OVA-specific sera IgG1 levels were checked in the 
diseased mice. Only diseased mice developed OVA-specific IgG1 antibody 
and maintain this high OVA-specific IgG1 titre throughout their life. The 
diseased mice were then allowed to rest for a period of at least 3 months.  
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Diagram 1: Allergic asthma disease model. 
(Courtesy M. M. Epstein) 
3.2. Chemokines and CKR expression in whole lung (RNA) 
To evaluate whether there are changes in the expression of 
chemokines and CKR during different stages of disease, we examined gene 
expression of chemokines and CKRs. Lungs from naïve, recovered and 2 
and 6 hrs after a single aerosol challenge with 1% OVA were flash frozen. 
mRNA was prepared using a Trizol - chloroform extraction method, 
followed by reverse transcription to cDNA. Total lung CKR mRNA 
expression (Figure 1a) was investigated at various time points. HPRT was 
used as an internal control to check for equal loading of the cDNA. The 
expression of eotaxin, MIP1α and TECK remained stable in naïve, 
recovered, 2hr rechallenged and 6hr rechallenged lungs. However, IP -10 
and MCP expression was upregulated at 2 hrs and 6 hrs after a single 
aerosol challenge compared to naïve and recovered lungs.  
We further investigated whether the upregulation in chemokine 
expression also correlated with an increase in CKR expression. The 
expression of CKRs in naïve, recovered and 2 hrs rechallenged and 6 hrs 
rechallenged lungs was investigated (Figure 1b). We observed a higher 
expression of CCR1 in naïve lungs compared to recovered lungs. The 
expression of CCR1 was upregulated at 2 hrs after aerosol challenge and 
then decreased at 6 hrs after aerosol challenge. The expression of CCR2 
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remained stable/constant in naïve, recovered and 2 hrs rechallenged and 6 
hrs rechallenged lungs. CCR3 expression was detected in naïve, recovered 
and 2 hrs rechallenged and 6 hrs rechallenged lungs; however the 
expression of CCR3 was the highest in 2 hrs rechallenged  time point, 
suggesting an infiltration of CCR3 bearing cells in the lungs  (Figure 1b). 
The expression of CCR4 was higher in recovered lungs compared to naïve 
lungs. Interestingly, CCR4 expression was not detected at 2 hrs after the 
rechallenge but the expression of CCR4 re-appeared at 6 hrs after 
rechallenge (Figure 1b). This indicates that in recovered lungs the number/ 
expression of CCR4 + cells is high, which upon rechallenge, due to 
migration of the cells to the draining LNs, decreases at early time points (2 
hrs rechallenged lung). The expression of CCR4 then upregulates in 6 hrs 
rechallenged lungs which could be due to homing of the CCR4+ cells back 
to the lungs. The expression of CCR5 was constant in the naïve, recovered 
and 2 hrs rechallenged lungs and increased only in 6 hrs rechallenged lungs 
(Figure 1b). The expression of CCR6 was comparable in the naïve, 2 hrs 
rechallenged and 6 hrs rechallenged lungs. Recovered lungs had higher 
expression of CCR6 compared to naïve lungs (Figure 1b). Naïve lungs also 
expressed CCR7 which was upregulated during recovery. Interestingly, 2 
hrs after aerosol challenge CCR7 was not detected in the lungs, suggesting 
either the down regulation of the CCR7 receptor or migration of CCR7+ 
cells from the lungs. CCR7 was detected again in the 6 hrs rechallenged 
lungs, indicating the homing of CCR7+ cells back to the lung at 6 hrs time 
point (Figure 1b). The expression of CCR8 was upregulated in recovered 
lungs compared to naïve lungs which decreased in 2 hrs rechallenged lungs 
and then was upregulated at 6 hrs after rechallenge. The expression pattern 
of CCR9, XCR1 and CX3CR1 was similar (Figure 1b). These CKRs were 
expressed the highest in the recovered lungs compared to naïve, 2 hrs 
rechallenged and 6 hrs rechallenged lungs. While no CXCR2 was detected 
in the naïve lungs, the expression of CXCR2 in recovered, 2 hrs 
rechallenged and 6 hrs rechallenged lungs remained comparable (Figure 
1b). The expression of CXCR3 was higher in recovered lungs compared to 
naïve lungs. Interestingly, the expression of CXCR3 was not detected in the 
2 hrs rechallenged  lungs and the expression of CXCR3 reappeared in the 6 
hrs rechallenged  lungs, indicating again that CXCR3+ cells were either 
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migrating or had downregulated the expression of CXCR3 during 2 hrs 
rechallenged  time point. The expression of CXCR4 was comparable in the 
naïve, recovered, 2 hrs rechallenged and 6 hrs rechallenged lungs (Figure 
1b). The expression of CXCR5 was upregulated in recovered and 2 hrs 
rechallenged lungs compared to naïve lungs followed by downregulation of 
CXCR5 expression in 6 hrs rechallenged lungs (Figure 1b). The 
downregulation of CXCR5 at late time point after rechallenged indicate that 
the CXCR5+ cells are maintained in the lungs during recovery and are not 
the recruited to the draining LNs immediately after Ag challenge.  
Figure 1: Lung chemokine and CKR expression. Lungs were pooled (n=3) and 
RNA was extracted. A). chemokine expression in the lungs. (Lanes 1 and4 =naïve, 
2and5 = recovered, 3=rechallenged 2hr, 6=rechallenged 6hr). B). Chemokine 
receptor expression in lungs during different stages of allergic asthma (lane 1= 
naïve, 2= recovered, 3= rechallenged 2hr, 4= rechallenged 6hr). HPRT was used 
as house keeping gene.  
 
In summary, the expression of chemokines IP-10 and MCP was 
elevated early upon OVA rechallenge in the lungs. Recovered lungs were 
characterized by an upregulation of CCR4-9, XCR1, CXCR2-3, CXCR5 
and CX3CR1 compared to naïve lungs. At early time points after OVA 
rechallenge (2 hrs rechallenged lungs) a downregulation or absence of 
CKRs; CCR4-9, XCR1, CX3CR1 and CXCR3, indicating the migration of 
the cells bearing these receptors out of the lungs. The upregualtion of 
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CCR4-5, CCR7-8 and CXCR3 at late time points after OVA rechallenge (6 
hrs rechallenged  lung) suggest the homing back of cells bearing these 
receptors at 6 hrs time point.  
 
3.3. CKR expression on lung tissue (Immunofluorescence data) 
To evaluate the expression of CKRs on the protein level, 
immunofluorescence was performed on frozen lung tissue. Recovered mice 
were intranasally challenged with 100µg OVA/50µl PBS and the lungs were 
obtained 24 hrs after the last aerosol challenge. The lungs were flushed with 
1:1 OCT in PBS and stored at -20°C. The frozen tissue was cut at 4µm and 
processed and stained with fluorochrome-conjugated mAbs. CCR3 is highly 
expressed in recovered and less in rechallenged mice lungs. This is 
surprising because CCR3 is present on eosinophils and we expected it to be 
more after rechallenge. The possible explanation could be that eosoinophils 
migrate to the lungs at 48 hrs after the aerosol challenge. CCR3 is also 
present on Th2 cells, and it is therefore possible that the upregulation in 
recovered mice could be caused by the presence of Th2 cells which upon 
rechallenge migrate to the draining LNs, and hence the decrease in the 
CCR3+ cells during Ag-rechallenge. CCR4 on the other hand, is present on 
Th2 cells and in recovered lungs; we see an upregulation of CCR4 
expression and downregulation during rechallenge, indicating migration to 
draining LNs. We observed varied expression of CCR5 in naive and 
recovered lungs (around the cell and punctate respectively) followed by a 
mixed (both cellular and punctate) expression of CCR5 upon rechallenge. 
CCR5 is associated with Th1 cells and its frequency does not change in 
different stages of disease. CCR6 is present on Th2, DCs and B cells is 
upregualted in recovered and down-regulated upon rechallenge. CCR8 is a 
Th2 associated CKR which is upregulated in recovered and downregulated 
in rechallenged lungs, suggesting migration after rechallenge. 
To determine whether CKRs are present on CD4+ cells and to 
narrow down our search for possible Th2 memory cell markers, we did a co-
staining of CKRs and CD4 (Figure 2). We saw a small number of CCR3+ 
CD4+ cells during recovery and upon rechallenge around the airway. CCR5, 
however, did not co-localize with CD4+ at any stage of disease (Figure 2). 
The expression of CCR8+ CD4+ cells was limited to very few cells during 
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recovery. CRTH2 is a memory Th2 cell marker and its expression is 
markedly increased during recovery and rechallenge compared to naïve 
where there was no co-localization of CD4+ and CRTH2+ cells. 
Interestingly, CRTH2 + cells were in close proximity to the CD4+ cells 
surrounding the airway. CXCR4 is another CKR present on eosinophils and 
did not co-localize with CD4+ in naïve, recovered and rechallenged lungs 
indicating that CXCR4 is present on eosinophils. CXCR5 had an interesting 
pattern of staining. CXCR5 is present on memory B cells and T cells (324-
326). The co-localization of CXCR5 and CD4+ in naive, recovered and 
rechallenged mice indicate the presence of memory T cells, however, we 
cannot tell if these memory cells are OVA-specific, especially due to the 
presence of CXCR5+CD4+ cells in naive lungs, where we would expect no 
co-localization if CXCR5 was present on OVA-specific memory T cells. 
 In summary, naïve mice expressed CCR5, CCR6 and CCR8 and 
recovered mice expressed CCR3, CCR4, CCR5, CCR6 and CCR8. The 
expression of CKRs on recovered lungs was higher compared to naïve 
lungs. The expression of CCR3, CCR4, CCR6 and CCR8 decreased in 24 
hrs rechallenged lungs compared to recovered lungs. Of these CKRs, only 
CCR3, CCR8, CXCR5 co-localized with CD4+ cells during recovery, 
implicating these CKRs as possible Th2 memory markers. 
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Figure 2: Lung expression of CKRs. Naïve, Recovered and 24 hrs rechallenged 
lungs were harvested and stored in OCT at -20°C. Lung tissue was cut at 4µm and 
stained with fluorochrome conjugated mAb. Yellow staining indicates cells 
positive for CD4 and CKR. Images were taken at 40X magnification.  
 
Mice that have recovered from allergic asthma, when rechallenged 
with 1% OVA 1hr b.i.d. on 2 consecutive days develop extensive lung 
eosinophilia 48 hrs after the last aerosol challenge. We determined whether 
48 hrs after the last aerosol challenge we could detect changes in the CKR 
expression in lungs CD4+ T cells. Lungs of naïve, recovered and 48 hrs 
rechallenged mice were embedded in OCT, were cut at 4 µm and stained 
with anti-CD4-AF488 and CKR mAb. Photomicrographs of tissue were 
taken at 40x magnification (Figure 3a). Naïve lungs had few CCR3+ cells 
that did not co-localize with CD4+ T cells. Recovered lungs had a few 
CCR3+ CD4+ T cells that indicated the presence of memory CD4 + T cells 
in recovered lungs (Figure 3a). Forty- eight hrs after the last aerosol 
challenge, there was an increase in the numbers of CD4+ T cells. However, 
there were few CD4+ CCR3+ T cells. The number of CCR3+ cells 
increased at 48 hrs after rechallenge, indicating infiltration of CCR3+ 
eosinophils in rechallenged lungs (Figure 3a). We did not detect any CCR4+ 
CD4+ T cells in the naïve, recovered or 48 hr rechallenged lungs (Figure 
3a). CCR4 is present on Th2 cells and we expected that the recovered lungs 
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would have few CCR4+ CD4+ Th2 cells that would further increase upon 
rechallenge. Since we did not detect any CCR4+ CD4+ Th2 cells in the 
recovered and rechallenged 48 hrs lungs, it could indicate either the few 
CCR4+CD4+ T cells are present in the lungs or they cannot be detected by 
microscopy or that CCR4+ CD4+ T cells have migrated out of the lung. The 
expression pattern of CCR5 was interesting (Figure 3a). CCR5 co-localizes 
with CD4+ T cells in naïve, recovered and 48 hrs rechallenged lungs. The 
expression of CCR5 was localized inside the CD4+ T cells. Naïve lungs had 
more CCR5+ CD4+ T cells which decreased in recovered lungs and were 
the lowest in 48 hrs rechallenged lungs (Figure 3a). The number of CCR6+ 
CD4+ T cells in naïve, recovered and 48 hrs rechallenged lungs were 
limited, few in number and we could not detect any changes in the numbers 
of CCR6+ CD4+ T cells within the three groups (Figure 3a). We did not 
detect any CCR7+ CD4+ cells in naïve, recovered and 48 hrs rechallenged 
lungs; however, there were CCR7+ and CD4+ single positive cells (Figure 
3a). CCR8 did not co-localize with CD4+ T cells in naïve and recovered 
lungs; however, there were a few CCR8+ CD4+ T cells in 48 hrs 
rechallenged lungs (Figure 3b). There were no CCR9+ CD4+ T cells in the 
naïve lung. Recovered lungs had few CCR9+ CD4+ T cells, indicating that 
memory Th2 cells may upregulate CCR9 expression (Figure 3b). We did 
not detect any CCR9+ CD4+ T cells in rechallenged 48 hrs lungs, 
suggesting that either there are few CCR9+ CD4+ T cells in the 
rechallenged lungs that cannot be detected by microscopy or that 
CCR9+CD4+ T cells have migrated out of the lungs to the draining LNs. 
There were single positive CCR10 and CD4+T cells in the naive lungs 
(Figure 3b). Reovered lungs had a few CCR10+ CD4+ T cells and single 
positive CCR10+ cells, indicating that the CCR10+ CD4+ T cells migrate 
out of the recovered lungs after rechallenge (Figure 3b). Naïve lungs had a 
few CXCR2+ CD4+ T cells in the naïve lungs. Recovered lungs had no 
CXCR2+ CD4+ T cells; however, rechallenged lungs had very high 
expression of CXCR2+ cells. 
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Figure 3a: Lung expression of Chemokine receptors 3- 7 in naïve recovered 
and 48 hrs rechallenged lungs. Naïve, Recovered and 48 hrs rechallenged lungs 
were harvested and stored in OCT at -20°C. Lung tissue was cut at 4µm and 
stained with fluorochrome conjugated mAbs. All CKRs are PE-conjugated and 
CD4-AF488-conjugated. Yellow staining indicates cells positive for CD4 and CKR.  
Images were taken at 40X magnification.  
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Figure 3b: Lung expression of Chemokine receptors 8- CXCR3 in naïve 
recovered and 48 hrs rechallenged lungs.  Naïve, Recovered and 48 hrs 
rechallenged lungs were harvested and stored in OCT at -20°C. Lung tissue was 
cut at 4µm and stained with fluorochrome conjugated mAbs. All CKRs are PE- 
conjugated and CD4-AF488-conjugated. Yellow staining indicates cells positive 
for CD4 and CKR. Images were taken at 40X magnification 
 
There were few CXCR2+ CD4+ T cells in the rechallenged lungs.  There 
were single positive CXCR3+ (Figure 3b) and CXCR4+ (Figure 3c) cells in 
the naïve, recovered and 48hrs rechallenged lungs. However we did not 
detect any double positive CXCR3+ CD4+ or CXCR4+ CD4+ T cells in 
naïve, recovered and 48 hrs rechallenged lungs. The expression of CXCR5 
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Figure 3c: Lung expression of CXCR4 - CX3CR1 in naïve recovered and 
48hrs rechallenged lungs.  Naïve, recovered and 48 hr rechallenged lungs were 
harvested and stored in OCT at -20°C. Lung tissue was cut at 4µm and stained 
with fluorochrome conjugated mAbs. All CKRs are PE-conjugated and CD4-
AF488-conjugated except for CX3CR1 conjugated to AF488 and CD4 conjugated 
to AF594. Yellow staining indicates cells positive for CD4 and CKR. Images were 
taken at 40X magnification.  
 
was detected in naïve and recovered lungs, however there were no CXCR5+ 
CD4+ T cells in the naïve and recovered lungs. There were few CXCR5+ 
CD4+ T cells in the rechallenged lungs. The expression of CXCR6 on 
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CD4+ T cells was limited to very few cells in naïve and recovered lungs. 
We detected few CRTH2+ cells in the naïve and recovered lungs. These 
CRTH2+ cells did not co-localize with CD4+ T cells indicating that these 
were not memory Th2 cells. In the rechallenged lungs, there were a few 
CRTH2+ CD4+ cells suggesting the migration of CD4+ T cells harboring 
CRTH2 into the lungs after rechallenge. CX3CR1 had an interesting pattern 
of expression. CX3CR1+ cells were mostly situated around the airway, but 
the CX3CR1+ cells did not co-localize with CD4+ T cells in naïve and 
recovered lungs. In rechallenged lungs we found a few CX3CR1+ CD4+ T 
cells (Figure 3c), indicating the migration of CX3CR1+ CD4+ cells into the 
rechallenged lungs. 
 
3.4. Characterization of Naïve and Recovered lung immune cells 
We evaluated whether there are differences in the immune cell 
population in the lungs of naïve and recovered mice. Naïve and recovered 
mice were killed and the lungs flushed through the right ventricle of the 
heart to get rid of circulating lymphocytes. The lungs were pooled (n=3), cut 
into small pieces and then digested with DNaseI- CollagenaseI solution for 
1hr at 37°C. The digested tissue was then manually homogenized and 
passed through a 70µm cell strainer. The cells were washed with RPMI 
1640 + 5% FCS to remove traces of digestive enzymes. The washed cells 
were then resuspended in RPMI 1640 + 5% FCS solution and overlaid on a 
Lympholyte- M for gradient centrifugation. The interphase containing 
viable lymphocytes was collected and washed with PBS + 2% FCS to 
remove traces of Lympholyte. The cells were then resuspended and the cell 
counts were determined by Trypan Blue. For FACS staining of lung cells 
106 cells / tube were taken and the FcR was blocked by CD16/CD32. The 
cells were then stained either singly or with a combination of fluorochrome 
conjugated monoclonal antibody. After staining the cells, 200000 cells were 
acquired on the FACS Calibur. The data was analyzed by CellQuest. 
We investigated the population of CD4+ T cells in both naïve and 
recovered lungs. CD3+ CD4+ T cells in the naïve lungs were about 19% 
and in recovered lungs it was 22%, indicating that there was no difference in 
the population of CD4+ T cells (Figure 4). CD3+ CD8+ T cells in the naïve 
lung were about 4.47% and in recovered lung it was found to be 4.80%  
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(Figure 4). Since we found no differences in the percentages of CD4+ and 
CD8+ T cell population in the lung, we further checked whether there were 
differences in naïve and memory CD4+ T cell subsets in naïve and 
recovered lungs. We defined CD4+ naïve cells as CD4+CD62Lhigh and 
memory CD4+ T cells were defined as CD4+CD62L low. The population of 
naive CD4+CD62Lhigh cells in naïve lungs was 8.70% and in recovered 
lungs, it was 7.94% (Figure 4). The memory subset defined as CD4+CD62L 
low was 13.38% in naive lungs and 16.30% in the recovered lungs (Figure 4). 
These data clearly demonstrated that in age-matched naïve and recovered 
lungs the T cell population is similar. Furthermore, there was no difference 
in the subsets of naïve and memory subsets in the naïve and recovered 
lungs. Additionally, we checked for activation status of the CD4+ T cells in 
naïve and recovered lung. The percentage of CD4+CD25+ cells in the naïve 
lung was 1.68% whereas in recovered lung it was 2.55% indicating that the 
CD4+ T cells in both naïve and recovered mice were not activated and were 
in a quiescent state (Figure 4). To check for the B cell population in the 
lungs of naïve and recovered lung cell suspension was co-stained with B 
cell surface marker CD19 and CD45R (B220) (Figure 4). The percentage of 
CD19+CD45R+ double positive cells in the naïve lung were 9.86% and in 
the recovered lung was 8.42%, demonstrating that there was no difference 
in the B cell population in the naïve and recovered lung. The percentage of 
MHC class II+ population was also determined in the naïve and recovered 
lungs (Figure 4). Naïve lung had 17.66% of MHC class II+ cells and 
recovered lungs had about 16.14% of MHC class II+ cells, demonstrating 
no differences in the MHC class II+ cells in the naïve and recovered lungs 
(Figure 4). 
 In summary, naïve and recovered lungs had the same percentage of 
CD4+ T cells, CD8+ T cells, B cells and MHC class II + cells. Moreover, 
CD4+ T cells in both naïve and recovered lungs were in inactive state 
(CD4+CD25- or low). Additionally, naïve and recovered lungs also had a 
similar profile for naïve and memory CD4+ T cell subsets.  
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Figure 4: Naïve and recovered lungs have the same immune cell phenotype. 
Age-matched naive and recovered mice were used for characterization of lung 
cells. Mouse lungs (n=3) were pooled, digested with DNase- Collagenase solution 
followed by lympholyte gradient. The single cell suspension was stained with mAb 
and 200000 cells were acquired on FACS Calibur. Values indicate percentage 
gated on the lymphocyte gate. 
 
3.4.1. Surface CKR expression in naïve, recovered and rechallenged 
lung (FACS) 
Since we did not see any differences in the immune cell phenotype 
between naïve and recovered mice, we investigated whether there are 
differences in the CKR expression in naïve and recovered lungs. Lung cells 
were differentiated based on their forward scatter (FSC) and side scatter 
(SSC) and a lymphocyte gate (R1) was defined. On the lymphocyte gate 
using a sample positive for CD4+ T cells, CD4+ cells were gated (R2) 
(Figure 5a). Naïve and recovered lung CKR expression was evaluated in the 
CD4+ gate (R2). We overlapped the histograms of recovered lung CKRs 
with naïve lung CKRs to determine changes in expression (Figure 5a). In 
the recovered lungs the expression of CCR3, CCR6, CCR7, CCR8, CCR9, 
CCR10, CXCR2 and CXCR3 was elevated compared to the naïve lungs 
(Figure 5a). The expression of CCR5, CXCR6 and CX3CR1 was decreased 
in recovered lung compared to naïve lungs. The expression of CCR4, 
CXCR4, CXCR5 and CRTH2 was comparable in recovered and naïve 
lungs. Although the differences in the expression of CKRs between naïve 
and recovered lungs was not significant, we observed a trend towards 
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increased expression of Th2 associated CKR (CCR3 and CCR8) in 
recovered lungs (Figure 5b). Interestingly, the expression of memory 
associated CKR (CRTH2 and CXCR5) was comparable in naïve and 
recovered lungs (Figure 5b). In summary, CKR expression in recovered 
lungs is characterized by elevated expression of CCR3, CCR6, CCR7, 
CCR8, CCR9, CCR10, CXCR2 and CXCR3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5a: 
Expression of CKRs 
in naïve and 
recovered lungs.  
Lungs were pooled 
(n=3-5) and stained 
for CKRs. Histograms 
show recovered lung 
CKR expression 
(black line) overlaid 
with naïve CKR 
(green line) 
expression.  
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Figure 5b). Graph indicating the expression of CKRs in naïve and recovered 
lungs. Geometric mean of the CKR in CD4+ gated cells in 5 independent 
experiments was plotted. 
 
We next asked whether the expression of CKRs differs after Ag 
aerosol challenge. Recovered mice were aerosol challenged with 1% OVA 1 
hr b.i.d. on 2 consecutive days and assessed 24 hrs and 48 hrs after the last 
aerosol challenge. Naïve, recovered and rechallenged 24 hr and 48 hr lungs 
were harvested and CD4+ T cells were purified using MACS beads. The 
percent purity of CD4+ T cells was between 60-90% (Figure 6). The 
activation markers CD25 and CD69 was similar in naïve and recovered lung 
CD4+ T cells which increased at 24 hrs and 48 hrs after the last aerosol 
challenge (Figure 6). The expression of CCR3+CD4+ cells in the naïve 
lungs was 4.60% and increased to 6.58% in recovered lungs. At 24 hrs after 
rechallenge CCR3+ CD4+ T cells were 1.87% and increased to 15.79% at 
48 hrs after rechallenge (Figure 7 a). The expression of CCR4+ CD4+ in 
naïve lungs were 2.79% which increased to 5.23% during recovery. At 24hr 
after rechallenge there were 8.49% CCR4+CD4+ T cells which further 
increased to 14.24% at 48 hrs after rechallenge. The expression of CCR5+ 
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CD4+ T cells were about 2% in naïve lungs and increased to 4.66% during 
recovery (Figure 7 a). 
Figure 6: Recovered lung CD4+ T cells have low activation marker. CD4+ T 
cells were purified from naïve, recovered, rechallenged 24 hr and rechallenged 
48hr lungs. 500000 cells were stained for CD25 and CD69. 200000 cells were 
acquired.  
 
At 24 hrs after rechallenge, there were 7.74% cells that were CCR5+CD4+ 
which further increased to 11.39%, 48 hrs after rechallenge  (Figure 7a). 
The expression of CCR6+ CD4+ T cells in naïve lungs were 9.35% and 
12.19% in recovered lungs  (Figure 7a). At 24 hrs after rechallenge the 
percent of CCR6+ CD4+ T cells were 14.81% and it increased to 22.83% at 
48 hrs after rechallenge  (Figure 7a). CCR7+ CD4+ cells in the naïve lungs 
were 1.89% which further increased to 6.93% during recovery (Figure 7a). 
At 24 hrs after rechallenge the percent of CCR7+ CD4+ T cells were 2.11% 
which decreased at 24 hrs after rechallenge to 1.56% and then increased to 
3.65% at 48 hrs after rechallenge (Figure 7a). This indicates that CCR7 is 
present on CD4+ T cells that are recruited to the lung at 48 hrs after 
rechallenge. CCR8 is a Th2 associated marker. CCR8+ CD4+ Tcells in the 
naïve lungs were 1.89% and increased to 6.93% in recovered lungs (Figure 
7a). The percentage of CCR8+CD4+ T cells in the recovered lungs 
increased to 19.50% at 24 hrs and further increased to 28.80% at 48 hrs after 
the aerosol challenge (Figure 7a). The percent of CCR9+ CD4+ T cells in 
the naïve lungs were 6.27% and increased to 10.80% during recovery 
(Figure 7 b). At 24 hrs after rechallenge the percent of CCR9+ CD4+ T cells 
decreased in the lungs to 8.62% (Figure 7b). At 48 hrs after rechallenge 
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however the percent of CCR9+ CD4+ T cells in the lungs increased to 
12.10% suggesting the recruitment of T cells bearing CCR9. Naïve lungs 
had 5.18% CCR10+ CD4+ T cells which increased to 6.18% during 
recovery (Figure 7b). The percent of CCR10+ CD4+ cells did not increase 
24 hrs after the aerosol challenge and was similar to recovered lungs. 
However, 48 hrs after rechallenge the percent of CCR10+ CD4+ T cells 
were 15.06% (Figure 7b). 
Figure 7a: Expression of chemokine receptor 3-8 in naive, recovered, 
rechallenged 24hr and rechallenged 48hr lung. Lungs were pooled (n=6) and 
stained for chemokine receptor. Lungs were digested and homogenized. CD4+T 
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cells were purified using MACS magnetic beads. The purified cells were stained 
with CD4 and CKR mAb. Dot blot shows naïve, recovered, rechallenged 24hr and 
rechallenged 48hr CKR+CD4+ populations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7b: Expression of chemokine receptor 9 – CXCR4 in naive, recovered, 
rechallenged 24hr and rechallenged 48hr lung. Lungs were pooled (n=6) and 
stained for chemokine receptor. Lungs were digested and homogenized. CD4+T 
cells were purified using MACS magnetic beads. The purified cells were stained 
with CD4 and CKR mAb. Dot blot shows naïve, recovered, rechallenged 24hr and 
rechallenged 48hr CKR+CD4+ populations.  
 
The percentage of CXCR2+CD4+ in naïve lungs was 0.01% and increased 
to 0.18% during recovery. At 24 hrs after rechallenge the percent of 
CXCR2+ CD4+ T cells in the lung decreased to 0.09%, however, at 48 hrs 
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the percent of CXCR2+ CD4+ T cells increased to 0.41% (Figure 7b). The 
expression of CXCR3+ CD4+ T cells in naïve lung was 7% which increased 
to 9.18% during recovery and was further increased 24 hrs after the 
rechallenge to10.56% (Figure 7b). The percent of CXCR3+ CD4+ T cells at 
16.34% was the highest at 48hr after rechallenge (Figure 7b). CXCR4+ 
CD4+ T cells in naïve lungs was 0.08% and increased to 0.20% in 
recovered lungs however, the percent of CXCR4+ CD4+ double positive T 
cells decreased to 0.06% 24 hrs after rechallenge and was the highest at 
0.57% at 48 hrs after rechallenge (Figure 7b). The expression of 
CXCR5+CD4+ T cells in naïve lungs was 0.63% and decreased to 0.11% 
during recovery and even 24 hrs after rechallenge the percent of CXCR5+ 
CD4+ did not increase (Figure 7c). CXCR5+ CD4+ T cells were highest 48 
hrs after the aerosol challenge. CXCR6+ CD4+ T cells in naïve lungs were 
0.37% and decreased to 0.12% during recovery and then increased slightly 
to 0.21%, 24 hrs after rechallenge and were highest (0.35%) at 48 hrs after 
rechallenge (Figure 7c).  
Figure 7c: Expression of CXCR5 – CX3CR1 in naive, recovered, rechallenged 
24hr and rechallenged 48hr lung. Lungs were pooled (n=6) and stained for 
chemokine receptor. Lungs were digested and homogenized. CD4+T cells were 
purified using MACS magnetic beads. The purified cells were stained with CD4 
and CKR mAb. Dot blot shows naïve, recovered, rechallenged 24hr and 
rechallenged 48hr CKR+CD4+ populations.  
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Table 1 a: Percentages of CD4+ CKR+ cells in lungs. A). CD4+ T cells were 
purified from lungs and stained with anti- CD4 mAb and CKRs. Values indicate 
percentage of CD4+ CKR+ cells. Values are mean from 2 independent 
experiments. 
 
B). 
 
 
% change 
recovered to 
naïve   
% change 
rechallenged 
48hrs to 
recovered 
CX3CR1 15.155  CCR8 11.63 
CCR9 5.305  CCR6 7.445 
CCR8 3.03  CCR10 4.845 
CCR4 2.59  CCR9 4.64 
CCR3 2.545  CCR3 4.305 
CCR7 2.365  CCR5 3.955 
CCR6 2.225  CXCR3 3.94 
CCR5 1.85  CCR4 2.37 
CCR10 1.365  CCR7 0.915 
CRTH2 0.31  CXCR2 0.545 
CXCR4 0.15  CXCR6 0.32 
CXCR2 0.085  CRTH2 0.275 
CXCR5 -0.055  CXCR4 0.115 
CXCR6 -0.12  CXCR5 0.045 
CXCR3 -1.275  CX3CR1 -13.745 
Table 1 b: Percentages of CD4+ CKR+ cells in lungs. Percentage changes in 
CKRs on lung CD4+ T cells from recovered to naïve and rechallenged 48hrs to 
recovered. Values are mean from 2 independent experiments. 
 
 Naive Recovered
Rechallenged
48hrs 
CCR3 5.24 7.785 12.09 
CCR4 3.51 6.1 8.47 
CCR5 3.445 5.295 9.25 
CCR6 12.805 15.03 22.475 
CCR7 0.295 2.66 3.575 
CCR8 4.105 7.135 18.765 
CCR9 7.04 12.345 16.985 
CCR10 5.74 7.105 11.95 
CXCR2 0.015 0.1 0.645 
CXCR3 12.59 11.315 15.255 
CXCR4 0.095 0.245 0.36 
CXCR5 0.5 0.445 0.49 
CXCR6 0.225 0.105 0.425 
CX3CR1 70.64 85.795 72.05 
CRTH2 0.21 0.52 0.795 
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Figure 8: Graph representing the CKR expression on lung CD4 + T cells from 
naïve, recovered and rechalleneged 48 hrs lungs. Data are representative of 2 
independent experiments. 
 
CX3CR1+CD4+ T cells were 51.01% in naïve lungs and the percentage of 
CX3CR1+ CD4+ T cells was highest during recovery at 80.20%. Twenty 
four hrs after the rechallenge, the percent of CX3CR1+CD4+ T cells 
decreased to 71.16% and was lowest at 48 hrs at 52.07% (Figure 7c). 
CRTH2+ CD4+ T cells in naïve lungs were 0.28% and increased to 0.87% 
in recovered lungs (Figure 7c). At 24 hrs after rechallenge the percent of 
CRTH2+ CD4+ T cells was 0.24% and at 48 hrs after rechallenge the 
percent increased to 1.07% (Figure 7c). 
In summary, the expression of CKRs on CD4+ T cells in recovered 
lungs was increased compared to naïve lungs (Table 1a and 1b). The 
percentage of CCR3+. CCR7+, CCR9+, CRTH2+, CXCR2+, CXCR4+ 
CD4+ cells decreased 24 hrs after the aerosol challenge and then increased 
at 48 hrs, suggesting the migration of CD4+ T cells harboring these 
receptors. Another possibility is that these receptors are involved in the 
recruitment of CD4+ T cells into lung at 48 hrs after the aerosol challenge. 
While all CKR expression on CD4+ T cells increased at 48hrs, CX3CR1 
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was the only CKR that was the highly expressed in recovered lungs and 
then decreased in rechallenged lungs (Figure 8, table 1a and 1b). This 
indicates that maybe CX3CR1 is present on memory Th2 cells and that 
upon Ag challenge, downregulates the expression to migrate to the draining 
LNs. 
 
3.5. Characterization of Naïve and Recovered spleen immune cells 
 We also determined whether there were differences between the 
naïve and recovered spleen cell phenotypes. Naïve and recovered spleen 
(n=3-5) cells were pooled and homogenized on top of a cell strainer prepare 
a single cell suspensions. RBC were lysed and cells were then stained either 
singly or with a combination of fluorochrome conjugated mAbs. After 
staining the cells, 200000 cells were acquired on the FACS Calibur. The 
data was analyzed by CellQuest. 
 We investigated the population of CD4+ T cells in both naïve and 
recovered splenocytes (Figure 9). CD3+ CD4+ T cells in naïve spleens were 
about 35.65% and in recovered spleens 39.92%, indicating that there was no 
difference in the populations of CD4+ T cells. CD3+ CD8+ T cells in naïve 
spleens were about 8.43% and in recovered spleen 10.57% (Figure 9). Since 
we found no differences in the percentages of CD4+ and CD8+ T cell 
populations, in spleen, we further checked whether there were differences in 
the naïve and memory CD4+ T cell subsets in naïve and recovered 
splenocytes. We defined CD4+ naïve cells as CD4+CD62Lhigh and memory 
CD4+ T cells were defined as CD4+CD62L low. The population of naive 
CD4+CD62Lhigh cells in naïve spleens was 27.29% and in recovered spleen 
it was 29.25% (Figure 9). The memory subset defined as CD4+CD62L low 
was 19.47% in naive spleen and 17.92% in recovered spleen (Figure 9). 
These data clearly demonstrated that in age-matched naïve and recovered 
splenocytes, the T cell populations are similar. Furthermore, there was no 
difference in naïve and memory subsets in naïve and recovered splenocytes.  
Additionally, we checked for the activation status of the CD4+ T 
cells in naïve and recovered splenocytes. The percentage of CD4+CD25+ 
cells in naïve spleen was 5.89%, whereas in recovered spleen it was 5.71%, 
indicating that CD4+ T cells in both naïve and recovered mice were not 
activated and were in a quiescent state (Figure 9). To check for B cells in 
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spleens, spleen cell suspensions were co-stained with B cell surface 
markers, CD19 and CD45R (B220) (Figure 9). The percentage of 
CD19+CD45R+ double positive cells in naïve spleen was 25.93% and in 
recovered spleen was 28.56%, demonstrating that there was no difference in 
B cell populations in naïve and recovered spleen (Figure 9). The percentage 
of MHC class II+ cells was also determined in naïve and recovered 
splenocytes. Naïve spleen had 28.89% MHC class II+ cells and recovered 
spleen had about 29.88%, demonstrating no differences in MHC class II+ 
cells in naïve and recovered splenocytes (Figure 9). 
 In summary, naïve and recovered splenocytes had the same 
percentage of CD4+ T cells, CD8+ T cells, B cells and MHC class II + 
cells. Moreover, the CD4+ T cells in both naïve and recovered spleens were 
in inactive state (CD4+CD25- or low). Additionally, naïve and recovered 
splenocytes also have a similar profile for naïve and memory CD4+ T cell 
subsets.  
Figure 9: Naïve and 
recovered spleen 
have the same 
immune cell 
phenotype. Age-
matched naive and 
recovered mice were 
used for 
characterization of 
splenocytes. Mouse 
spleens (n=3) were 
pooled and single cell 
suspensions were 
prepared. The single 
cell suspension was 
stained with mAbs 
and 200000 cells 
were acquired on 
FACS Calibur. Values indicate percentage gated on the lymphocyte gate. 
 
3.5.1. Surface CKR expression in naïve, recovered and rechallenged 
spleens (FACS) 
We further investigated whether there are differences in CKR 
expression in the naïve and recovered splenocytes. Spleen cells were 
differentiated based on their forward scatter (FSC) and side scatter (SSC) 
and a lymphocyte gate (R1) was defined. On the lymphocyte gate using a 
sample positive for CD4+ T cells, CD4+ cells were gated (R2). Naïve and 
recovered splenocyte CKR expression was evaluated in the CD4+ gate (R2) 
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(Figure 10a). We overlapped the histograms of recovered splenocyte CKRs 
with naïve splenocytes CKRs to determine changes in the expression 
(Figure 10a). In the recovered splenocytes the expression of CCR3, CXCR5 
and CXCR6 was elevated compared to the naïve spleen. The expression of 
CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR2, CXCR3, 
CXCR4 and CRTH2 was decreased in recovered splenocytes compared to 
naïve splenocytes. The expression of CCR7, and CX3CR1 was comparable 
in recovered and naïve splenocytes. Although the differences in the 
expression of CKR between naïve and recovered splenocytes were not 
significant, but we observed a trend towards decreased expression of CKR 
in recovered splenocytes compared to naïve splenocytes (Figure 10b).  
Figure 10a: Expression of CKR in naïve and recovered splenocytes. Spleen 
cells were pooled (n=3-5) and stained for chemokine receptor. Histogram shows 
recovered spleen CKR expression (black line) overlaid with naïve CKR expression 
(green line).  
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Figure 10b). Graph indicating the expression of CKR in naïve and recovered 
splenocytes. Geometric mean of the CKR in CD4+ gated cells in 3 independent 
experiments was plotted. 
 
In summary, recovered splenocyte CKR expression is characterized 
by elevated expression of CCR3, CXCR5 and CXCR6 and reduced 
expression of most of the other CKRs.  
 
3.6. Characterization of Naïve and Recovered lung draining LN cells  
We investigated whether there were differences in the cellular 
composition of LNs of naïve and recovered mice that, in turn, results in 
rapid recall responses. To determine whether there are differences in the 
cellular composition of mediastinal and cervical LNs in naïve and recovered 
mice, single cell suspension was prepared by homogenizing pooled LNs on 
top of a cell strainer. The cells were then stained with a combination of 
fluorochrome conjugated mAbs. A total of 200000 cells were acquired on 
the FACS Calibur. The data was analyzed by CellQuest. 
 We investigated the population of CD4+ T cells in both naïve and 
recovered LNs (Figure 11). CD3+ CD4+ T cells in naïve LNs were 
approximately 44.42% and 50.94% in recovered LNs, indicating that there 
was no difference in the populations of CD4+ T cells (Figure 11). CD3+ 
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CD8+ T cells in naïve LNs were about 17.70% and in recovered LNs 
18.49% (Figure 11). Since we found no differences in the percentages of 
CD4+ and CD8+ T cell populations in LNs, we further analyzed the 
differences in the naïve and memory CD4+ T cell subsets in naïve and 
recovered LNs. We defined CD4+ naïve cells as CD4+CD62Lhigh and 
memory CD4+ T cells were defined as CD4+CD62L low. The population of 
naive CD4+CD62Lhigh cells in naïve LNs was 48.49% and in recovered LNs 
it was 51.98% (Figure 11). The memory subset defined as CD4+CD62L low 
was 10.03% in naive LNs and 6.85% in recovered LNs (Figure 11). These 
data clearly demonstrate that in age- matched naïve and recovered LNs the 
T cell populations are similar. Furthermore, there was no difference in the 
subsets of naïve and memory subsets in naïve and recovered LNs. 
Additionally, we checked for the activation status of the CD4+ T cells in 
naïve and recovered LNs. The percentage of CD4+CD25+ cells in naïve 
LNs was 8.27%, whereas in recovered LNs it was 62.85%, indicating that 
CD4+ T cells in recovered mice were activated and not in a quiescent state 
(Figure 11).  
Rapid rechallenge response could also be attributed to an increased 
number of B cells in the LNs. We determined the percentage of B cells in 
LNs of naïve and recovered mice. LN cell suspensions were co-stained with 
B cell surface markers, CD19 and CD45R (B220). The percentage of 
CD19+CD45R+ double positive cells in naïve LNs was 27.75% and in the 
recovered LNs was 21.67% (Figure 11), demonstrating that there was no 
difference in B cell populations in naïve and recovered LNs.  
The possibility of increased number of APCs present in recovered 
LNs which, in turn, results in rapid recall responses was evaluated by 
determining the percentage of MHC class II+ cells in naïve and recovered 
LNs. Naïve LNs had 29.42% MHC class II+ cells and recovered LNs had 
about 24.03%, demonstrating no differences in the MHC class II+ cells in 
naïve and recovered LNs. 
 In summary, naïve and recovered LNs had the same percentage of 
CD4+ T cells, CD8+ T cells, B cells and MHC class II + cells. This 
indicates that at the cellular level there are no differences in the naïve and 
recovered LN composition. Interestingly, the CD4+ T cells in recovered 
LNs were activated (CD25high) which could contribute to a rapid 
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rechallenge response. However, naïve and recovered LNs had a similar 
profile for naïve and memory CD4+ T cell subsets. 
 
Figure 11: Cellular composition of naïve and recovered lung draining LNs. 
Age - matched 
naive and 
recovered mice 
were used for 
characterization of 
lung draining LNs. 
Mouse cervical and 
mediastinal LNs 
(n=3) were pooled 
and single cell 
suspensions were 
prepared. The 
single cell 
suspension was 
stained with mAbs 
and 200000 cells 
were acquired on 
FACS Calibur. Values indicate percentage gated on the lymphocyte gate. 
 
3.6.1. Surface CKR expression in naïve and recovered lung draining 
LNs (FACS) 
We further investigated whether there were differences in CKR 
expression in the naïve and recovered lung draining LNs (Figure 12a). The 
presence of CCR7 on CD4+ T cells have been reported to facilitate the entry 
of central memory cells into the LNs (72). We determined whether 
differences in the expression of CKRs on the LN CD4+ T cells from naïve 
and recovered mice would allow us to characterize the OVA-specific Th2 
memory cell. Cervical and mediastinal LNs (n=5 mice) were pooled and a 
lymphocyte gate (R1) was defined based on the forward scatter (FSC) and 
side scatter (SSC) of the cells (Figure 12a). On the lymphocyte gate (R1), 
using a CD4+ stained sample CD4+ cells were gated (R2). Naïve and 
recovered LN cell CKR expression was evaluated in the CD4+ gate (R2). 
We overlapped the histograms of recovered LN CKRs with naïve LN CKRs 
to determine changes in the expression. In the recovered LNs, the 
expression of CCR3, CCR5-9, CXCR2-6 and CX3CR1 was elevated 
compared to the naïve LNs (Figure 12a). The expression of CCR4 and 
CCR10 was similar in recovered LNs and naïve LNs (Figure 12a). 
Interestingly, the expression of CRTH2 was decreased in recovered LNs 
compared to naïve LNs (Figure 12a). Although the differences in the 
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expression of CKR between naïve and recovered LNs were not significant, 
we observed a trend towards increased expression of CKR in the recovered 
LNs compared to naïve LNs (Figure 12b).  
 In summary, recovered LN CKR expression is characterized by 
elevated expression of CCR3, CCR5-9, CXCR2-6 and CX3CR1 and 
reduced expression of CRTH2. This indicates that in recovered lung 
draining LNs the CD4+ T cells maintain higher CKR expression which 
enables them to continually migrate to the LN. Another possibility could be 
that the high CKR expression maintains the LN CD4+ T cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12a: Expression of CKR in naïve and recovered lung draining LNs. 
Cervical and mediastinal LNs were pooled (n=3-5 mice) and stained for CKRs. 
Histogram shows recovered LN CKR expression (black line) overlaid with naïve 
CKR expression (green line).  
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Figure 12b). Graph indicating the expression of CKR in naïve and recovered 
lung draining LNs. Geometric mean of the CKR in CD4+ gated cells in 3 
independent experiments was plotted. 
 
3.7. Lung cells from recovered mice can be stimulated in vitro 
To ensure that recovered lung had Ag-specific memory Th2 cells, 
lung cell suspensions from recovered mice (2 x 106 cells/well) were plated 
with a titrated dose of OVA (0µg/ml, 0.1µg/ml, 1µg/ml, 10µg/ml, 100µg/ml 
and 1000µg/ml OVA). The cells were incubated at 37°C + 5% CO2 for 40-
43 hrs. Culture supernatants were collected and pooled for cytokine 
ELISAs. The cells were evaluated for up-regulation of early activation 
markers (Diagram 2).  
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Diagram 2: Flow chart of in vitro stimulation experiment 
 
3.7.1. Detection of activation marker CD25 and CD69  
Both CD25 and CD69 are early activation markers that are 
upregulated on recently activated lymphocytes. We tested whether in vitro 
OVA stimulation, upregulated the expression of CD25 and CD69 in the 
recovered lung and splenocytes. If there are OVA specific memory cells 
residing in the lung of recovered mice, then in vitro OVA stimulation would 
result in Th2 cytokine production, which could be detected at 48 hrs in 
culture supernatants.  
Unstimulated recovered lung cells had low expression of CD25 
(Figure 13) and CD69 (Figure 14). Upon stimulation with titrated dose of 
OVA, there was a dose-dependent up-regulation of activation markers 
CD25 and CD69. The expression of CD25 and CD69 upon restimulation 
was highest with 1000µg/ml of OVA.  
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Figure 13: Upregulated expression of CD25 on CD4+ cells upon in vitro OVA 
stimulation. 
Lung single cell 
suspensions from 
recovered mice 
was prepared and 
then stimulated 
with titrated 
doses of OVA for 
43 hrs. A).FACS 
dot blot showing 
the expression of 
CD25 on CD4+ 
cells was 
determined by 
FACS Calibur. 
B). Graph 
representing the 
percentage 
positive of CD4+ 
CD25+ plotted 
against the 
titrated doses of OVA (µg/ml) 
 
 
Figure 14: Upregulated expression of CD69 on CD4+ cells upon in vitro OVA 
stimulation. 
Lung single cell 
suspensions from 
recovered mice 
was prepared and 
then stimulated 
with titrated 
doses of OVA for 
43 hrs. A).The 
expression of 
CD69 on CD4+ 
cells was 
determined by 
FACS Calibur. 
B). Graph 
representing the 
percentage 
positive of CD4+ 
CD69+ plotted against the titrated doses of OVA (µg/ml). 
 
3.7.2 Recovered lung cells produce IL-4, IL-5 and IFNg upon in vitro 
stimulation 
 After in vitro restimulation recovered lung cells with OVA, the 
production of Th2 cytokines would reflect the presence of Th2 cells in the 
lung. We determined the production IL-4, IL-5 and IFNg in the culture 
supernatants after 43 hrs of OVA restimulation. If there are OVA-specific 
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memory cells residing in the lung of recovered mice, then in vitro OVA 
stimulation would result in Th2 cytokine production, which could be 
detected at 48 hrs in culture supernatants.  
 Lung cells cultured with only media produced no IL-4, IL-5 and 
IFNg. However, IL-4 (Figure 15), IL-5 (Figure 16) and IFNg (Figure 17) 
levels increased with increasing doses of OVA in culture supernatants. 
Stimulation with the highest dose (1000µg/ml) of OVA resulted in the 
highest production of IL-4, IL-5 and IFNg by recovered lung cells in culture 
supernatants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Recovered lung cells produce IL-4 upon in vitro stimulation. 
Recovered lung cells were stimulated in vitro with titrated doses of OVA for 4 3hrs. 
The culture supernatant was obtained at 43 hrs and IL-4 levels in culture 
supernatant was determined by ELISA. A). Standard curve of IL-4. B). Production 
of IL-4 by lung cells in vitro after stimulation with titrated doses of OVA. Data are 
expressed as the mean ± SEM of optical density of TMB from duplicate samples 
from individual mice (n=3). The results are representatives of 2 independent 
experiments. 
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Figure 16: Recovered 
lung cells produce IL-5 
upon in vitro 
stimulation. Recovered 
lung cells were stimulated 
in vitro with titrated doses 
of OVA for 43 hrs. The 
culture supernatant was 
obtained at 43 hrs and IL-
5 levels in culture 
supernatants were 
determined by ELISA. A). 
Standard curve of IL-5. 
B). Production of IL-5 by 
lung cells in vitro after 
stimulation with titrated 
doses of OVA. Data are 
expressed as the mean ± 
SEM of optical density of 
TMB from duplicate 
samples from individual 
mice (n=3). The results 
are representatives of 2 
independent experiments. 
 
 
 
 
Figure 17: Recovered 
lung cells produce 
IFNg upon in vitro 
stimulation. Recovered 
lung cells were 
stimulated in vitro with 
titrated doses of OVA 
for 43 hrs. The culture 
supernatant was 
obtained at 43 hrs and 
IFNg levels in culture 
supernatant were 
determined by ELISA. 
A). Standard curve of 
IFNg. B). Production of 
IFNg by lung cells in 
vitro upon stimulation 
with titrated doses of 
OVA. Data are 
expressed as the mean 
± SEM of optical 
density of TMB from 
duplicate samples from 
individual mice (n=3). 
The results are representatives of 2 independent experiments. 
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3.8. Splenocytes from recovered mice cannot be stimulated in vitro 
 Spleen also maintains a fraction of memory Th2 cells (86) that can 
be stimulated Ag-specifically in vitro to produce Th2 cytokines. To verify 
whether splenocytes would upregulate the activation marker and produced 
Th2 cytokines upon in vitro OVA stimulation, splenocytes from recovered 
mice were cultured with titrated doses of OVA for 43 hrs and the culture 
supernatants were analysed for cytokine production. 
 
3.8.1 Recovered splenocytes fail to produce IL-4, IL-5, and IFNg in 
culture supernatant upon OVA stimulation 
 Previous data from our lab demonstrated that splenocytes from 
recovered mice could be stimulated in vitro with OVA and produced Th2 
cytokines. Splenocyte culture supernatants were evaluated for production of 
IL-4, IL-5 and IFNg. Unstimulated splenocytes produced no IL-4, IL-5 or 
IFNg. Surprisingly, even after 43 hrs of OVA restimulation, splenocytes 
failed to produce IL-5 and minimally produced IL-4 (Figure 18), and IFNg 
(Figure 19). This result was in contrast to previously published data from 
our laboratory (86), where splenocytes could be stimulated in vitro to 
produce Th2 cytokines and IFN-g. However, the differences in method for 
detection of cytokines (ELISPOT vs. ELISA) could account for the 
differences in the results. ELISPOT is a more sensitive method for detection 
and presumably the low numbers of memory Th2 cells producing 
interleukins upon restimulation can be better detected using ELISPOT.  
Figure 18: Recovered 
splenocytes produce 
minimal IL-4 upon in 
vitro stimulation 
Recovered splenocytes 
were stimulated in vitro 
with titrated doses of 
OVA for 43 hrs. The 
culture supernatant was 
obtained at 43 hrs and 
IL-4 levels in culture 
supernatant were 
determined by ELISA. 
A). Standard curve of IL-
4. B). Production of IL-4 
by splenocytes in vitro 
after stimulation with 
titrated doses of OVA. 
Data are expressed as 
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the mean ± SEM of optical density of TMB from duplicate samples from individual 
mice (n=3). The results are representatives of 2 independent experiments. 
 
Figure 19: Recovered splenocytes produce minimal IFN-g upon in vitro 
stimulation. Recovered splenocytes were stimulated in vitro with titrated doses of 
OVA for 43 hrs. The culture supernatant was obtained at 43hrs and IFNg levels in 
culture supernatant 
were determined by 
ELISA. A). Standard 
curve of IFNg. B). 
Production of IFNg 
by splenocytes in 
vitro upon stimulation 
with titrated doses of 
OVA. Data are 
expressed as the 
mean ± SEM of 
optical density of 
TMB from duplicate 
samples from 
individual mice 
(n=3). The results are 
representatives of 2 
independent 
experiments. 
 
3.8.2. Detection of activation markers CD25 and CD69  
Splenocytes upon stimulation with a titrated dose of OVA did not 
upregulate the expression of CD25 (Figure 20) and CD69 (Figure 21), 
suggesting that there is a small percentage of OVA-specific memory Th2 in 
the spleen or the spleen memory Th2 cells are not functionally active and do 
not respond to OVA in vitro. Since we did not detect IL-5 and minimal IL-4 
and IFNg after OVA restimulation in culture supernatant, we examined the 
activation status of the recovered and in vitro stimulated CD4+ T 
splenocytes.  
Figure 20: Expression 
of CD25 on CD4+ cells 
upon in vitro OVA 
stimulation. Spleen 
single cell suspension 
from recovered mice 
was prepared and then 
stimulated with titrated 
doses of OVA for 43 
hrs. A).The expression 
of CD25 on CD4+ cells 
was determined by 
FACS Calibur. B). 
Graph representing the 
percentage positive of 
CD4+ CD69+ plotted 
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against the titrated doses of OVA(µg/ml). The results are representatives of 2 
independent experiments. 
 
Figure 21: Expression 
of CD69 on CD4+ cells 
upon in vitro OVA 
stimulation. Spleen 
single cell suspension 
from recovered mice 
was prepared and then 
stimulated with titrated 
doses of OVA for 43 
hrs. A).The expression 
of CD69 on CD4+ cells 
was determined by 
FACS Calibur. B). 
Percentage positive of 
CD4+ CD69+ plotted 
against the titrated 
doses of OVA(µg/ml). The results are representatives of 2 independent 
experiments. 
 
3.9. Inhibition of Th2 memory cells and allergic asthma 
3.9.1. Treatment with Dexamethasone to abolish allergic asthma  
Glucocorticoids are used to treat inflammatory diseases and are 
especially beneficial in asthma. Previous experiments from our laboratory 
demonstrated that treatment with dexamethasone  was effective in 
decreasing inflammation during overt disease but less efficient during 
relapse (313). We tested the effect of dexamethasone on inhibition of 
relapse in our model of allergic asthma. Previous experiment from our 
laboratory demonstrated that dexamethasone  treatment effectively reduces 
inflammation by 75% during overt disease and less than 1% during relapse 
(313). We tested whether dexamethasone would have the same effect in our 
memory model of allergic asthma and abrogate memory Th2 cells that are 
maintained in the recovered lungs. We allowed mice to recuperate for a 
period of at least 3 months after disease induction followed by treatment 
with dexamethasone before aerosol challenge. Three i.n. doses of 
dexamethasone 10mg/kg b.wt. was administered to recovered mice during 
recovery and one i.n. dose 1 hr before each aerosol challenge. In total, the 
mice received seven i.n. doses of dexamethasone. Mice were assessed 48 
hrs after the last aerosol challenge. Lungs were flushed with 1X PBS and 
BAL cytospins were prepared. The slides were stained with May- 
Grünwald- Giemsa and at least 300 cells were counted.  
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Intranasal treatment with dexamethasone reduced the total BAL cells 
by three fold compared to placebo treated group (Figure 22). 
Dexamethasone treated group had reduced BAL eosinophilia compared to 
placebo treated group (Figure 22). The percentage of lymphocytes in both 
placebo and dexamethasone treated group were comparable, suggesting that 
treatment with corticosteroid during recovery did not eradicate memory 
CD4+ Th2 cells. In summary, dexamethasone treatment of recovered mice 
reduced BAL eosinophilia with no effect on the percentage of lymphocytes. 
This suggests that dexamethasone -mediated anti-inflammatory action 
during relapse in our memory model was due to inhibition of eosinophils 
and memory CD4+ Th2 cells are difficult to target. 
 
Figure 22: Dexamethasone treatment decreases lung inflammation. Recovered 
mice were intranasally 
treated with either 
placebo or 7 i.n doses of 
dexamethasone (10mg/kg 
B.wt.); 3 doses during 
recovery and 1 dose 
before 1hr before each 
OVA aerosol challenge. 
A). Total BAL cells in 
placebo treated and 
dexamethasone treated 
mice. B). Percentage of 
cells in the BAL of 
placebo or 
dexamethasone treated 
mice. C). Absolute cell 
number in BAL of placebo 
or dexamethasone treated 
mice (n=3). 
M=Macrophages, E= 
eosinophils, N= 
Neutrophils, L= 
Lymphocytes 
 
 
 
 
 
 
3.9.2. Splenectomy of recovered mice to abate allergic asthma  
We found that the recovered splenocytes upon in vitro stimulation 
with OVA did not produce Th2 cytokines and did not upregulate activation 
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markers CD25 and CD69. To verify whether removal of spleen would 
influence a rechallenge response, we performed splenectomy on recovered 
mice. One month or four months post splenenctomy, mice were 
rechallenged with 1% OVA 1hr b.i.d on two consecutive days. Mice were 
assessed for the disease 48 hrs after the last aerosol challenge (Diagram 3).  
Diagram 3: Flow chart of Splenectomy experiment 
 
3.9.2.i. Splenectomized rechallenged mice develop increased lung 
eosinophilia  
Mice recovered from acute allergic asthma were splenectomized (on 
day 190) and allowed to recover for 1 month. Splenectomized recovered 
mice were then aerosol challenged along with non splenectomized 
recovered mice for 1hr b.i.d on two consecutive days (days 223 and 224). 
Forty- eight after the last aersol challenge the mice were killed and BAL 
was obtained by flushing lungs with 1X PBS and 105 cells / slides were 
stained with May- Grünwald- Giemsa for differential cell counts. BAL 
obtained from naïve, recovered and recovered splenectomized mice 
consisted mostly of macrophages (approximately 95%) and few 
lymphocytes (approximately 4%) (Figure 23b). Rechallenged mice had 
elevated (approximately 20%) eosinophils in BAL compared to naïve and 
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recovered mice (Figure 23b). Surprisingly, splenectomized rechallenged 
mice developed severe lung eosinophilia (approximately 60%). 
Splenectomized rechallenged mice had 3 fold more eosinophilia compared 
to rechallenged non splenectomized mice. These results were surprising 
because we had hypothesized that in absence of spleen the extent of disease 
would either be decreased or unaffected. Increased BAL eosinophilia could 
imply that in absence of spleen there is increased migration and homing of 
Th2 cells to the lung. Upon Ag rechallenge, the cells migrated more rapidly 
to the lung. Another possibility could be that the spleen, by some unknown 
mechanisms suppresses lymphocyte infiltration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Rechallenged splenectomized mice develop severe lung 
eosinophilia. Splenectomized recovered and non- splenectomized recovered mice 
were rechallenged with 1%OVA for 1hr b.i.d. on two consecutive days. Mice were 
assessed 48 hrs after the last aerosol challenge. A).BAL slides stained with May 
Grundwald- Giemsa and images taken at 10x. Inset shows cells from respective 
BAL slides. (B) Percentage of cells in BAL and (C) absolute cell numbers in BAL. 
M=Macrophages, E= eosinophils, N= Neutrophils, L= Lymphocytes 
 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: Recallenged splenectomized mice develop severe lung eosinophilia 
4 months post splenectomy. Splenectomized recovered and non- splenectomized 
recovered mice were rechallenged with 1% OVA for 1 hr b.i.d. on two consecutive 
days. Mice were assessed 48 hrs after the last aerosol challenge. (A) Percentage of 
cells in BAL and (B) absolute cell numbers in BAL. M=Macrophages, E= 
eosinophils, N= Neutrophils, L= Lymphocytes 
 
To verify, whether circulating Th2 cells were abolished 4 months 
after splenectomy, we splenectomized the recovered mice on day 387 and 
allowed them to rest for 4 months. Splenectomized mice were then 
rechallenged along with non splenectomized mice on days 509 and 510 with 
1% OVA 1hr b.i.d. and assessed on day 512. Mice were killed 48 hrs after 
the last aerosol challenge and BAL was performed. The BAL cells were 
stained with May-Grünwald- Giemsa for differential cell counts. The BAL 
results from 4 month time points were similar to 1 month post-splenectomy 
time point. BAL obtained from naïve, recovered and recovered 
splenectomized mice consisted mostly of macrophages (approximately 
90%) and few lymphocytes (approximately 5%) (Figure 24a). Rechallenged 
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mice had elevated (approximately 13%) eosinophils in BAL compared to 
naïve and recovered mice (Figure 24a). Surprisingly, splenectomized 
rechallenged mice developed severe lung eosinophilia (approximately 40%). 
Splenectomized rechallenged mice had 2 fold more eosinophilia compared 
to rechallenged non-splenectomized mice. Although the percentage of 
eosinophils in the rechallenged-splenectomized group decreased at the 4-
month time point (to 40%); it was still higher compared to the rechallenged 
group at 4-month time point (Figure 24a). In summary, spelenctomized 
rechallenged mice developed more severe eosinophilia compared to 
rechallenged non splenectomized mice. 
 
3.9.2.ii. Infilterates in the lungs of splenectomized recovered and 
splenectomized rechallenged mice  
To determine whether there is inflammatory cell infiltration in lung 
tissue of splenectomized mice, lungs were harvested at 48 hrs after the last 
aerosol challenge. Lungs were stored in 4% paraformaldehyde and 
embedded in paraffin. Lung tissue was cut at 4µm section, and stained with 
H&E (Figure 25).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25a: Splenectomized rechallenged mice maintain infiltration one 
month post splenectomy. Lungs were harvested 48 hrs after the last aerosol 
challenge and processed for paraffin sections. 4µm tissue sections were cut and 
stained with H&E. A).Photomicrograph of lung tissue taken at 4x magnification. 
Inset shows cells in the respective tissue at 40X magnification. 
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We observed that recovered non-splenectomized mice maintained 
infiltrates that consisted mainly of macrophages and lymphocytes. 
Interestingly, recovered splenectomized mice appeared to have less lung 
infiltrates compared to recovered non splenectomized mice one month post 
splenectomy (Figure 25a ). However, 4 months post-splenectomy, recovered 
splenectomized mice had more lung infiltrates (Figure 25 b). Rechallenged 
non-splenectomized mice had extensive lung infiltration and there were 
eosinophils in the infiltrates. The rechallenged splenectomized mice also 
had lung infiltration, however, the extent of infiltration was lower compared 
to rechallenged non-splenectomized mice at one month post splenectomy. 
Recovered mice that were splencetomized and then rechallenged 4 months 
post splectomy developed inflammatory infiltrates in the lungs that 
resembeled the rechallenged non-splenectomized group (Figure 25b). One 
possibility could be that the spleen regulates the extent of infiltration. In the 
absence of spleen, the infiltrates in the lung are not efficiently maintained. 
Figure 25b: Splenectomized rechallenged mice maintain infiltration four 
months post splenectomy. Lungs were harvested 48 hrs after the last aerosol 
challenge and processed for paraffin sections. 4µm tissue sections were cut and 
stained with H&E. A).Photomicrograph of lung tissue taken at 4x magnification. 
Inset shows cells in the respective tissue at 40X magnification. 
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In summary, rechallenged non- splenectomized mice had extensive 
lung infiltration consisting mainly of eosinophils which was higher 
compared to rechallenged splenectomized mice, one month post 
splenectomy. At 4 months post splenectomy however, the extent of 
infiltration in rechallenged non-splenectomized and rechallenged 
splenectomized mice was comparable. 
 
3.9.2.iii. Decrease mucus production in splenctomized rechallenged 
mice 
To determine whether there was a change in mucus production in 
splenectomized mice, lungs were harvested at 48 hrs after the last aerosol 
challenge. Lungs were stored in 4% paraformaldehyde and embedded in 
paraffin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26a: Splenectomized rechallenged mice have mucus hypersecting 
globlet cells one month post splenectomy. Lungs were harvested 48 hrs after the 
last aerosol challenge and processed for paraffin sections. 4µm tissue sections 
were cut and stained with PAS. Photomicrograph of lung tissue taken at 10X 
magnification. Inset shows cells in the respective tissue at 40X magnification 
 
Lung tissue was cut at 4µm section, and stained with PAS. Recovered non-
splenectomized and splenectomized recovered mice had no mucus-
producing goblet cells in the lung (Figure 26). Rechallenged non-
splenectomized mice had an increased number of mucus-producing goblet 
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cells. Splenectomized rechallenged mice also had mucus-producing goblet 
cells. However, the extent of mucus production was less compared to 
rechallenged non-splenectomized mice. In contrast, naïve mice showed no 
mucus hypersecretion. In summary, splenectomized rechallenged mice 
produce less mucus compared to rechallenged non-splenectomized mice.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26b: Splenectomized rechallenged mice have mucus hypersecting 
globlet cells four months post splenectomy. Lungs were harvested 48 hrs after 
the last aerosol challenge and processed for paraffin sections. 4µm tissue sections 
were cut and stained with PAS. Photomicrograph of lung tissue taken at 10X 
magnification. Inset shows cells in the respective tissue at 40X magnification. 
 
3.9.2.iv. Splenectomized rechallenged mice have increased tissue 
eosinophilia 
Our BAL results demonstrated that the splenectomized rechallenged 
mice had a 3-fold increase in eosinophilia compared to rechallenged mice 
(Figure 23b). To check whether this increase in eosinophilia could also be 
seen at the tissue level in lung, mice were sacrificed 48 hrs after the last 
aerosol challenge and lungs were fixed in 4 % paraformaldehyde. Lung 
sections were stained with LUNA, which allows for differential staining of 
tissue eosinophils (Figure 27 a and b). LUNA staining revealed that 
splenectomized rechallenged mice had more eosinophils compared to 
rechallenged non-splenectomized mice. Recovered non-splenectomized  
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Figure 27a: Splenectomized rechallenged mice develop tissue eosinophilia one 
month post splenectomy. Lungs were harvested 48 hrs after the last aerosol 
challenge and processed for paraffin sections. 4µm tissue sections were cut and 
stained with LUNA. Photomicrograph of lung tissue taken at 10X magnification. 
Inset shows cells in the respective tissue at 40X magnification 
Figure 27b: Splenectomized rechallenged mice develop tissue eosinophilia four 
months post splenectomy. Lungs were harvested 48 hrs after the last aerosol 
challenge and processed for paraffin sections. 4µm tissue sections were cut and 
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stained with LUNA. Photomicrograph of lung tissue taken at 10X magnification. 
Inset shows cells in the respective tissue at 40X magnification. 
 
mice, splenectomized recovered and naïve mice had no lung eosinophilia. 
Our finding in the BAL is also mirrored in the lung tissue. We found the 
highest lung eosinophilia in the splenectomized rechallenged mice. In 
summary, splenectomized rechallenged mice developed more lung 
eosinophilia compared to rechallenged non splenectomized mice.  
 
.3.9.2.v. Sera IgG1 for splenectomy experiment 
To evaluate whether there are differences in the OVA-specific IgG1 
levels in splenectomized rechallenged and rechallenged non-splenectomized 
mice, ELISAs were performed on sera obtained 48 hrs after the last aerosol 
challenge. Recovered non-splenectomized mice and splenectomized 
recovered mice maintained high levels of sera OVA-specific IgG1 titres 
(Figure 28a). Rechallenged non-splenectomized and splenectomized 
rechallenged mice also had high sera OVA- specific IgG1 titres compared to 
naïve mice (Figure 28a).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28a: Splenectomized rechallenged mice maintain elevated sera OVA-
specific IgG1 levels one month post splenectomy. Sera was obtained from mice 
(n=3 per group) 48 hrs after the last aerosol challenge. Levels of sera OVA-
specific IgG1 was determined by ELISA. Data are expressed as the mean ± SEM of 
optical density of TMB from duplicate samples from individual mice (n=3). 
 
Futhermore, we analysed sera OVA specific IgG1 titre; 1 month 
(Figure 28a) and 4 months (Figure 28b) post-splenectomy and found similar 
trends of high OVA specific IgG1 titers at both time points in recovered, 
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rechallenged, splenectomized recovered and splenectomized rechallenged 
mice. 
 
Figure 28b: Splenectomized rechallenged mice maintain elevated sera OVA-
specific IgG1 levels four months post splenectomy. Sera was obtained from mice 
(n=3 per group) 48 hrs after the last aerosol challenge. Levels of sera OVA-
specific IgG1 was determined by ELISA. Data are expressed as the mean ± SEM of 
optical density of TMB from duplicate samples from individual mice (n=3). 
 
In summary, splenectomized recovered and splenectomized 
rechallenged mice maintain high sera OVA- specific IgG1 titres. 
Furthermore, the levels of OVA- specific IgG1 titres in splenectomized 
recovered and splenectomized rechallenged were comparable to recovered 
and rechallenged mice. 
 
3.9.2.vi. Sera IgE for splenectomy experiment 
To evaluate whether there are differences in the OVA-specific IgE 
levels in splenectomized rechallenged and rechallenged non splenectomized 
mice, ELISAs were performed on sera obtained 48 hrs after the last aerosol 
challenge. Splenectomized rechallenged and splenectomized recovered mice 
maintained high levels of sera OVA -specific IgE titres at both one and four 
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 Figure 29: Splenectomized rechallenged mice maintain elevated sera OVA-
specific IgE levels post splenectomy. Sera was obtained from mice (n=3 per 
group) 48 hrs after the last aerosol challenge. Levels of sera OVA-specific IgE was 
determined by ELISA. A).IgE titer of naïve, recovered, splenectomized recovered 
and splenectomized rechallenged one month post splenectomy. B). .IgE titer of 
naïve, recovered, splenectomized recovered and splenectomized rechallenged four 
months post splenectomy. Data are expressed as the mean ± SEM of optical density 
of TMB from duplicate samples from individual mice (n=3). 
 
months post splenectomy (Figure 29 a and b). Rechallenged non-
splenectomized and splenectomized rechallenged mice also had high sera 
OVA- specific IgE titres compared to naïve mice. 
In summary, splenectomized recovered and splenectomized 
rechallenged mice maintain high sera OVA- specific IgE titres.  
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Furthermore, the levels of OVA-specific IgE titres in 
splenectomized recovered and splenectomized rechallenged were elevated 
compared to recovered and rechallenged non -splenectomized mice. 
 
3.9.3. Irradiation as method for depleting memory Th2 cells and 
disrupting allergic asthma 
 We asked whether we could diminish or abrogate allergic asthma if 
we depleted T lymphocytes and APCs during recovery period, allow re-
establishment of the immune system followed by allergen rechallenge. 
Recovered mice received a sublethal dose of 6.5Gy of Cobalt 60. The mice 
were allowed to recover from the irradiation and the immune system was 
allowed to re-establish for 1 week post irradiation. One week post 
irradiation, mice were rechallenged with 1% OVA for 1hr on 2 consecutive 
days. The mice were assessed 48 hrs after the last aerosol challenge 
(Diagram 4).  
Diagram 4: Flow chart of irradiation experiment 
 
3.9.3.i. Irradiation experiment BAL results 
To evaluate disease in the lung, BAL cytospins were prepared by 
spinning 105 cells /slide. The slides were stained with May- Grünwald- 
Giemsa and at least 300 cells were counted. BAL of naïve irradiated mice 
contained mostly macrophages, few lymphocytes and no eosinophils 
(Figure 29a). Lungs from irradiated rechallenged mice also consisted mostly 
of macrophages, few lymphocytes and no eosinophils in BAL. 
Rechallenged mice had around 55% eosinophils and 15% lymphocytes 
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(Figure 29a). The BAL findings indicate that recovered mice after being 
sublethally irradiated followed by rechallenge did not develop secondary 
disease. 
Figure 29: Irradiated rechallenged mice do not develop lung inflammation. 
Irradiated rechallenged and rechallenged mice (n=3 per group) were assessed 48 
hrs after the last aerosol challenge. BAL cytospins stained with May- Grünwald- 
Giemsa solution. Percentage of BAL cells (A) and absolute cells number (B) in 
various groups. M=Macrophages, E= Eosinophils, N= Neutrophils, L= 
Lymphocytes 
 
3.9.3.ii. H&E staining of lung tissue for irradiation experiment 
To evaluate inflammatory cell infiltration in lung tissue, lungs of 
irradiated mice were harvested at 48 hrs after the last aerosol challenge. 
Lungs were stored in 4% paraformaldehyde and embedded in paraffin. Lung 
sections were stained with H&E (Figure 30). We observed that rechallenged 
mice had both central lung (grade 1.5 - 3) and central airway (grade 1.5- 
2.7) infiltrates. Infiltration was also observed in the lung periphery (grade 0-
1) and peripheral airway (grade 0-1.8) in rechallenged mice. Irradiated 
rechallenged mice had infiltrates only in the central lung (grade 0.5 - 1) and 
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no infiltrates in the lung periphery. The extent of infiltration was also 
reduced compared to rechallenged mice. The infiltrates in the central airway 
was reduced (grade 0.5-1) and no peripheral airway infiltrate was detected 
in irradiated rechallenged mice. Naïve irradiated mice had no infiltration in 
the lung. 
 In summary, rechallenged mice developed both central and 
peripheral infiltration, whereas irradiated rechallenged mice had reduced 
lung infiltration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Irradiated rechallenged mice maintain central infiltrates. Lungs 
were harvested 48 hrs after the last aerosol challenge and processed for paraffin 
sections. 4µm tissue sections were cut and stained with H&E. Lungs were 
embedded in paraffin and stained with H&E. Representative photomicrographs 
taken at 10X from 3 individual mice. Inflammatory foci are marked with arrows. 
 
3.9.3.iii. PAS staining of lung tissue for irradiation experiment 
To evaluate OVA- specific mucus production, lung tissue from 
irradiated naïve, irradiated rechallenged and rechallenged mice were stained 
with PAS. 48 hrs after the last aerosol challenge the mice were killed and 
lungs were stored in 4% paraformaldehyde and embedded in paraffin. Lung 
sections were stained with PAS. Analysis of PAS stained lung tissue 
sections of rechallenged mice indicated an increased number of mucus-
producing goblet cells compared to naïve mice (Figure 31). Additionally, 
there were PAS positive cells in both central and peripheral lung of 
rechallenged mice. Irradiated rechallenged mice had less PAS positive cells 
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and these were restricted to the central lung. In contrast naïve mice showed 
no mucus hypersecretion.  
 In summary, we observed that OVA-specific mucus hypersecretion 
in rechallenged mice and to a lesser extent in irradiated rechallenged mice. 
Figure 31: Irradiated rechallenged lungs maintain mucus secreting goblet 
cells. Lungs were harvested 48 hrs after the last aerosol challenge and processed 
for paraffin sections. 4µm tissue sections were cut and stained with PAS. 
Photomicrograph of lung tissue taken at 4x magnification. Inset shows cells in the 
respective tissue at 40X magnification. 
 
3.9.3.iv. LUNA staining of lung tissue for irradiation experiment 
To evaluate lung eosinophilia in irradiated mice, mice were 
sacrificed 48 hrs after the last aerosol challenge and lungs were fixed in 4 % 
paraformaldehyde. Lung sections were stained with LUNA. Rechallenged 
mice demonstrated extensive tissue eosinophilia in central and peripheral 
lung and airway (Figure 32). In contrast, irradiated rechallenged and naïve 
mice had no lung tissue eosinophilia. 
  
Figure 32: Irradiated rechallenged lungs have tissue eosinophilia. Lungs were 
harvested 48 hrs after the last aerosol challenge and processed for paraffin 
sections. 4µm tissue sections were cut and stained with LUNA. A). 
Photomicrograph of lung tissue taken at 10X magnification. Inset shows cells in 
the respective tissue at 40X magnification. 
 
 113 
In summary, rechallenged mice had extensive lung eosinophilia, 
whereas irradiated rechallenged mice had no lung eosinophilia. 
 
3.9.3.v. Immunofluorescence staining of lung tissue demonstrate 
depletion of CD4+, MHC class II+ and B220+ cells in the lung post 
irradiation  
To check for the presence of CD4+ T cells, B cells and APCs, 
immunofluorescence staining was done on lung tissue obtained from naïve 
irradiated, rechallenged irradiated and rechallenged non-irradiated mice. 
Mice were sacrificed 48 hrs after the last aerosol challenge and lung tissue 
was embedded in OCT and stored at -20°C. Frozen lung tissue was cut at 
4µm and stained with fluorochrome-conjugated mAb for 
immunofluorescence microscopy. Irradiated naïve and irradiated 
rechallenged mice had few CD4+ T cells, B220+ cells (Figure 33) and 
MHC class II + cells (Figure 34), whereas in rechallenged mice there were 
higher numbers of CD4+ T cells, B220+ and MHC class II+ cells.  
Figure 33: Irradiated rechallenged mice have few T and B cells in the lung. 
Lungs were harvested 48 hrs after the last aerosol challenge and processed for 
frozen sections. 4µm tissue sections were cut and stained with fluorochrome 
conjugated mAb. Representative photomicrographs taken at 40X from 3 individual 
mice. Inset shows cells in the respective lung tissue. 
Figure 34: Irradiated rechallenged mice have few T and MHC class II positive 
cells in the lung. Lungs were harvested 48 hrs after the last aerosol challenge and 
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processed for frozen sections. 4µm tissue sections were cut and stained with 
fluorochrome conjugated mAb. Representative photomicrographs taken at 40X 
from 3 individual mice. Inset shows cells in the respective lung tissue. 
 
To conclude, rechallenged mice had high number of CD4+ T cells, 
B220+ cells and MHC class II + cells, and irradiated rechallenged mice had 
reduced numbers of T, B and MHC class II cell populations. 
 
3.9.3.vi. Sera IgG1 for irradiation experiment 
To determine whether the reduced response seen in BAL and lung 
tissue was also reflected in the sera, sera was collected 48 hrs after the last 
aerosol challenge and tested for OVA-specific IgG1. Measurement of OVA-
specific IgG1 was done by ELISA. Rechallenged mice had higher serum 
OVA-specific IgG1 compared to irradiated rechallenged group. Both naïve 
irradiated and irradiated rechallenged mice had low titres of OVA-specific 
IgG1 response (Figure 35).  
In summary, rechallenged mice had higher OVA –specific sera IgG1 
compared to irradiated rechallenged mice. Irradiated naïve and irradiated 
rechallenged mice had lower sera IgG1 levels compared to rechallenged 
mice. 
Figure 35: Serum OVA-specific IgG1 in naive, irradiated rechallenged and 
rechallenged mice. Forty – eight hrs after the last aerosol challenge with OVA, 
mice were bled and sera were collected and tested for OVA-specific IgG1 by 
ELISA. Data are expressed as the mean ± SEM of optical density of TMB from 
duplicate samples from individual mice (n=3) 
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3.9.3.vii. Sera IgE levels for irradiation experiment 
To evaluate the sera IgE levels, mice were sacrificed 48 hrs after the 
last aerosol challenge and OVA –specific IgE was performed. At 48 hrs 
after aerosol challenge, rechallenged mice had higher serum OVA-specific 
IgE titres compared to irradiated rechallenged mice. Both irradiated naïve 
and irradiated rechallenged mice had lower OVA-specific IgE response 
compared to rechallenged mice (Figure 36).  
In summary, rechallenged mice had higher OVA-specific IgE titres 
compared to irradiated rechallenged mice. 
Figure 36: Serum OVA-specific IgE in naïve, irradiated rechallenged and 
rechallenged mice. Forty – eight hrs after the last aerosol challenge with OVA, 
mice were bled and sera were collected and tested for OVA-specific IgE by ELISA. 
Data are expressed as the mean ± SEM of optical density of TMB from duplicate 
samples from individual mice (n=3) 
 
3.10. Milk as an allergen and milk model of allergic asthma 
Most mouse models of allergic asthma use ovalbumin (OVA) as an 
allergen. OVA generates a well defined immune response and the 
immunodominant epitope is known. We were interested to develop a model 
where we could use 1) A naturally occurring clinically relevant allergen, 2) 
Generate an immune response to a variety of proteins and thus mimic the 
conditions of allergic patients, 3) Be cost effective. Milk is a common food 
allergen that consists of several proteins and fits the criteria mentioned 
above. We tested whether milk could induce allergic asthma in 2 different 
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strains of mice; BALB/c and B6. Furthermore, we were also interested to 
see whether the individual milk components induce sera IgG1 levels.  
To induce allergic asthma using milk as an allergen, B6 and BALB/c 
mice were sensitized on days 0 and 21 with 10µg milk/200µl of PBS. The 
sensitized mice were then aerosol challenged with 2% milk solution for 1hr 
b.i.d on days 28 and 29. Acute disease was assessed on day 31. To check 
whether, milk as an allergen could also induce relapse (i.e. after day 90), 
recovered mice were rechallenged with 2% milk on 2 consecutive days for 
1hr b.i.d. and assessed 48 hrs after the last aerosol challenge. For sera IgE 
levels, mice were assessed 96 hrs after the last aerosol challenge. 
 
3.10.1. Bronchoalveolar lavage (BAL) evaluation 
BAL was obtained by flushing the lungs of naïve and diseased mice 
twice with 1 ml of 1X PBS. BAL cytospins were prepared and stained with 
May- Grünwald for differential cell counts. During primary disease, milk 
induced a significant increase in the total cell number in BAL of B6 mice 
compared to naïve B6 mice (Figure 37a). This increase in total cell number 
was attributed to a significant increase in the number of eosinophils and 
macrophages in the BAL. However, in BALB/c mice, milk induced a 
marginal increase in the total cell counts in BAL of BALB/c mice. There 
was increased number of macrophage and eosinophils in the BAL of 
BALB/c diseased mice compared to BALB/c naïve mice. However, milk 
induced significantly higher airway inflammation in B6 mice compared to 
BALB/c mice.  
To check for recall responses, mice were allowed to recover from 
the primary disease for at least 3 months and then rechallenged for 1hr b.i.d. 
with 2% milk on 2 consecutive days. During secondary disease (Figure 37 
b), also the B6 mice developed significantly higher airway infiltration 
compared to BALB/c mice, which was attributed to an increase in 
eosinophil numbers. 
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Figure 37 : Airway inflammation in B6 and BALB/c mice during acute and 
relapsing allergic asthma. For acute disease, A) mice were immunized with 10 mg 
milk on days 0 and 21. Seven days later, they were challenged with nebulized with 
a 2% milk solution for 1 h twice daily for 2 consecutive days (days 28 and 29). 
BAL fluid was harvested 48 h after the last aerosol challenge. Following acute 
disease, B) mice were allowed to recuperate and were rechallenged with nebulized 
with a 2% milk solution for 1 h twice daily for 2 consecutive days (days 88 and 89). 
BAL fluid was harvested 48 h after the last aerosol challenge. The data are 
presented as cells/ml of BAL fluid ± SD and percentages ± SD of individual cell 
types (n=4). TBC= total BAL cell counts, E=eosinophils, M=macrophages, 
N=neutrophils, L=lymphocytes. (■) Diseased, (□) Naïve  
 
3.10.2. Sera IgG1 results of whole milk induced allergic asthma 
To determine whether there are differences in the production of 
IgG1 in BALB/c vs. B6 mice, sera from naïve, recovered and rechallenged 
BALB/c and B6 was obtained 48 and 96 hrs after the last aerosol challenge. 
Recovered B6 mice had elevated milk specific IgG1 titres compared to 
naïve B6 mice (Figure 38). Rechallenged B6 mice had higher IgG1 titres 
compared to recovered and naïve B6 mice. Recovered BALB/c mice also 
had elevated milk specific IgG1 compared to naïve BALB/c mice and the 
titres of IgG1 was highest in rechallenged BALB/c mice. Comparing the 
rechallenged IgG1 titres of BALB/c and B6 mice; rechallenged B6 mice had 
higher IgG1 antibody titres compared to BALB/c rechallenged mice. These 
data indicate that B6 mice developed higher IgG1 antibody titres against 
milk compared to BALB/c mice. 
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Figure 38: Serum OVA-specific IgG1 in naive, recovered and rechallenged 
BALB/c and B6 
mice. Sera IgG1 
levels was 
determined by 
ELISA for naïve 
(J), recovered 
(?), and 
rechallenged (Q) 
mice. Data are 
expressed as the 
mean ± SEM of 
optical density of 
OPT substrate from 
duplicate samples 
from individual 
mice (n=3) 
 
3.10.3. Sera IgG1 levels for individual milk components 
Milk consists of several proteins and to determine the antibody titres 
against the various components of milk, sera IgG1 levels were tested and 
compared for naïve, recovered and rechallenged B6 and BALB/c mice. 
 
3.10.3.i. Levels of Casein specific IgG1 in sera 
B6 rechallenged mice had higher casein specific IgG1 antibody titre 
compared to BALB/c rechallenged mice (Figure 39). Casein specific IgG1 
antibody was also detected in recovered B6 and BALB/c mice. Although the 
titres in recovered mice were lower than in rechallenged mice. Naïve mice 
had no casein specific IgG1 antibody. High IgG1 titres against casein in 
rechallenged B6 compared to BALB/c mice indicate that the B6 mice 
develop disease against the most immunodominant epitope of milk, and thus 
mimics the disease development like in humans.  
Figure 39: Sera Casein specific IgG1 titres in B6 and BALB/c mice 
Sera from B6 recovered 
(?) and rechallenged 
(Q) and BALB/c 
recovered (?) and 
rechallenged (J) and 
naïve (?) mice were 
incubated with Casein. 
Data are expressed as 
the mean ± SEM of 
optical density of OPT 
substrate from 
duplicate samples from 
individual mice ( n=3) 
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3.10.3.ii. Levels of Beta lactglobulin (BLG) specific IgG1 in sera 
The Ab titres against BLG in B6 and BALB/c rechallenged mice 
were comparable. In both these mice there was high BLG specific IgG1 
antibody titres compared to naive mice. Interestingly, BLG specific IgG1 
antibody was also high in recovered B6 and BALB/c mice. Naïve mice had 
no BLG specific IgG1 antibody (Figure 40). 
Figure 40: Sera Beta lactglobulin specific IgG1 titres in B6 and BALB/c mice 
Sera from B6 recovered 
(?) and rechallenged 
(Q) and BALB/c 
recovered (?) and 
rechallenged (J) and 
naïve (?) mice were 
incubated with Beta 
lactglobulin. Data are 
expressed as the mean 
± SEM of optical 
density of OPT 
substrate from 
duplicate samples from 
individual mice ( n=3) 
 
 
 
3.10.3.iii. Levels of Alpha lactalbumin (ALA) specific IgG1 in sera 
The Ab titres for ALA in rechallenged B6 and BALB/c mice were 
lower compared to the levels of Casein and BLG. In rechallenged B6 and 
BALB/c mice, ALA specific IgG1 were comparable. Recovered B6 and 
BALB/c mice also had ALA specific IgG1 in the sera (Figure 41). 
Figure 41: Sera 
Alpha lactalbumin 
specific IgG1 titres 
in B6 and BALB/c 
mice. Sera from B6 
recovered (?) and 
rechallenged (Q) 
and BALB/c 
recovered (?) and 
rechallenged (J) 
and naïve (?) mice 
were incubated 
with Alpha 
lactalbumin. Data 
are expressed as 
the mean ± SEM of 
optical density of 
OPT substrate from 
duplicate samples 
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from individual mice (n=3) 
 
3.10.3.iv. Levels of BSA specific IgG1 in sera 
Rechallenged B6 mice had significantly higher sera BSA-specific 
IgG1 compared to B6 recovered mice. Rechallenged BALB/c mice had low 
BSA specific IgG1 antibody titre. The IgG1 specific antibody titres for BSA 
in recovered BALB/c and B6 were comparable to naïve mice (Figure 42). 
Figure 42: Sera BSA specific IgG1 titres in B6 and BALB/c mice. Sera from B6 
recovered (?) and 
rechallenged (Q) and 
BALB/c recovered 
(?) and rechallenged 
(J) and naïve (?) 
mice were incubated 
with BSA. Data are 
expressed as the 
mean ± SEM of 
optical density of 
OPT substrate from 
duplicate samples 
from individual mice ( 
n=3) 
 
 
 
3.10.4. PCR for IL-4, IL-5, IFN-g in naïve, recovered and rechallenged 
lung in BALB/c vs. B6 mice 
To determine whether there are differences in Th2 cytokine 
expression between B6 and BALB/c mice, whole lung RNA was extracted. 
The RNA was reverse transcribed to cDNA and the expression of IL-4, IL-
5, IL-10, IL-13 and IFN-g was determined in the B6 and BALB/c lung. In 
the whole lung mRNA of naïve BALB/c and B6 mice there was no 
expression of IL-4, IL-5, IL-10 and IFN-g (Figure 43). However, lungs from 
both the different strain of mice showed low expression of IL-13 in the 
naïve lung. Comparing the naïve BALB/c and B6 lung, here was no IL-4, 
IL-5, IL-10 and IFN-g production in naïve lung. IL-13 was expressed in the 
naïve lungs of both BALB/c and B6 mice; however, the expression of IL-13 
was slightly more in B6 naïve mice compared to BALB/c naïve mice 
(Figure 43). 
Recovered lungs from BALB/c mice had increased expression of IL-
4, IL-5, IL-13 and IFN-g compared to naïve BALB/c lung. Recovered B6 
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lung had low /no expression of Il-4 and IL-5 similar to naïve B6 lungs 
(Figure 43). However, there was higher expression of IL-10 and IFNg in 
recovered B6 lung compared to naïve B6 lung. Comparing the recovered 
BALB/c mice vs. recovered B6, there was higher expression of IL-4, IL-5, 
IL-13 and IFN-g in BALB/c recovered lung compared to B6 recovered lung. 
IL-10 however, was only expressed in the recovered B6 lung and not in the 
BALB/c recovered lung.  
 
Figure 43: Th2 cytokine 
expression in the lungs 
of B6 and BALB/c mice. 
Lungs from Naïve, 
recovered and 
rechallenged 2h (n=2-4) 
was pooled and RNA was 
extracted. Expression of 
IL-4, IL-5, IL-10, IL-13 
and IFNg in BALB/c 
(lanes 1= naive,3= 
recovered,5= 
rechallenged) and B6 (2= 
naïve, 4= recovered,6 
=rechallenged). HPRT 
was used as the house 
keeping gene.  
 
Furthermore, mice were aerosol challenged with 2% milk for 1 hr 
and the lungs extracted 2 hrs after the aerosol challenge. Aerosol challenge 
increased the expression of the interleukins in the lungs of mice. There was 
more expression of IL-4, IL-13 and IFN-g in rechallenged BALB/c mice 
compared to recovered BALB/c mice. B6 rechallenged mice also had 
increased expression of IL-4, IL-5, IL-10, IL-13 and IFN-g compared to 
recovered B6 mice. Interestingly, the expression of IL-10 increased upon 
rechallenged in both BALB/c and B6 mice, with more expression of IL-10 
in the B6 recovered lung (Figure 43). In conclusion, both BALB/c and B6 
mice increased the expression of IL-4- IL-5, IL-10, Il-13 and IFNg upon 
rechallenged. However, B6 rechallenged mice had higher expression of Th2 
cytokines compared to BALB/c rechallenged mice. 
In summary, B6 rechallenged mice responded better to milk aerosol 
challenge and produced higher amounts of IL-4, IL-5. IL-10 and IL-13 
compared to BALB/c rechallenged mice. 
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4. Discussion 
Allergic asthma is a Th2 mediated disease characterized by the 
presence of eosinophilic infiltration of the lung, mucus production and 
AHR. Elicitation of the immune response in allergic asthma involves the 
presentation of immunogenic peptide by the APC to the T cells. T cells 
produce Th2 cytokines and result in production of allergen specific IgE and 
IgG1 by B cells. There is a relapsing and remitting course of the disease 
because re-exposure to the same allergen results in rapid elicitation of the 
immune reaction. This indicates the presence of allergen-specific memory 
Th2 cells in allergic patients that are maintained for long durations. Ag 
persistence, anti-apoptosis, survival signals provided by cytokines could all 
contribute to the long-term survival and maintenance of memory cells. We 
aimed to understand the mechanism underlying the maintenance of 
pathogenic Th2 memory cells in the lungs of recovered mice leading to 
exacerbation in allergic asthma. To approach this we used a mouse model of 
allergic asthma established in our laboratory. In our model of allergic 
asthma, there is maintenance of long- lived Th2 memory cells and mice 
recovered from a single episode of allergic asthma maintain elevated 
allergen specific sera IgG1 levels throughout their life. We explored the 
possible role of CKRs in the maintenance of pathogenic Th2 cells in the 
lungs of mice remitting from allergic asthma.  
We first determined whether there are differences in the cellular 
composition of immune cells in naïve and recovered lungs. Age-matched 
naïve and recovered mice had similar percentages of T cells, B cells and 
APCs in the lungs.  Because we did not find any differences in the immune 
cellular composition of naïve and recovered lungs, we investigated the 
differences in the expression of CKRs on naïve, recovered and rechallenged 
lung CD4+ T cells. We evaluated the difference in the expression of CKRs 
in naïve, recovered and rechallenged lungs in our mouse model of allergic 
asthma. The expression of CKRs on recovered lung CD4+ T cells was 
higher than in naïve lung CD4+ T cells. Upon rechallenge CKR expression 
was further increased in the lungs. Similarly, the expression of activation 
markers was also elevated upon rechallenge on the CD4+ T cells in the 
rechallenged lungs. In vitro data suggests that the stimulation of recovered 
lung cells with titrated doses of OVA resulted in production of Th2 
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cytokines indicating the presence of Th2 cells in the recovered lungs. 
Additionally, treatment with high doses of dexamethasone or sublethal 
irradiation during remission did not completely abrogate the disease. We 
further evaluated the role of spleen in the maintenance of pathogenic Th2 
cells in allergic asthma and found that the splenectomized-rechallenged 
mice developed exaggerated disease. 
 
4.1. Differences in cellular composition between the naïve and 
recovered lungs 
Previous data from our laboratory demonstrated that recovered lungs 
maintain infiltrates that harbor Th2 cells with a memory phenotype (86). We 
further investigated whether there were differences in the cellular 
composition of naïve and recovered lungs that would allow the maintenance 
of these memory Th2 cells. We first determined that there were no 
differences between the percentages of T cells, B cells and MHC class II 
cells in naïve and recovered lungs. Additionally, the percentages of CD4+ 
T, CD8+ T, CD19+ B cells and MHC II+ cells were similar in naïve and 
recovered lungs. Moreover, we observed that the activation markers, CD25 
and CD69, on CD4+ T cells were similar in naïve and recovered lungs. This 
suggests that naïve and recovered lungs have a similar immune cell profile. 
However, generation of a distinct immune response after Ag re-exposure in 
recovered lungs indicates that the cells are functionally distinct and have 
properties that enable them to respond immediately to Ags.  
 
4.2. Differences in CKR gene expression 
We investigated whether the gene expression of CKRs in naïve and 
recovered lungs could lead to the maintenance of Th2 cells. We first 
investigated gene expression of CKRs primarily because the unavailability 
of mAbs for mouse CKRs at the time of initial experiments and analysis of 
gene expression would indicate which CKRs to focus on for further 
evaluation when the mAbs became available.  
 We assessed mRNA expression of CKRs in total lung. This does 
not allow for information about the specific cells expressing CKRs, but it 
does provide insights into the overall lung environment during distinct 
phases of disease. Interestingly, recovery was characterized by an 
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upregulation of 10 of the 16 CKR genes evaluated compared to naïve lungs. 
Two hrs after OVA-rechallenge, gene expression was downregulated in 8 of 
16 CKRs, suggesting that there is early migration of cells out of the lungs 
and potentially to the draining LNs. Four hrs later, we detected increased 
gene expression of 5 CKRs including, CCR4, CCR5, CCR7, CCR8 and 
CXCR3, suggesting homing of cells back to the lungs. It is tempting to 
speculate that the changes in gene expression detected in total lung is 
attributed to CD4 Th2 cells, but CXCR5 is also found on B cells, CCR5, 
CCR6, CX3CR1, CXCR4 are found on MHC class II + cells, and CCR4, 
CCR5, CCR6, CCR7, CCR8, CXCR3, CXCR4 are found on other T cells. 
Thus, making it impossible to determine whether the differences in 
expression have anything to do with CD4 Th2 cells. Therefore, to identify 
the CKRs important for memory cell migration, it was necessary to measure 
cell surface expression on CD4+ T cells.  
 
4.3. Cell surface CKR expression on CD4+ T cells in naïve, recovered 
and rechallenged lungs 
Several studies in human asthmatics demonstrate either no 
differences in the CKR expression pattern on lung T cells between normal 
and asthmatics patients (267), or increased infiltration of CCR6+ and 
CXCR3+ T cells in BAL after allergen provocation (268). Both these 
studies were based on subjects that exhibited mild disease or after allergen 
provocation. Using our mouse model of allergic asthma, we could monitor 
the CD4+ T cell CKR expression in naïve, recovered and after allergen 
provocation.  
We found that several CKRs were expressed on the cell surface at 
high levels in mice during recovery compared with naïve mice. The CKR 
that was most highly expressed during recovery was CX3CR1. This was 
unexpected because CX3CR1 is a Th1 associated CKR (327). However, 
there are some reports showing that it is also upregulated in asthmatic 
patients (328, 329) and in lungs of patients with systemic sclerosis (330). 
This receptor is thought to be involved in the recruitment of activated 
leukocytes to the site of inflammation. It has also been shown to be 
upregulated in lungs of mice exposed to cigarette smoke in a mouse 
emphysema model (331). Interestingly, CX3CR1 gene expression and cell 
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surface expression on CD4+ T cells were upregulated during recovery and 
reduced following OVA aerosol challenge, which suggests that the high 
expression may be associated with the propensity for CD4+ T cells to 
remain in the lungs and upon activation with Ag, migrate to draining LNs. 
In one study by Rimaniol et al., they found that CD4+ CX3CR1+ cells were 
recruited to lungs 24hrs after segmental challenge in response to increased 
production of fractalkine (329). This appears to contradict our findings, 
however, we hypothesize that during active acute inflammation cells 
expressing CX3CR1 are recruited to the lungs, they then maintain the 
expression of the receptor based on a gradient of their ligand leading them 
to reside in the lungs. When the cells are re-stimulated this CKR is 
downregulated and the cells are then free to migrate out of the lung. 
Therefore, CX3CR1 may be a particularly important CKR for the 
maintenance of ‘sentinel’ CD4+ T cells in the lungs during the recovery 
phase of disease.  
Human alveolar T cells are reported to express CCR2, CCR4, 
CCR5, CCR6, and CXCR and following allergen provocation, the 
percentages of CCR4+, CCR7+ increase, whereas CXCR3+ CD4+ T cells 
decrease (332). In our studies, we detected increases in CCR4+ and CCR7, 
CXCR3+ CD4+ T cells but found that CCR7+ CD4+ T cells were reduced 
48hrs after rechallenge. The differences between these results may be due to 
differences related to humans and mice or experimental conditions. 
Although CCR9 is a gut homing receptor (333) involved in the 
migration of CD4+ and CD8+ T cells to the intestine, it is expressed on 
invariant NKT (iNKT) in asthmatic patients (273). Interestingly, CCR9 
expressing iNKT cells induce CD3+ T cells towards a Th2 bias by signaling 
through CD226 (273). Our data demonstrate that recovered mice have 
CD4+ T cells expressing CCR9 but we did not measure expression on iNKT 
cells and are not aware that CCR9 is preferentially expressed on CD4+ T 
cells in human lungs. Our finding that CCR9 is associated with lung CD4+ 
T cells may be novel and requires some further investigation. 
Both CCR4 and CCR8 CKRs have been associated with Th2-
mediated diseases (271, 334). In support of these findings, we found that 
these CKRs were expressed on lung CD4+ T cells during recovery. CCR4 is 
on human mast cells in asthmatics (335) and on IL-4 producing cells in 
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atopic asthmatic patients (334). In another study, 28% of CD4+ T cells 
expressed CCR4 and CCR8 24 hrs after allergen challenge (334), 
suggesting that both receptors are important for T cells in the lungs during 
asthma. CCR4 KO mice develop less airway eosinophilia and AHR 
following Ag-challenge than their WT controls (269), suggesting that CCR4 
plays an essential role in allergic asthma. However, in a study using guinea 
pigs, blocking CCR4 with mAbs did not reduce allergic airway 
inflammation (336). Although these are seemingly contrasting data, it is 
possible that CCR4 might play a role in an established, ongoing disease but 
not in acute disease. For CCR8, we find increased expression on lung CD4+ 
T cells during recovery, which is further increased at 48 hrs after 
rechallenge. This is in contrast to reports showing that CCR8 is unimportant 
in the development of allergic airway inflammation (270, 271) but these 
studies did not investigate a potential role for this CKR during established 
disease.  
CCR5, CCR6, and CXCR3 are highly expressed on lung T cells in 
OVA-sensitized mice (282). We also observed an increase in expression of 
these CKRs during recovery and following rechallenge. There are reports 
indicating that CCR6 is of particular interest in the field of memory. CCR6 
KO mice have reduced AHR, reduced eosinophilia, IL-5 and IgE levels 
(279), indicating an important role of CCR6. Furthermore, it is present on 
memory T cells, DCs, and B cells (274, 276, 337) and in humans, CCR6 is 
expressed on memory T cells (71). Our support of the notion that CCR6 
expressing cells may mark a subpopulation of memory T cells in the lungs 
and while they are important for residing in the lungs during remission, this 
receptor is also upregulated during the initial activation period and may be 
important in the lung during recruitment and disease relapse because it is 
further elevated at 48 hrs when the animals develops fulminant allergic lung 
inflammation. 
Another CKR that we discovered upregulated during recovery and at 
48 hrs after aerosol OVA rechallenge was CCR10. It is known to be a skin 
homing receptor (60) and there are no reports of expression of CCR10 in the 
lung. Like CCR9, CCR10 may be a yet unrecognized receptor that defines a 
subset of inflammatory CD4+ T cells in lungs.  
 127 
CRTH2 has been reported to be expressed on eosinophils, basophils 
and Th2 cell in humans (338-341). We expected that CRTH2 would enable 
us to mark the Th2 cells during remission and after rechallenge. However, 
we did not observe CD4+ CRTH2+ cells in recovered or 48 hrs 
rechallenged lungs. It is possible that human anti-CRTH2 mAb is not 
specific for mouse CRTH2. Furthermore, several studies demonstrated the 
presence of CRTH2 on eosinophils or the gene expression of CRTH2 (288, 
289, 342), and to our knowledge there are no studies demonstrating the cell 
surface expression of CRTH2 on CD4+ T cells in the lungs of mice. 
Although, Matsuoka et al. demonstrated the presence of the receptors for 
prostaglandin D2 in the lungs of mice with allergic asthma (342), it is not 
clear whether these receptors are present on eosinophils or CD4+T cells or 
both. In view of these data, the presence of CRTH2 on lung CD4+ T cells in 
mouse is not clearly established. 
Our findings that there are elevated CKR expression in recovered 
lungs compared to naïve lungs lead us to speculate that this panel of CKRs 
enable memory T cells to remain in the lung, where they become ‘sentinels’ 
that are able to respond rapidly to inhaled Ags. Overall, we observed an 
upregulation of known memory CKR markers, CCR6, CCR7 and CXCR6 in 
the lungs during recovery. Furthermore, there was a concomitant increase in 
the expression of Th2 associated markers CCR4, CCR8 and CCR3 in the 
recovered lungs. We have not yet determined that the cells expressing these 
receptors are OVA-specific; however, in ongoing studies in the lab, we are 
attempting to sort subpopulations of CCR+ cells from recovered lungs and 
stimulate them in vitro with OVA to determine specificity.  
  
4.4. Cell surface CKR expression in splenocytes and lung draining LNs  
Upon Ag rechallenge, memory CD4+ T cells in the lungs migrate to 
the lung draining LNs, where Ag is presented to the CD4+ T cells and 
results in Th2 cytokine production and clonal expansion of CD4+ T cells.  
Although, this is the paradigm, we hypothesize that lung CD4+ T cells are 
activated by APC and inhaled Ags within the lungs and then either remain 
in the lungs as they produce effector cytokines that recruit inflammatory 
cells or migrate out of the lungs. Our speculation is based on the fact that 
the cells remain in the lung and respond very rapidly upon Ag aerosol by 
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expressing effector cytokines. In fact, we have data showing that in the first 
hr during OVA aerosol, Th2 cytokine message is expressed (data not 
shown).  
It has been demonstrated that presence of CCR7 on CD4+ T cells 
facilitates the entry of central memory cells into the LNs (72). We found 
that in recovered mice that there are Th2 memory cells in spleen but not 
draining LNs (86). However, we also found increased expression of CKRs 
on CD4+ T cells in draining LNs from recovered mice compared to naïve 
mice. Since they are not Ag-specific, we have no explanation for this result. 
In contrast, recovered splenocytes had lower expression of CKRs on CD4+ 
T cells compared to naïve splenocytes, suggesting that Ag-specific CD4+ T 
cells may reduce CKR expression to migrate out of the lung, into circulation 
and into the spleen. These cells also produce less Th2 cytokines upon in 
vitro OVA stimulation compared to the memory cells in the lungs. The 
differences between CKR expression and cytokine production between cells 
in the lungs and spleen remain unclear to us.  
 
4.5. Th2 cytokines by recovered lungs upon in vitro stimulation 
indicates presence of OVA-specific memory Th2 cells 
 Previous experiments from our laboratory demonstrated that OVA-
specific memory cells resided in the lungs and in the spleen. There were no 
OVA-specific CD4+ Th2 cells in the LNs (86). The method employed for 
detection was ELISPOT, which is a sensitive method for detection. We 
stimulated recovered lung cells with titrated doses of OVA in vitro for 48 
hrs. There was an upregulation of CD25 and CD69 by lung cells and 
production of Th2 cytokines IL-4 and IL-5. Unstimulated recovered lung 
cells did not produce Th2 cytokines and did not upregulate the activation 
markers CD25 and CD69. This indicates that OVA-specific memory Th2 
cells are present in the recovered lung. Presence of OVA in the culture 
resulted in the presentation of OVA to the CD4+ Th2 cells that were 
activated and upregulated CD25 and CD69, in addition, to production of 
Th2 cytokines.  
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4.6. Splenocytes from recovered mice stimulated in vitro 
The spleen is a secondary lymphoid organ where lymphocytes from 
the blood continually circulate. If OVA-specific memory Th2 cells were 
circulating to the spleen and residing in the spleen, then in vitro stimulation 
of splenocytes would have resulted in the production of Th2 cytokines and 
upregulation of CD25 and CD69. Upon in vitro stimulation of recovered 
splenocytes, there was minimal production of IL-4 and IFNg. These data 
were observed with ELISAs rather than the more sensitive ELISPOTS used 
previously in our lab. It does illustrate that there are that there are Th2 
memory cells in spleen, but the numbers are much lower than that in the 
lungs. 
 
4.7. Removal of spleen during remission augments allergic asthma 
One part of our approach to understanding memory Th2 cells in our 
model is to study additional factors that are important for their maintenance. 
We reasoned that since there were Ag-specific memory cells in the spleen 
that the spleen may be involved in this process. To determine whether the 
spleen is involved, we performed survival splenectomy during the recovery 
period. Our hypothesis is that if the Th2 memory cells in the spleen were 
participating in the maintenance of memory, the removal of the spleen 
would potentially eliminate memory, thereby reducing allergic 
inflammation following OVA-rechallenge. This hypothesis was based on 
previous experiments that showed that splenectomy either no effect on 
recall responses to respiratory syncytial virus (156) or a reduced effect 
chronic relapsing experimental autoimmune encephalomyelitis (155). To 
our surprise, 1 month and 4 months after splenectomy, allergic lung 
inflammation was not only enhanced in the lungs 48 hrs after OVA 
rechallenge, but the recovered mice had more inflammation. There are some 
explanations for this result that we suggest. Firstly, the spleen may act as a 
regulatory organ, important for the maintenance of T cell homeostasis. If 
this explanation were correct, then there would be potentially regulatory 
factors that maintain peripheral T cell numbers. There is abundant literature 
indicating that homeostasis is carefully controlled (343). For example, 
Torres and coworkers demonstrated that the spleen in involved in the 
clearance of IL-10, TNF-a and IL-6 production (157). Moreover, 
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splenectomy was associated with increased leukocytes in the periphery that 
appeared to be related to reduced apoptosis of leukocytes (344, 345). 
Without these regulatory or suppressive mechanisms in the spleen, 
homeostasis is affected leading to the increased accumulation of memory T 
cells. A second possibility is that the spleen is simply a reservoir for 
memory T cells and when absent, the T cells having nowhere else to go end 
up returning and staying in peripheral tissue. This would, thus, lead to the 
accumulation of these cells in the lungs of our experimental mice. This is a 
very interesting finding that requires further investigation. 
 
4.8. Treatment with dexamethasone reduces but does not abolish 
allergic asthma 
In another approach to understand the character of the Th2 memory 
response, we attempted to disrupt memory by eliminating inflammation. 
Currently, glucocorticoids are the best treatment available for allergic 
disease. We, therefore, attempted to inhibit disease relapse using high dose 
steroids. Previous experiments from our laboratory demonstrated that 
treatment with dexamethasone was effective in decreasing inflammation in 
different models of allergic asthma (313). Thus, we repeated these 
experiments in the memory model, during recovery. Remarkably, treatment 
with dexamethasone decreased eosinophilic inflammation but we were not 
able to complete inhibit disease relapse. Inhaled corticosteroids typically 
inhibit T cell recruitment into the airway (307-309), which we expected 
would be the case in our experimental model. In fact, lymphocyte numbers 
were lower in treated mice compared with untreated controls. However, it 
merely reduced the overall disease response. We hypothesize that while the 
recruitment might have been reduced, the effector function of the memory 
cells within the lungs was not affected effectively by the treatment. We 
would argue that the Th2 memory cells were resistant to treatment and 
produced cytokines important for recruiting eosinophils and for inducing 
mucus production. Of great interest, is that this model may reflect a 
subpopulation of patients that are steroid resistant. 
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4.9. Rechallenged-irradiated mice maintain central infiltrates and 
mucus-producing goblet cells 
 Another even more aggressive approach to further characterize and 
determine the tenacity of Th2 memory cells was to treat mice with sublethal 
gamma irradiation, which should normally abrogate immune responses. 
Recovered mice were irradiated with a sublethal dose of 6.5Gy of Cobalt 
60. To ensure that immune cells were eliminated, we waited 1 week before 
examining the mice with and without Ag rechallenge. As expected, CD4+ 
T, B220+ and MHC II+ cells were reduced and this reduction was 
associated with significant reduction of the immune response leading to 
disease relapse. Airway eosinophilia was abrogated and tissue eosinophilia 
and mucus production was greatly reduced. While we anticipated that 
disease relapse would be completely eliminated, there is evidence that long-
lived lymphocytes and plasma cells are resistant to x – irradiation (161) and 
memory T cells survive after sublethal gamma irradiation in presence of Ag 
presentation by immunostimulatory APCs (164). Thus, the reduced but 
evident response after irradiation may be due to a very small population of 
radiation resistant memory cells. 
 
4.10. Whole milk induce allergic asthma and there are strain 
differences (BALB/c vs. B6) in disease induction 
Although the OVA models of allergic asthma dominate the 
literature, we questioned whether our findings in memory using OVA were 
applicable to other Ags. We used a polyantigenic natural Ag in BALB/c and 
B6 mice, namely milk. We found that there were significant differences in 
the extent of disease between mouse strains. Surprisingly, disease was more 
severe in the ‘so-called’ Th1-type B6 mice compared to Th2-type BALB/c 
mice (346-351). The reasons for the remarkable difference in magnitude of 
the response to milk remain unknown. However, it was clear that memory 
responses were maintained in both strains, as we have observed with OVA 
as the Ag. One feature of the response to milk that seemed to differ between 
milk and OVA is that the recovery period from the acute onset of allergic 
asthma is longer with milk than with OVA. It may correlate with a larger 
number of memory T cells because there are multiple Ags in milk and 
therefore it is expected that there would be an increase in the number of Ag-
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specific memory T cells. Memory studies with the milk model are ongoing 
in the laboratory.  
 
5. Summary 
Our lab previously established that mice recovered from allergic 
asthma maintain memory Th2 cells in the lung. Since these Th2 cells are 
involved in the relapsing and remitting course of the disease, our aim was to 
further characterizes and understand the mechanisms involved in 
maintenance of the pathogenic lung Th2 cells in experimental allergic 
asthma. One possibility is that chemokine –CKR interactions play a role in 
the survival of T cells. We, thus, investigated the gene and cell surface 
protein expression of these receptors and their ligands on lung cells during 
remission and relapse. Recovered lung CD4+ T cells expressed a wide array 
of CKRs compared with naïve cells and these receptors were further 
elevated upon Ag rechallenge. To further characterize memory Th2 cells, 
we attempted to eliminate them by splenectomy, sublethal irradiation and 
corticosteroids. Corticosteroid and sublethal irradiation could not 
completely abrogate disease relapse and splenectomy actually increased 
disease relapse.  These data further illustrate the interesting properties of 
long-lived memory Th2 cells that reside in the lungs of mice with allergic 
asthma and have important clinical implications as they may shed light on 
the mechanisms involved in chronic and steroid-resistant allergic asthma. 
 
6. Zussammenfassung 
Unser Labor hat bereits nachgewiesen, dass Mäuse welche sich von 
allergischem Asthma erholt haben, verbleibende Th2 Gedächtnis T-Zellen 
in der Lunge aufweisen. Da diese Th2 Zellen bei einem erneuten Auftreten 
der Krankheit involviert sind, war unser Ziel, die Mechanismen, die an der 
Erhaltung der pathogenen Th2 Zellen in der Lunge bei experimentellem 
allergischem Asthma beteiligt sind, besser zu charakterisieren. Eine 
Möglichkeit ist, dass Chemokin-Chemokinrezeptor (CKR) Interaktionen 
eine Rolle bei dem Überleben dieser T-Zellen spielen. Deswegen 
erforschten wir die Genexpression dieser Rezeptoren und deren Liganden 
auf Lungen-Zellen, während der Remission und einem Rückfall der 
Krankheit. CD4+ T-Zellen aus Lungen von genesenen Mäusen exprimieren 
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eine breitere Palette an CKR, verglichen zu naiven Zellen. Die Expression 
dieser Rezeptoren war nach erneuter Antigen-Exponierung noch weiter 
erhöht. Um die Funktion der Gedächtnis Th2 Zellen genauer zu 
charakterisieren, versuchten wir diese durch Splenektomie, subletale 
Bestrahlung, oder durch Verabreichung von Corticosteroiden zu beseitigen. 
Die Corticosteroidbehandlung und eine subletale Bestrahlung konnten einen 
Rückfall der Krankheit nicht vollständig verhindern, wobei Splenektomie 
den Rückfall der Krankheit sogar verschlimmerte. Diese Daten erläutern die 
interessanten Eigenschaften dieser langlebenden Gedächtnis Zellen, die in 
den Lungen von Mäusen mit allergischem Asthma residieren. Weiters 
beinhaltet diese Studie wichtige klinische Implikationen, da sie Einblicke in 
die Mechanismen von chronischem und Steroid-resistentem allergischem 
Asthma gewährt.   
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